<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="pmc-domain-id">3416</journal-id><journal-id journal-id-type="pmc-domain">molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430568</article-id><article-id pub-id-type="pmcid-ver">PMC12430568.1</article-id><article-id pub-id-type="pmcaid">12430568</article-id><article-id pub-id-type="pmcaiid">12430568</article-id><article-id pub-id-type="doi">10.3390/molecules30173457</article-id><article-id pub-id-type="publisher-id">molecules-30-03457</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Metabolism, a Blossoming Target for Small-Molecule Anticancer Drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0024-596X</contrib-id><name name-style="western"><surname>Puxeddu</surname><given-names initials="M">Michela</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2489-0178</contrib-id><name name-style="western"><surname>Silvestri</surname><given-names initials="R">Romano</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3252-1161</contrib-id><name name-style="western"><surname>Regina</surname><given-names initials="GL">Giuseppe La</given-names></name><xref rid="c1-molecules-30-03457" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>He</surname><given-names initials="Q">Qiuqin</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-30-03457">Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy; <email>michela.puxeddu@uniroma1.it</email> (M.P.); <email>romano.silvestri@uniroma1.it</email> (R.S.)</aff><author-notes><corresp id="c1-molecules-30-03457"><label>*</label>Correspondence: <email>giuseppe.laregina@uniroma1.it</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>30</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496502</issue-id><elocation-id>3457</elocation-id><history><date date-type="received"><day>10</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>08</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="molecules-30-03457.pdf"/><abstract><p>Reprogramming is recognized as a promising target in cancer therapy. It is well known that the altered metabolism in cancer cells, in particular malignancies, are characterized by increased aerobic glycolysis (Warburg effect) which promotes rapid proliferation. The effort to design compounds able to modulate these hallmarks of cancer are gaining increasing attention in drug discovery. In this context, the present review explores recent progress in the development of small molecule inhibitors of key metabolic pathways, such as glycolysis, glutamine metabolism and fatty acid synthesis. In particular, different mechanisms of action of these compounds are analyzed, which can target distinct enzymes, including LDH, HK2, PKM2, GLS and FASN. The findings underscore the relevance of metabolism-based strategies in developing next-generation anticancer agents with potential for improved efficacy and reduced systemic toxicity.</p></abstract><kwd-group><kwd>metabolism</kwd><kwd>cancer</kwd><kwd>aerobic glycolysis</kwd><kwd>glutamine metabolism</kwd><kwd>fatty acid synthesis</kwd></kwd-group><funding-group><award-group><funding-source>AIRC IG</funding-source><award-id>24703</award-id></award-group><award-group><funding-source>European Union-Next Generation EU</funding-source><award-id>MIUR PRIN 2022 2022TPPNTK</award-id></award-group><award-group><funding-source>Sapienza University of Rome</funding-source><award-id>RG11816428A9B4D5</award-id><award-id>RM120172A7EAD07C</award-id><award-id>RM1241904EB3828D</award-id><award-id>RG123188B4D193AE</award-id><award-id>AR224190786E7FA3</award-id></award-group><funding-statement>The authors wish to acknowledge AIRC IG 2020 n. 24703 granted to R.S.; MIUR PRIN 2022 2022TPPNTK (European Union-Next Generation EU) awarded to G.L.R.; Sapienza University of Rome RG11816428A9B4D5 and RM120172A7EAD07C granted to R.S.; RM1241904EB3828D and RG123188B4D193AE awarded to G.L.R; and AR224190786E7FA3 granted to M.P.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-30-03457"><title>1. Introduction</title><p>The cancer metabolism was first suggested by the Nobel Prize Otto Warburg who observed that cancer cells produce additional energy in vitro by converting a larger amount of glucose into lactate compared to healthy cells [<xref rid="B1-molecules-30-03457" ref-type="bibr">1</xref>]. This event, known as the Warburg effect, is referred to as aerobic glycolysis. The abnormal aerobic glycolysis promotes cell differentiation and cancer cell proliferation [<xref rid="B2-molecules-30-03457" ref-type="bibr">2</xref>]. Under normal conditions, differentiated cells metabolize glucose to yield two molecules of pyruvate, two molecules of adenosine triphosphate (ATP) and two molecules of reduced nicotinamide adenine dinucleotide (NADH) (<xref rid="molecules-30-03457-f001" ref-type="fig">Figure 1</xref>). The two pyruvates are then converted into acetyl CoA, which enters the mitochondria and combines with oxaloacetate in the tricarboxylic acid (TCA) cycle to form citric acid [<xref rid="B3-molecules-30-03457" ref-type="bibr">3</xref>]. Normally, one molecule of glucose produces about 30&#8211;34 molecules of ATP in the presence of oxygen [<xref rid="B4-molecules-30-03457" ref-type="bibr">4</xref>]. In low-oxygen conditions or in the absence of oxygen, glucose is metabolized through anaerobic respiration. However, even in the presence of oxygen, cancer cells tend to convert pyruvate into lactate by lactate dehydrogenase (LDH) after glycolysis, producing four molecules of ATP [<xref rid="B5-molecules-30-03457" ref-type="bibr">5</xref>,<xref rid="B6-molecules-30-03457" ref-type="bibr">6</xref>]. Although this conversion is less efficient in terms of ATP yield compared to mitochondrial oxidation, it is faster [<xref rid="B7-molecules-30-03457" ref-type="bibr">7</xref>] and continuously provides the cancer cell with amino acid, lipid, and nucleotide building blocks required for tumor proliferation [<xref rid="B8-molecules-30-03457" ref-type="bibr">8</xref>,<xref rid="B9-molecules-30-03457" ref-type="bibr">9</xref>,<xref rid="B10-molecules-30-03457" ref-type="bibr">10</xref>]. As a consequence, a smaller proportion of pyruvate is converted into acetyl CoA prior to entering the TCA cycle, resulting in reduced production of NADH, FADH2 and ATP (<xref rid="molecules-30-03457-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B11-molecules-30-03457" ref-type="bibr">11</xref>].</p></sec><sec id="sec2-molecules-30-03457"><title>2. Developing Therapeutic Agents Based on Metabolism</title><p>Targeting metabolism in medicinal chemistry holds significant potential for developing effective agents with highly specific mechanisms of action at catalytic and allosteric sites within hydrophobic pockets of metabolic enzymes. The success achieved by metabolism-targeting chemotherapy has demonstrated the effectiveness of this strategy for tumor treatment. The hallmarks of cancer include acquired capabilities, such as sustaining proliferative signaling, evading growth suppressors, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis [<xref rid="B12-molecules-30-03457" ref-type="bibr">12</xref>]. Deregulated cellular metabolism can be considered a core hallmark of cancer [<xref rid="B13-molecules-30-03457" ref-type="bibr">13</xref>]. In addition to the Warburg effect, relevant reprogramming events that promote cancer cell survival and growth include de novo biosynthesis of proteins, nucleic acids and lipids. The anabolic metabolism of cancer cells includes increased lipid synthesis during proliferation to face the elevated demand for energy and for the formation of biological membranes [<xref rid="B14-molecules-30-03457" ref-type="bibr">14</xref>,<xref rid="B15-molecules-30-03457" ref-type="bibr">15</xref>]. The growing interest in compounds that interfere with cancer metabolism has been well documented in recent excellent reviews, such as that by Montesdeoca on lipogenic enzymes inhibitors [<xref rid="B16-molecules-30-03457" ref-type="bibr">16</xref>], Stine on precision oncology [<xref rid="B17-molecules-30-03457" ref-type="bibr">17</xref>] and Masci on colorectal cancer therapy [<xref rid="B18-molecules-30-03457" ref-type="bibr">18</xref>]. Herein, we present the most recent advances in small molecules targeting metabolism, focusing on mechanism of action and their potential as antitumor drugs.</p><sec id="sec2dot1-molecules-30-03457"><title>2.1. Aerobic Glycolysis</title><sec id="sec2dot1dot1-molecules-30-03457"><title>2.1.1. Lactate Dehydrogenase (LDH)</title><p>The release of the LDH in the tumor microenvironment promotes cancer cell proliferation and increases the likelihood of metastasis [<xref rid="B19-molecules-30-03457" ref-type="bibr">19</xref>,<xref rid="B20-molecules-30-03457" ref-type="bibr">20</xref>]. Inhibition of LDH by decreasing lactate release in the tumor microenvironment produces an useful anticancer effect [<xref rid="B21-molecules-30-03457" ref-type="bibr">21</xref>]. Consequently, the search for LDH inhibitors as potential anticancer agents has become a topic of considerable interest [<xref rid="B22-molecules-30-03457" ref-type="bibr">22</xref>,<xref rid="B23-molecules-30-03457" ref-type="bibr">23</xref>,<xref rid="B24-molecules-30-03457" ref-type="bibr">24</xref>]. LDH exists in five major isoforms, resulting from combinations of M and H monomers forming homo- and hetero-tetramers. The 4M and 4H tetramers correspond to LDHA and LDHB, respectively. LDHA catalyzes the conversion of pyruvate to lactate, whereas LDHB drives the reverse conversion (<xref rid="molecules-30-03457-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B25-molecules-30-03457" ref-type="bibr">25</xref>,<xref rid="B26-molecules-30-03457" ref-type="bibr">26</xref>].</p><p>LDHA is induced by hypoxia or MYC activation, enabling glycolysis to become the primary source of ATP production in response to oxygen deprivation and the tumor&#8217;s ability to recruit new blood vessels [<xref rid="B27-molecules-30-03457" ref-type="bibr">27</xref>]. As such, several research projects have focused on the discovery of natural [<xref rid="B28-molecules-30-03457" ref-type="bibr">28</xref>] and small-molecule [<xref rid="B29-molecules-30-03457" ref-type="bibr">29</xref>] LDH inhibitors.</p><p>Sodium oxamate (<bold>1</bold>, <xref rid="molecules-30-03457-ch001" ref-type="fig">Chart 1</xref>, <xref rid="molecules-30-03457-t001" ref-type="table">Table 1</xref>) inhibits LDH and aspartate aminotransferase (AAT) and competes in vitro with pyruvate for the human LDHA. Oxamate and the AAT inhibitor amino oxyacetate suppressed proliferation of MDA-MB-231 cells and decreased tumor growth in MDA-MB-231 breast cancer xenografts in mice lacking the normal thymus gland [<xref rid="B30-molecules-30-03457" ref-type="bibr">30</xref>]. Tumor suppressor p53 expression was strongly upregulated by (<bold>1</bold>), but only in glucose-treated cells, suggesting a connection with glycolysis inhibition [<xref rid="B31-molecules-30-03457" ref-type="bibr">31</xref>]. While useful as a pharmacological tool, compound <bold>1</bold> shows limited enzymatic selectivity, weak potency and poor cellular uptake restricting its clinical utilization [<xref rid="B32-molecules-30-03457" ref-type="bibr">32</xref>].</p><p>A series of quinoline 3-sulfonamides was found to inhibit potently and selectively LDHA and to rapidly reduce lactate production. GSK2837808A (<bold>2</bold>) inhibited LDHA at low nanomolar concentrations (IC<sub>50</sub> = 2.6 &#177; 1.9 nM) and showed 80-fold selectivity over LDHB (IC<sub>50</sub> = 43 &#177; 14 nM) in hepatocellular carcinoma cell lines [<xref rid="B33-molecules-30-03457" ref-type="bibr">33</xref>]. LDHA inhibition by (<bold>2</bold>) suppressed glycolytic activity in temporomandibular joint osteoarthritis (TMJOA) synovial fluid (SF) containing &gt;1000 kDa hyaluronic acid (HA). In the TMJOA microenvironment, vascularization and extracellular matrix (ECM) degradation correlate with increased nutrient consumption and active synovial proliferation [<xref rid="B34-molecules-30-03457" ref-type="bibr">34</xref>]. As a result of LDHA inhibition by (<bold>2</bold>), HA production increased, and inflammation was reduced along with suppression of AMPK phosphorylation [<xref rid="B35-molecules-30-03457" ref-type="bibr">35</xref>]. In Snu398 cells, which exhibit elevated glycolysis and pentose phosphate pathway activity, compound 2 reduced proliferation and induced strong changes in cell metabolism [<xref rid="B33-molecules-30-03457" ref-type="bibr">33</xref>]. Pyruvate kinase (PK) activity increased in Snu398 but not in HepG2 cells, where the mitochondrial metabolism is significantly higher. Compound <bold>2</bold> also induced, in a dose-dependent manner, the inactive monomer of pyruvate kinase (PKM2) to form the M2 isoform, which catalyzes the final and rate-limiting reaction in the glycolytic pathway [<xref rid="B36-molecules-30-03457" ref-type="bibr">36</xref>].</p><p>The 1,3-dihydropyrimidine GNE-140 (<bold>3</bold>) LDHA inhibitor rapidly affected the metabolism in MIA PaCa-2 human pancreatic cells, although cell death occurred only after two days of treatment [<xref rid="B37-molecules-30-03457" ref-type="bibr">37</xref>]. Pancreatic cell lines relying primarily on oxidative phosphorylation (OXPHOS) for ATP production [<xref rid="B38-molecules-30-03457" ref-type="bibr">38</xref>] were resistant to <bold>3</bold>, due to activation of the AMPK-mTOR-S6K signaling pathway, which promoted OXPHOS; the OXPHOS inhibitor phenformin (<bold>4</bold>) could resensitize these cells to <bold>3</bold>. Histone lysine lactylation (HKla) is a novel post-translational modification that connects cellular metabolism with epigenetic regulation. Although its role in the development of cardiac hypertrophy is still unclear, LDH inhibitor <bold>3</bold>, as well as <bold>1</bold>, has been shown to reduce HKla levels and mitigate cardiac hypertrophy development [<xref rid="B39-molecules-30-03457" ref-type="bibr">39</xref>]. Compound <bold>3</bold> has also been shown to suppress osteogenic differentiation, proliferation, and migration while promoting apoptosis in alveolar bone marrow mesenchymal cells (ABMMCs). Mechanistically, these regulatory effects of lactate were thought to be mediated by HKla [<xref rid="B40-molecules-30-03457" ref-type="bibr">40</xref>]. Compound <bold>3</bold> blocked dimethylsulfoxide-induced expression of Arg1, an M2 macrophage polarization marker, by lactate-H3K18la pathway in a methicillin-resistant Staphylococcus aureus (MRSA) disease model [<xref rid="B41-molecules-30-03457" ref-type="bibr">41</xref>].</p><p>A screening of 2-thio-6-oxo-1,6-dihydropyrimidine derivatives led to the identification of a moderately potent LDHA inhibitor with an IC<sub>50</sub> of 8.8 &#956;M. Surface plasmon resonance (SPS) experiments indicated that simultaneous association with the NADH co-factor was required for an optimal binding to the LDHA. Based on these findings, medicinal chemistry work was conducted that aimed to improve the compound&#8217;s LDHA inhibition properties. As a result, compound TODP (<bold>5</bold>) inhibited LDHA with IC<sub>50</sub> = 0.75 &#956;M and LDHB with IC<sub>50</sub> = 3.7 &#956;M. A crystal structure of compound <bold>5</bold> in complex with LDHA at 1.90 &#197; resolution showed binding to Arg168, His192 and Asp165 residues of the LDH catalytic site and only the R-Me enantiomer was observed in the co-crystal structure [<xref rid="B42-molecules-30-03457" ref-type="bibr">42</xref>].</p><p>Pyrazole-based LDH inhibitors were identified by quantitative high-throughput screening (qHTS) and structure-based design [<xref rid="B42-molecules-30-03457" ref-type="bibr">42</xref>,<xref rid="B43-molecules-30-03457" ref-type="bibr">43</xref>]. A lead compound effectively inhibited highly glycolytic MIA PaCa-2 (human pancreatic cancer) and A673 (human Ewing&#8217;s sarcoma) cell lines and showed favorable in vitro ADME properties although its PK profile was not suitable for in vivo use [<xref rid="B44-molecules-30-03457" ref-type="bibr">44</xref>]. Optimization of the pyrazole-based chemotype yielded compounds <bold>6</bold> (NCI-006 NCATS-SM1440) and <bold>7</bold> (NCATS-SM1441), which stabilized LDHA in cells (IC<sub>50</sub> 57 nM and 40 nM, respectively). Increasing the concentrations of compounds <bold>6</bold> and <bold>7</bold> resulted in NAD<sup>+</sup> depletion and full glycolytic pathway inhibition, as evidenced by decreased extracellular acidification rate (ECAR). Both compounds <bold>6</bold> and <bold>7</bold> showed excellent metabolic profiles in hepatocytes and high plasma protein binding in mouse and human plasma. Structure&#8211;activity relationship (SAR) studies highlighted that the 5-methylthienyl group in the alkyne region is required for robust in vivo LDH inhibition [<xref rid="B44-molecules-30-03457" ref-type="bibr">44</xref>,<xref rid="B45-molecules-30-03457" ref-type="bibr">45</xref>]. Compound <bold>6</bold> and its analog NCI-737 (structure unavailable) were evaluated in in vitro and in vivo preclinical models of Ewing sarcoma (EWS), a highly metastatic bone cancer, constituting 10% to 15% of all bone sarcomas [<xref rid="B46-molecules-30-03457" ref-type="bibr">46</xref>], predominantly afflicting adolescents [<xref rid="B47-molecules-30-03457" ref-type="bibr">47</xref>]. Both compounds suppressed the glycolytic flux by impairing the conversion of pyruvate to lactate, disrupted the NAD<sup>+</sup>/NADH ratio and decreased the extracellular acidification rate (ECAR) in multiple EWS cell lines. Intravenous administration led to intratumoral drug accumulation, induced cell death and reduced tumor growth [<xref rid="B48-molecules-30-03457" ref-type="bibr">48</xref>].</p><p>New phthalimide- and dibenzofuran-based selective LDHA allosteric inhibitors with sub-micromolar in vitro activity were identified. Co-crystal structures demonstrated that compounds <bold>8</bold> and <bold>9</bold>, with IC<sub>50</sub> values of 308 nm and 757 nm, respectively, bound to a novel binding pocket distant from the polar, extended orthosteric substrate/cofactor site, while compound <bold>10</bold> (IC<sub>50</sub> = 21.9 nm) was shown to hinder cofactor binding in an NADH competitive mode. Since few LDHA crystal structures show an allosteric pocket in an open conformation, the authors speculated that enzyme inhibition by (<bold>8</bold>) and (<bold>9</bold>) may depend on ligand-dependent conformational changes. Compound <bold>10</bold> also inhibited the LDHB, due to the high similarity among LDH isoforms active sites [<xref rid="B49-molecules-30-03457" ref-type="bibr">49</xref>]. Allosteric inhibitors may take advantage by avoiding competition with endogenous substrates [<xref rid="B50-molecules-30-03457" ref-type="bibr">50</xref>]. The architecture of the LDH protein plays a key role in enzymatic catalysis by tuning vibrational modes that promote chemical reactions [<xref rid="B51-molecules-30-03457" ref-type="bibr">51</xref>]. Therefore, LDHA inhibition may result from conformational changes and/or dynamic processes crucial for enzymatic turnover [<xref rid="B49-molecules-30-03457" ref-type="bibr">49</xref>].</p><p>AZD3965 (<bold>11</bold>) is a potent and selective inhibitor of monocarboxylate transporter 1 (MCT1), encoded by SLC16A1 [<xref rid="B52-molecules-30-03457" ref-type="bibr">52</xref>], which is involved in lactate efflux following MYC-induced glycolysis [<xref rid="B53-molecules-30-03457" ref-type="bibr">53</xref>]. Compound <bold>11</bold> potently inhibited MCT1 and MCT2, while sparing MCT3 and MCT4. It showed GI<sub>50</sub> &lt;100 nM (MTS growth assay) in diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphomas (NHL) cell lines. Inhibition of MCT1 led to decreased lactate efflux by (<bold>11</bold>). In in vivo studies, compound <bold>11</bold> was combined with doxorubicin or rituximab in DLBCL and Burkitt&#8217;s lymphoma models. Finally, when co-administered with a glutaminase (GLS) inhibitor, compound <bold>11</bold> enhanced cell death and growth inhibition compared to monotherapy treatment [<xref rid="B53-molecules-30-03457" ref-type="bibr">53</xref>]. In a xenograft model of Raji lymphoblast-like cell in immunodeficient mice, compound <bold>11</bold> inhibited tumor growth, downregulated choline kinase alpha (which converts choline + ATP into phosphocholine + ADP + H<sup>+</sup>), and altered mRNA expression. These effects correlated with intracellular lactate accumulation induced by (<bold>11</bold>) [<xref rid="B54-molecules-30-03457" ref-type="bibr">54</xref>]. In a multicenter phase I clinical trial, compound <bold>11</bold> was well tolerated at doses effective against MCT1-expressing cancers. Dose-limiting toxicities were mostly reversible, asymptomatic ocular changes. A dose of 10 mg twice daily was recommended for phase II trials [<xref rid="B55-molecules-30-03457" ref-type="bibr">55</xref>].</p></sec><sec id="sec2dot1dot2-molecules-30-03457"><title>2.1.2. Glucose Transporter 1 (GLUT1)</title><p>Glucose transporter type 1 (GLUT1) is the main transporter responsible for glucose uptake in many tissues (<xref rid="molecules-30-03457-f003" ref-type="fig">Figure 3</xref>). It is expressed in most tissues, but is highly abundant in brain endothelial cells, glial cells, erythrocytes and placenta [<xref rid="B56-molecules-30-03457" ref-type="bibr">56</xref>]. GLUT1 is a glycoprotein belonging to the GLUT family of carriers and is responsible for the basal glucose uptake across the blood&#8211;tissues barriers, including the blood&#8211;brain barrier (BBB) [<xref rid="B57-molecules-30-03457" ref-type="bibr">57</xref>]. Alterations in GLUT1 impair the glucose supply to glial cells and neurons. A reduction in brain glucose transport, primarily caused by mutations in the SLC2A1 gene encoding GLUT1 [<xref rid="B58-molecules-30-03457" ref-type="bibr">58</xref>], is the etiological basis of the glucose transporter type 1 deficiency syndrome (GLUT1DS), an autosomal dominant disorder [<xref rid="B59-molecules-30-03457" ref-type="bibr">59</xref>,<xref rid="B60-molecules-30-03457" ref-type="bibr">60</xref>]. The classical form of GLUT1DS presents as early-onset encephalopathy (during the first year of life), characterized by severe epilepsy, a complex movement disorder and developmental delay, including microcephaly, due to immature tight junctions in the BBB that allow paracellular glucose transport [<xref rid="B61-molecules-30-03457" ref-type="bibr">61</xref>].</p><p>Approximately 80% of renal cell carcinomas (RCCs), similar to many other cancers, are associated with the loss of the von Hippel&#8211;Lindau (VHL) tumor suppressor gene, which is correlated with the Warburg effect and partially results from GLUT1 upregulation. Compound STF-31 (<bold>12</bold>) (<xref rid="molecules-30-03457-ch002" ref-type="fig">Chart 2</xref>) was identified through a high-throughput screening of ~64,000 small molecules, aimed at discovering agents with selective lethality in VHL-deficient RCC cells. Two classes of compounds emerged from this screening: sulfonamides and pyridyl anilino thiazoles, including compound <bold>12</bold> and STF-62247 (<bold>13</bold>), respectively. RCC4 cells lacking VHL showed reduced viability in the presence of (<bold>12</bold>) in a dose-dependent manner compared to their wild-type cells RCC4/VHL. The clonogenic assay confirmed that compound <bold>12</bold> selectively targeted RCC4 cells. It did not induce any morphological or biochemical features of autophagy, nor did it deregulate HIF expression in VHL-deficient cells. Importantly, lactate production and extracellular acidification were significantly inhibited. Compound <bold>12</bold> decreased glycolysis by inhibiting glucose transport rather than targeting a particular glycolytic enzyme. Moreover, it was toxic to RCCs expressing GLUT1 but low or undetectable levels of GLUT2, indicating that STF-31 acts as a high-affinity GLUT1 inhibitor [<xref rid="B62-molecules-30-03457" ref-type="bibr">62</xref>].</p><p>STF-62247 (<bold>13</bold>) was identified by screening for small molecules targeting selectively VHL-deficient RCC cells. Compound <bold>13</bold> induced cytotoxicity and reduced tumor growth in VHL-deficient RCC cells compared to VHL wild-type (WT) cells. The cytotoxicity of (<bold>13</bold>) was mediated through autophagy in a HIF-independent mechanism [<xref rid="B63-molecules-30-03457" ref-type="bibr">63</xref>]. SAR studies identified several key features necessary for selective cytotoxicity against VHL-negative RCC cells: the aniline-NH and the 4-pyridyl-N groups likely participate in H-bonding, while an unsubstituted thiazole is required for VHL selectivity. Small lipophilic substituents at the 3- and 4-positions of the aniline ring suggested the presence of a lipophilic pocket within the target protein [<xref rid="B64-molecules-30-03457" ref-type="bibr">64</xref>].</p><p>Fasentin (<bold>14</bold>) is a small molecule that sensitizes the Fas-signaling pathway (central to programmed cell death) by effecting glucose uptake. At 80 &#956;M, (<bold>14</bold>) dramatically reduced glucose uptake in leukemia and prostate cancer cells [<xref rid="B65-molecules-30-03457" ref-type="bibr">65</xref>]. Compound <bold>14</bold> was also used to shed light on the role played by GLUT1 in corticotropin-releasing hormone (CRH)-mediated glucose uptake in adenomatous corticotropes [<xref rid="B66-molecules-30-03457" ref-type="bibr">66</xref>]. These findings have prompted the development of anticancer strategies based on glucose metabolism. Compound <bold>14</bold> inhibited endothelial cells growth without compromising their survival and reduced the number of enterochromaffin (EC) cells, tumor cells and, to a lesser extent, fibroblasts. At 50 nM, it impaired angiogenesis in the chick chorioallantoic membrane (CAM) assay. Notably, this anti-angiogenic activity was independent of glucose metabolism modulation. In human dermal microvascular endothelial cells, (<bold>14</bold>) reduced the uptake of glucose. It is worthy to note that <bold>13</bold> failed to inhibit tube formation in these cells [<xref rid="B67-molecules-30-03457" ref-type="bibr">67</xref>].</p><p>Compounds Wzb27 (<bold>15</bold>) and Wzb115 (<bold>16</bold>) (IC<sub>50</sub> = 5 &#956;M and 0.3 &#956;M, respectively) were serendipitously identified as inhibitors of basal glucose transport [<xref rid="B68-molecules-30-03457" ref-type="bibr">68</xref>] during a screening for molecules that stimulate insulin receptor-mediated glucose uptake [<xref rid="B69-molecules-30-03457" ref-type="bibr">69</xref>]. These compounds proved more potent than other GLUT1-inhibitory agents, such as (<bold>14</bold>) or apigenin, a natural product with anti-inflammatory and antitumor activity, in inhibiting basal glucose transport and cancer cell proliferation. Both (<bold>15</bold>) and (<bold>16</bold>) induced G1/S cell cycle arrest and apoptosis in lung and breast cancer cells without significantly affecting their normal cell counterparts. Apoptosis was mediated by caspase-3 activation, independent of p53, consistent with a glucose deprivation mechanism [<xref rid="B68-molecules-30-03457" ref-type="bibr">68</xref>]. The analog compound WZB117 (<bold>17</bold>) inhibited cancer cell proliferation both in vitro and in vivo in a nude mouse model. It proved to inhibit glucose transport in human RBCs having GLUT1 as the only transporter. Compound <bold>17</bold> reduced GLUT1 protein levels, intracellular ATP, and glycolytic enzymes, while increasing AMP-activated protein kinase (AMPK). ATP depletion and induction of senescence were observed in GLUT1 inhibitor-treated cancer cells [<xref rid="B70-molecules-30-03457" ref-type="bibr">70</xref>]. Compound <bold>17</bold> reversibly and competitively inhibited 3-O methylglucose (3MG) uptake in human erythrocytes but acted as a non-competitive inhibitor of glucose efflux. In HEK293 cells, (<bold>17</bold>) inhibited Glut4 more potently than GLUT1 and GLUT3 [<xref rid="B71-molecules-30-03457" ref-type="bibr">71</xref>].</p><p>A high-throughput screening campaign was led to identify <italic toggle="yes">N</italic>-(1H-pyrazol-4-yl)quinoline-4-carboxamides as a promising scaffold for the development of GLUT1-selective small-molecule inhibitors. SAR studies led to single-digit nanomolar inhibitors with selectivity over GLUT2, GLUT3 and GLUT4. The most promising compound, BAY-876 (<bold>18</bold>), showed high GLUT1 potency and selectivity thanks to the presence of an unsubstituted amide at position 2 and a fluorine atom at position 7, respectively, of the quinoline ring. Compound <bold>18</bold> exhibited good in vitro metabolic stability and high oral bioavailability in vivo, with low clearance in rats and dogs [<xref rid="B72-molecules-30-03457" ref-type="bibr">72</xref>]. Inhibition of GLUT1 by (<bold>18</bold>) halted glucose uptake in cancer cells, induced apoptosis, and suppressed the TNF-&#945;-induced interleukin-8 (IL-8) production in head and neck squamous cell carcinoma (HNSCC) cells. BAY-876 reduced the viability of SCC47, RPMI2650, and FaDu cells after 24 h and induced apoptosis at higher concentrations in some cancers. These results highlight GLUT1 as a promising target in HNSCC of the upper aerodigestive tract [<xref rid="B73-molecules-30-03457" ref-type="bibr">73</xref>].</p></sec><sec id="sec2dot1dot3-molecules-30-03457"><title>2.1.3. Hexokinase (HK)</title><p>HK catalyzes the conversion of glucose to glucose-6-phosphate (G6P), the first irreversible step of glycolysis, and is involved in pathways associated with cancer cell growth, such as nucleotide and lipid synthesis, tricarboxylic acid cycle and pentose phosphate [<xref rid="B74-molecules-30-03457" ref-type="bibr">74</xref>]. In humans, five HK isoenzymes are recognized: HK1, HK2, HK3, HK4 and the HK domain-containing protein 1 (HKDC1) [<xref rid="B75-molecules-30-03457" ref-type="bibr">75</xref>]. Among them, HK2 isoenzyme was found to be overexpressed in various cancer types [<xref rid="B76-molecules-30-03457" ref-type="bibr">76</xref>,<xref rid="B77-molecules-30-03457" ref-type="bibr">77</xref>], while HK1 is the predominant isoform in normal cells. Due to its key role in reprogrammed glucose metabolism, HK2 has emerged as an attractive target for anticancer drug discovery [<xref rid="B78-molecules-30-03457" ref-type="bibr">78</xref>]. The transport of mitochondrial metabolites across the outer mitochondrial membrane (OMM) is mediated by voltage-dependent anion channels (VDACs) [<xref rid="B79-molecules-30-03457" ref-type="bibr">79</xref>] (<xref rid="molecules-30-03457-f004" ref-type="fig">Figure 4</xref>), with VDAC1 being the most prominent isoform, frequently overexpressed in several types of cancer [<xref rid="B80-molecules-30-03457" ref-type="bibr">80</xref>]. HK2 was found to be associated with VDAC1 at the OMM, allowing ATP transport from mitochondria to the cytosol as ADP to convert glucose into glucose-6-phosphate. Moreover, HK2 contributes to apoptosis evasion in cancer cells by binding to VDAC1 and competing with Bax [<xref rid="B81-molecules-30-03457" ref-type="bibr">81</xref>]. Thus, inhibition of the HK2-VDAC1 interaction turned out to be a promising strategy for cancer therapy. The crystal structure of HK2 (PDB ID: 2NZT, resolution: 2.45 &#197;) was used to design HK2 inhibitors. Additional inhibitors were developed to target the G6P-binding site by mimicking the G6P interaction.</p><p>Due to the high sequence similarity between rat HK1 (PDB ID: 1BG3, resolution: 2.80 &#197;) and human HK2, a homology model was constructed to study how VDAC1 phosphorylation may disrupt HK2 binding. For docking studies to HK2, the structure of VDAC1 (PDB ID: 2JK4, resolution: 4.10 &#197;) was used [<xref rid="B78-molecules-30-03457" ref-type="bibr">78</xref>].</p><p><underline>HK2-VDAC1 inhibitors</underline>. Metformin (<bold>19,</bold><xref rid="molecules-30-03457-ch003" ref-type="fig">Chart 3</xref>) was shown to impair energy balance in cancer cells in vitro by the selective enzymatic inhibition of HK1 and HK2 isoforms [<xref rid="B82-molecules-30-03457" ref-type="bibr">82</xref>]. This activity was demonstrated in MDA-MB-231 triple-negative breast cancer cells in xenograft models [<xref rid="B83-molecules-30-03457" ref-type="bibr">83</xref>]. Both isoforms were localized to the mitochondrial outer membrane; HK2&#8242;s membrane association was found to be partially dependent on G6P [<xref rid="B84-molecules-30-03457" ref-type="bibr">84</xref>]. HK2 inhibition restricts cancer cell growth by limiting ATP access for glucose phosphorylation [<xref rid="B85-molecules-30-03457" ref-type="bibr">85</xref>]. Notably, prolonged treatment with compound <bold>19</bold> caused a marked reduction in tumor growth without any visible necrosis, whereas acute drug administration resulted in profound cytotoxic effects [<xref rid="B83-molecules-30-03457" ref-type="bibr">83</xref>].</p><p>3-Bromopyruvate (3-BrPA, <bold>20</bold>) covalently modifies the HK2 protein, leading to the release of the apoptosis-inducing factor (AIF) from the mitochondria to cytosol as a consequence of the interaction of HK2 with AIF. The dissociation of HK2 from mitochondria alone was sufficient to cause apoptosis, particularly in the mitochondria-deficient &#961;<sup>0</sup> cells with high HK2 expression, without affecting mitochondrial membrane potential, ROS generation, or oxidative phosphorylation [<xref rid="B86-molecules-30-03457" ref-type="bibr">86</xref>].</p><p>Pachymic acid (<bold>21</bold>) is a triterpenoid compound obtained from <italic toggle="yes">Poria cocos</italic> (Polyporaceae), a saprophytic fungus that grows on various Pinus species [<xref rid="B87-molecules-30-03457" ref-type="bibr">87</xref>]. Compound <bold>21</bold> has demonstrated anti-inflammatory, anticancer, anti-aging, and insulin-like properties, which directly inhibited the HK2 with an IC<sub>50</sub> of 5.01 &#956;M, inducing mitochondrial dysfunction, ATP depletion, and ROS generation. Compound <bold>21</bold> acts as a competitive activator of PKM2 by mimicking fructose-1,6-bisphosphate, the natural activator. It was suggested that this compound could be a G6P mimic [<xref rid="B88-molecules-30-03457" ref-type="bibr">88</xref>].</p><p>Lonidamine (<bold>22</bold>) is an anticancer agent approved as a monotherapy for advanced breast, prostate, lung and brain cancers. Its mechanism of action involves selective inhibition of aerobic glycolysis in tumor cells [<xref rid="B89-molecules-30-03457" ref-type="bibr">89</xref>] through HK inhibition [<xref rid="B90-molecules-30-03457" ref-type="bibr">90</xref>] and disruption of the mitochondrial membrane [<xref rid="B91-molecules-30-03457" ref-type="bibr">91</xref>]. Compound <bold>22</bold> was administered alone or in combination with other chemotherapeutic agents (i.e., paclitaxel, docetaxel, 5-fluorouracil and 2-desoxy-2-glucose), surgery or radiation therapy in a sustained-release formulation to treat cancer, inflammation and autoimmune disease [<xref rid="B92-molecules-30-03457" ref-type="bibr">92</xref>].</p><p>Chrysin (<bold>23</bold>) is a flavonoid compound extracted from natural sources, such as blue passion flower, propolis and honey, commonly used in traditional Chinese medicine. It showed antitumor activity in several human cancer cell lines and also possesses antioxidant, anti-inflammatory and antibacterial properties. Its antitumor activity involves activation of the extrinsic apoptosis pathway [<xref rid="B93-molecules-30-03457" ref-type="bibr">93</xref>], alteration of cyclin-dependent kinases (CDKs) [<xref rid="B94-molecules-30-03457" ref-type="bibr">94</xref>] and interference with key signaling pathways, including Ras-Raf-MAPKs, PI3K-Akt, STAT, NF-&#954;B, Wnt-&#946;-catenin and Notch [<xref rid="B95-molecules-30-03457" ref-type="bibr">95</xref>,<xref rid="B96-molecules-30-03457" ref-type="bibr">96</xref>]. Compound <bold>23</bold> inhibited glycolysis and induced apoptosis in hepatocellular carcinoma (HCC) cells both in vitro and in vivo, through inhibition of HK-2 (which was found to be overexpressed in the majority of HCC tissue) and tumor glycolysis and activation of mitochondria-associated apoptosis [<xref rid="B97-molecules-30-03457" ref-type="bibr">97</xref>].</p><p>Piperlongumine (<bold>24</bold>), a natural compound isolated from long pepper piper longum L, showed anticancer activity against several human tumor types, including lung, liver, prostate, breast and colorectal cancers. Compound <bold>24</bold> inhibited the non-small-cell lung cancer (NSCLC) both in vitro and in vivo by downregulating glycolysis, decreasing HK2 expression and inducing mitochondrial apoptosis. The glycolytic suppression induced by (<bold>24</bold>) was mediated by the Akt signaling pathway [<xref rid="B98-molecules-30-03457" ref-type="bibr">98</xref>].</p><p><underline>Glucose-binding site inhibitors</underline>. 2-Deoxy-D-glucose (2-DG) (<bold>25</bold>) is a glucose analog bearing a hydrogen atom replacing the hydroxyl group at position 2, functioning as a competitive inhibitor of glycolysis [<xref rid="B99-molecules-30-03457" ref-type="bibr">99</xref>,<xref rid="B100-molecules-30-03457" ref-type="bibr">100</xref>]. It inhibits several glycolytic enzymes, leading to cell death. Compound <bold>25</bold> fulfills Lipinski&#8217;s rule of five and shows activity against hypoxic tumor cells, while also reducing oxygen dependency, including in the context of COVID-19 [<xref rid="B101-molecules-30-03457" ref-type="bibr">101</xref>]. Due to its structural similarity to D-mannose, (<bold>25</bold>) interferes with glycosylation processes and induces endoplasmic stress [<xref rid="B102-molecules-30-03457" ref-type="bibr">102</xref>,<xref rid="B103-molecules-30-03457" ref-type="bibr">103</xref>]. Compound <bold>25</bold> has shown potential as a cancer and antiviral agent and enhanced the efficacy of paclitaxel when co-administered or co-encapsulated in nanoparticles for a lung cancer model [<xref rid="B104-molecules-30-03457" ref-type="bibr">104</xref>]. Compound <bold>25</bold> was also shown to suppress the inflammation in innate immune cells [<xref rid="B105-molecules-30-03457" ref-type="bibr">105</xref>] and the expression of herpes simplex virus type-1 receptor [<xref rid="B106-molecules-30-03457" ref-type="bibr">106</xref>] by modulating anti-inflammatory mediators and the polarization of macrophages [<xref rid="B107-molecules-30-03457" ref-type="bibr">107</xref>]. Applications of (<bold>25</bold>) as an anticancer agent have been reported in combination with the Bcl-2 antagonist ABT-263 and ABT-737 (ABT) [<xref rid="B108-molecules-30-03457" ref-type="bibr">108</xref>], or with other therapeutic agents or radiotherapy to overcome its limited therapeutic effect [<xref rid="B109-molecules-30-03457" ref-type="bibr">109</xref>]. 2-Halogenated D-glucose analogs were found to be more potent than (<bold>25</bold>) in killing hypoxic tumor cells and may be more clinically effective when combined with standard chemotherapeutic protocols [<xref rid="B110-molecules-30-03457" ref-type="bibr">110</xref>]. The combination of low-dose (<bold>25</bold>) and (<bold>19</bold>) synergically inhibited cyst formation and human polycystic kidney cell proliferation [<xref rid="B111-molecules-30-03457" ref-type="bibr">111</xref>] and proved effective across a broad spectrum of preclinical cancer models [<xref rid="B112-molecules-30-03457" ref-type="bibr">112</xref>].</p><p>Benserazide (<bold>26</bold>) was identified as an HK2 inhibitor (K<sub>d</sub> of 149 &#177; 4.95 &#956;M) by structure-based virtual screening studies on FDA-approved drugs and nutraceuticals from the ZINC Drug Database [<xref rid="B113-molecules-30-03457" ref-type="bibr">113</xref>]. Due to its inhibitory effect on peripheral dopa decarboxylase, compound <bold>26</bold> is used as a levodopa coadjuvant in standard Parkinson&#8217;s disease treatment. It showed approximately 8-fold selectivity for HK2, versus HK4, and about 5-fold selectivity against HK2 over HK1. (<bold>26</bold>) inhibited SW480 cancer cells proliferation and CRC xenograft growth by targeting HK2, inducing apoptotic cell death through energetic stress and activation of AMPK&#945;, p53 and p27, along with loss of mitochondrial membrane potential [<xref rid="B114-molecules-30-03457" ref-type="bibr">114</xref>].</p><p>Benitrobenrazide (<bold>27</bold>) is a nanomolar inhibitor of HK2 (IC<sub>50</sub> of 0.53 &#177; 0.13 &#956;M), induces apoptosis and inhibits proliferation of HK2-overexpressed cancer cells. It significantly inhibited glycolysis and cancer cell proliferation both in vitro and in vivo with low toxicity by directly targeting HK2. Upon oral administration, compound <bold>27</bold> effectively suppressed tumor growth in SW1990 and SW480 xenograft models [<xref rid="B115-molecules-30-03457" ref-type="bibr">115</xref>].</p><p><underline>Glucose-6P-mimicking binding site inhibitors</underline>. Metformin (<bold>19</bold>) has also been reported to inhibit HK2 at &#956;M concentrations similar to those of G6P (85). Glucose-6P binds to an allosteric site near, but distinct from, the glucose-binding site in the HK1 [<xref rid="B116-molecules-30-03457" ref-type="bibr">116</xref>]. Co-crystallography studies revealed that the first structure of HK2 bound a ligand and G6P at 2.76 &#197; [<xref rid="B117-molecules-30-03457" ref-type="bibr">117</xref>]. The co-crystal structure of HK2 highlighted the presence of a highly flexible binding site. SAR studies were conducted to enhance HK2 selectivity over HK1, given their high sequence similarity and conserved glucose-binding sites [<xref rid="B118-molecules-30-03457" ref-type="bibr">118</xref>]. A 6-sulfonamide linker turned out to optimally mimic the phosphate group of G6P. Compounds <bold>28</bold>&#8211;<bold>30</bold> (<xref rid="molecules-30-03457-ch004" ref-type="fig">Chart 4</xref>) were identified as potent and selective HK2 inhibitors, with IC<sub>50</sub> values of 0.025, 0.0079 and 0.050 &#956;M, respectively [<xref rid="B117-molecules-30-03457" ref-type="bibr">117</xref>].</p></sec><sec id="sec2dot1dot4-molecules-30-03457"><title>2.1.4. Pyruvate Kinase (PK)</title><p>Pyruvate kinase (PK) is a rate-limiting glycolytic enzyme that catalyzes the final step of glycolysis, converting phosphoenolpyruvate (PEP) into pyruvate [<xref rid="B119-molecules-30-03457" ref-type="bibr">119</xref>] (<xref rid="molecules-30-03457-f005" ref-type="fig">Figure 5</xref>). Among the four reported PK isoforms, PKM1 and PKM2 are expressed in several cell types, including neutrophils, while PKL is mainly found in the liver and PKR in erythrocytes [<xref rid="B120-molecules-30-03457" ref-type="bibr">120</xref>]. The enzymatic activity of PKM2 is tightly regulated by endogenous allosteric effectors and intracellular signaling pathways, which influence both its enzymatic activity and oligomeric state. PKM2 can assume a dimeric or monomeric form, leading to the accumulation of glycolytic intermediates. The dimeric form of PKM2 can translocate to the cell nucleus, where it co-activates transcription factors, regulating genes involved in cell proliferation and glycolysis. Upon allosteric activation, PKM2 adopts a tetrameric conformation with high glycolytic activity [<xref rid="B121-molecules-30-03457" ref-type="bibr">121</xref>]. ROS production in neutrophils is dependent on glycolytic flux. PKM2 regulates the dihydroxyacetone phosphate (DHAP) and diacylglycerol (DAG) levels, which activate protein kinase C (PKC), and, in turn, the NADPH oxidase complex, thereby promoting ROS production and neutrophil cytotoxic activity [<xref rid="B122-molecules-30-03457" ref-type="bibr">122</xref>]. PKM2 was identified as a promising target for cancer therapy, with subcellular localization of PKM2 proposed as a potential biomarker for therapeutic response in non-small-cell lung cancer (NSCLC) cell lines [<xref rid="B123-molecules-30-03457" ref-type="bibr">123</xref>].</p><p>The previously cited compound <bold>26</bold> was also identified as a novel inhibitor targeting PKM2 for melanoma treatment [<xref rid="B124-molecules-30-03457" ref-type="bibr">124</xref>]. It also showed cystathionine-&#946;-synthase (CBS) inhibitory activity among 8871 clinically used drugs, with relative selectivity versus cystathionine-&#947; lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST). Benserazide (<bold>26</bold>) inhibited colon cancer cell proliferation in HCT116 and HT29 cell lines, both highly expressing CBS, impaired cellular bioenergetics in HCT116 cells and suppressed colon cancer tumor growth in mice [<xref rid="B125-molecules-30-03457" ref-type="bibr">125</xref>].</p><p>SAR studies on naphthoquinone derivatives led to the identification of thiocarbamate 3k (<bold>31</bold>, <xref rid="molecules-30-03457-ch005" ref-type="fig">Chart 5</xref>) as a selective PKM2 inhibitor (IC<sub>50</sub> = 2.95 &#177; 0.53 &#956;M) with antiproliferative activity in PKM2-overexpressing HCT116, HeLa and H1299 cells, superior to the known PKM2 inhibitor shikonin [<xref rid="B126-molecules-30-03457" ref-type="bibr">126</xref>]. Two novel 2,3-didithiocarbamate analogs of compound <bold>31</bold> exhibited even stronger inhibition of PKM2; their activities were superior to (<bold>31</bold>), showing dose-dependent cytotoxicity with IC<sub>50</sub> values in nanomolar concentrations against HCT116, MCF7, HeLa, H1299 and B16 cells [<xref rid="B127-molecules-30-03457" ref-type="bibr">127</xref>].</p><p>A series of benzoxepane derivatives, inspired by marine-derived natural products, was synthesized as novel anti-inflammatory agents. PKM2 was identified as the molecular target of compound 10i (<bold>32</bold>) (IC<sub>50</sub> = 4.1 &#956;m) [<xref rid="B128-molecules-30-03457" ref-type="bibr">128</xref>]. Compound <bold>32</bold> exhibited anti-inflammatory activity in lipopolysaccharides (LPS)-stimulated RAW264.7 macrophages by inhibiting TNF-a protein release. In mouse primary microglia 10 &#956;M of (<bold>32</bold>) showed potent anti-neuroinflammatory effects, with an inhibition rate of 87.9% and low toxicity. It inhibited PKM2 kinase activity without affecting PKM2 protein expression in vitro in a cell-free assay. After incubation in both RAW264.7 and mouse primary microglia, compound <bold>32</bold> caused a significant reduction in LDHA and NOD-like receptor protein 3 (NLRP3) inflammasome activation, consistent with the role of PKM2 in promoting glycolysis through transcriptional regulation of glycolysis-related genes [<xref rid="B129-molecules-30-03457" ref-type="bibr">129</xref>,<xref rid="B130-molecules-30-03457" ref-type="bibr">130</xref>].</p><p>ML-265 (<bold>33</bold>) was identified to study the neuroprotective effects of pharmacologically reprogramming photoreceptor metabolism by altering PKM2 function (AC<sub>50</sub> = 108 &#177; 20&#8201;nM) during outer retinal apoptotic stress [<xref rid="B131-molecules-30-03457" ref-type="bibr">131</xref>]. Compound <bold>33</bold> increased pyruvate kinase activity in 661W cells, a retinal ganglion precursor-like cell line in which glaucoma-associated optineurin mutants selectively induce cell death [<xref rid="B132-molecules-30-03457" ref-type="bibr">132</xref>], both in vitro and in vivo following intravitreal injection in rat eyes, without affecting the expression of glucose metabolism-related genes [<xref rid="B131-molecules-30-03457" ref-type="bibr">131</xref>]. After showing good microsomal stability, aqueous solubility and CaCO<sub>2</sub> permeability, compound <bold>33</bold> was progressed to in vivo PK, where it showed good oral bioavailability, sustained exposure, long half-life and low clearance. In a 7-week mouse xenograft model, ML265 significantly reduced tumor size and occurrence without showing signs of acute toxicity [<xref rid="B133-molecules-30-03457" ref-type="bibr">133</xref>].</p><p><underline>Natural products</underline>. Silibinin (<bold>34</bold>) and ellagic acid (<bold>35</bold>) showed competitive inhibition of PKM2, with Ki values of 0.61 &#956;M and 5.06 &#956;M, respectively, while curcumin (<bold>36</bold>) and resveratrol (<bold>37</bold>) acted as non-competitive inhibitors of PKM2, with Ki values of 1.20 &#956;M and 7.34 &#956;M, respectively [<xref rid="B134-molecules-30-03457" ref-type="bibr">134</xref>].</p><p>Silibinin (<bold>34</bold>) is the most bioactive component of silymarin, an extract obtained from milk thistle (Silybum marianum L. Gaertn.) [<xref rid="B135-molecules-30-03457" ref-type="bibr">135</xref>]. Silymarin has demonstrated anticancer effects against several tumors, including lung, prostate, colon, breast, bladder and hepatocellular carcinoma [<xref rid="B136-molecules-30-03457" ref-type="bibr">136</xref>]. Treatment with 75&#8211;100 &#956;M of (<bold>34</bold>) for 24&#8211;48 inhibited histone deacetylases (HDAC) and DNA methyltransferase (DNMT) in H1299 human H1299 NSCLC cell lines [<xref rid="B137-molecules-30-03457" ref-type="bibr">137</xref>]. At 300 &#956;M, silibinin significantly inhibited DNMT activity in SW480 and SW620 colon cancer cells, with only weak HDAC inhibition [<xref rid="B138-molecules-30-03457" ref-type="bibr">138</xref>]. Combined treatment with trichostatin A (TSA) and (<bold>34</bold>) demonstrated a synergistic effect on cancer cell death via DNMT inhibition [<xref rid="B138-molecules-30-03457" ref-type="bibr">138</xref>]. Furthermore, compound <bold>34</bold> was shown to modulate non-coding RNAs (ncRNAs), which play a critical role in the epigenetic regulation of gene expression. In triple-negative breast cancer (TNBC) cells, (<bold>34</bold>) disrupted the metabolic reprogramming via modulation of the EGFR-MYC-TXNIP signaling pathway. Drug combination of compound <bold>34</bold> with paclitaxel demonstrated synergistic antiproliferative activity in TNBC models [<xref rid="B139-molecules-30-03457" ref-type="bibr">139</xref>].</p><p>Ellagic acid (<bold>35</bold>) is a polyphenolic compound found in various plant-derived foods that was approved by the Japanese Ministry of Health, Labor and Welfare as an antioxidant supplement [<xref rid="B140-molecules-30-03457" ref-type="bibr">140</xref>]. Beyond its free radical scavenging activity, (<bold>35</bold>) has gained interest as a tumor chemopreventive agent [<xref rid="B141-molecules-30-03457" ref-type="bibr">141</xref>], also showing protective effects against chronic alcohol-induced liver damage in rats [<xref rid="B142-molecules-30-03457" ref-type="bibr">142</xref>]. Its antitumor activity has been mostly correlated to direct inhibition of cell proliferation and induction of apoptosis. In small clinical studies, it has been evaluated in combination with standard chemotherapy in colorectal and prostate cancer patients [<xref rid="B143-molecules-30-03457" ref-type="bibr">143</xref>]. Compound <bold>35</bold> showed high binding affinity to Cyclin-Dependent Kinase 6 (CDK6), downregulated its protein expression at the translational level [<xref rid="B144-molecules-30-03457" ref-type="bibr">144</xref>] and inhibited cell growth in different human cancer cells lines [<xref rid="B145-molecules-30-03457" ref-type="bibr">145</xref>]. In A549 cells, ellagic acid induced apoptosis via phosphoinositide 3-kinase/protein kinase B pathway in a CDK6-dependent manner [<xref rid="B144-molecules-30-03457" ref-type="bibr">144</xref>].</p><p>Curcumin (<bold>36</bold>) is a plant-derived polyphenolic compound, found in turmeric (Curcuma longa), widely used in both traditional and modern medicine. It exhibits antioxidant, anti-inflammatory, antiviral, anti-angiogenic, anti-HIV-1 and anticancer activity due to its ability to adopt different conformations that facilitate interaction with different targets [<xref rid="B146-molecules-30-03457" ref-type="bibr">146</xref>]. Compound <bold>36</bold> inhibited glucose uptake and lactate production in several cancer cell lines by downregulating PKM2 expression through the inhibition of the mTOR-HIF1&#945; axis [<xref rid="B147-molecules-30-03457" ref-type="bibr">147</xref>].</p><p>Resveratrol (<bold>37</bold>) (3,4&#8242;,5-trihydroxystilbene) is a phytoalexin found in the skin of red grapes and other fruits [<xref rid="B148-molecules-30-03457" ref-type="bibr">148</xref>]. It exerts anticancer activity in all stages of tumor development: initiation, promotion and progression [<xref rid="B149-molecules-30-03457" ref-type="bibr">149</xref>]. Compound <bold>37</bold> exerts a PKM2-mediated effect on cancer metabolism, decreasing PKM2 mRNA and protein expression via mTOR inhibition in HeLa, HepG2 and MCF-7 cells [<xref rid="B150-molecules-30-03457" ref-type="bibr">150</xref>]. Since the mTOR pathway regulates PKM2 expression [<xref rid="B151-molecules-30-03457" ref-type="bibr">151</xref>], PKM2 overexpression can reverse the effects of resveratrol. Several signaling pathways, involved in carcinogenesis and host defense response, are also modulated by resveratrol, accounting for its pleiotropic anticancer activity. In combination with 5-f or cisplatin, (<bold>37</bold>) displayed a synergistic effect and increased cancer cell sensitivity [<xref rid="B152-molecules-30-03457" ref-type="bibr">152</xref>].</p><table-wrap position="anchor" id="molecules-30-03457-t001" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-t001_Table 1</object-id><label>Table 1</label><caption><p>Compounds targeting aerobic glycolysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Stage</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Limitation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Sodium oxamate (<bold>1</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">LDHA, AAT</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">1965</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Not suitable for clinical utilization</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B30-molecules-30-03457" ref-type="bibr">30</xref>,<xref rid="B31-molecules-30-03457" ref-type="bibr">31</xref>,<xref rid="B32-molecules-30-03457" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">GSK2837808A (<bold>2</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">LDHA</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Poor oral bioavailability; very rapid clearance in vivo; very low plasma concentrations</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B33-molecules-30-03457" ref-type="bibr">33</xref>,<xref rid="B34-molecules-30-03457" ref-type="bibr">34</xref>,<xref rid="B35-molecules-30-03457" ref-type="bibr">35</xref>,<xref rid="B36-molecules-30-03457" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">GNE-140 (<bold>3</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">LDHA</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Unfavorable pharmacokinetics; rapid clearance</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B37-molecules-30-03457" ref-type="bibr">37</xref>,<xref rid="B38-molecules-30-03457" ref-type="bibr">38</xref>,<xref rid="B39-molecules-30-03457" ref-type="bibr">39</xref>,<xref rid="B40-molecules-30-03457" ref-type="bibr">40</xref>,<xref rid="B41-molecules-30-03457" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">TODP (<bold>5</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">LDHA</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Unfavorable pharmacokinetics</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B42-molecules-30-03457" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">NCI-006 (<bold>6</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">LDHA</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Advanced preclinical candidate</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Low cell permeability; high plasma binding; potential target saturation</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B45-molecules-30-03457" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">(<bold>8</bold>), (<bold>9</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">LDHA</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical<break/>Studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Only enzymatic assay</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B49-molecules-30-03457" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">(<bold>10</bold>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Allosteric site LDH</td><td align="center" valign="middle" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" rowspan="1" colspan="1">Only enzymatic assay; not selective for LDHA (also active on LDHB)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B49-molecules-30-03457" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">AZD3965 (<bold>11</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">MCT1/2</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Phase I (2020)</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Reduced efficacy in glycolytic/resistant tumors; potential ocular and cardiac toxicities; limited to lymphomas; limited systemic pharmacology and long-term data</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B52-molecules-30-03457" ref-type="bibr">52</xref>,<xref rid="B53-molecules-30-03457" ref-type="bibr">53</xref>,<xref rid="B54-molecules-30-03457" ref-type="bibr">54</xref>,<xref rid="B55-molecules-30-03457" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">STF-31 (<bold>12</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">GLUT1</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">No PK data available; necrotic cell death; complex mechanism</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B62-molecules-30-03457" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">STF-62247 (<bold>13</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">GLUT1</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Undefined pharmacokinetics</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B62-molecules-30-03457" ref-type="bibr">62</xref>,<xref rid="B63-molecules-30-03457" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Fasentin (<bold>14</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Fas pathway<break/>GLUT1</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2006</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Undefined pharmacokinetics</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B66-molecules-30-03457" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">WZB27 (<bold>15</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">GLUT1</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2010</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Moderate potency; no PK studies</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B68-molecules-30-03457" ref-type="bibr">68</xref>,<xref rid="B69-molecules-30-03457" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">WZB115 (<bold>16</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">GLUT1</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2010</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Moderate potency; no PK studies</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B68-molecules-30-03457" ref-type="bibr">68</xref>,<xref rid="B69-molecules-30-03457" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">WZB117 (<bold>17</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">GLUT1</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2012</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Limited selectivity; no PK studies; in vivo instability</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B70-molecules-30-03457" ref-type="bibr">70</xref>,<xref rid="B71-molecules-30-03457" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">BAY-876 (<bold>18</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">GLUT1</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Limited cellular activity; effects on normal cells; tumor metabolic adaptation</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B72-molecules-30-03457" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Metformin (<bold>19</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">HK1, HK2</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Cytotoxic effect</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B82-molecules-30-03457" ref-type="bibr">82</xref>,<xref rid="B83-molecules-30-03457" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">]3-BrPA (<bold>20</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">HK2</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2009</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Systemic toxicity; non-selective reactivity; acidic pH dependence; metabolic adaptation;</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B86-molecules-30-03457" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">]Pachymic acid (<bold>21</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">HK2, PKM2</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Poor in vivo bioavailability; narrow therapeutic window; moderate potency; multiple and partly selective mechanisms; lack of systematic toxicity data</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B87-molecules-30-03457" ref-type="bibr">87</xref>,<xref rid="B88-molecules-30-03457" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Lonidamine (<bold>22</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">HK2, MCT</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">1981</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Fase II&#8211;III (only in combination)</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Mitochondrial toxicity; low oral bioavailability</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B89-molecules-30-03457" ref-type="bibr">89</xref>,<xref rid="B90-molecules-30-03457" ref-type="bibr">90</xref>,<xref rid="B91-molecules-30-03457" ref-type="bibr">91</xref>,<xref rid="B92-molecules-30-03457" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Chrysin (<bold>23</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">HK2, PI3K/Akt, NF-&#954;B</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2010</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Poor oral bioavailability</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B93-molecules-30-03457" ref-type="bibr">93</xref>,<xref rid="B94-molecules-30-03457" ref-type="bibr">94</xref>,<xref rid="B95-molecules-30-03457" ref-type="bibr">95</xref>,<xref rid="B96-molecules-30-03457" ref-type="bibr">96</xref>,<xref rid="B97-molecules-30-03457" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">]Piperlongumine (<bold>24</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">PI3K/Akt/mTOR e HIF-1&#945;</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Low bioavailability; poor metabolic stability</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B98-molecules-30-03457" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2-DG (<bold>25</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Glycolysis competitive inhibitor</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Phase II completed</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Systemic toxicity; metabolic compensation</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B99-molecules-30-03457" ref-type="bibr">99</xref>,<xref rid="B100-molecules-30-03457" ref-type="bibr">100</xref>,<xref rid="B101-molecules-30-03457" ref-type="bibr">101</xref>,<xref rid="B102-molecules-30-03457" ref-type="bibr">102</xref>,<xref rid="B103-molecules-30-03457" ref-type="bibr">103</xref>,<xref rid="B104-molecules-30-03457" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Benserazide (<bold>26</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">HK2, PKM2</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Off-label repositioning; neurological effects</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B113-molecules-30-03457" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Benitrobenrazide (<bold>27</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">HK2</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Advanced preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Aggregation tendency; poor ADME/Tox characterization; activity on minor HK isoenzymes</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B115-molecules-30-03457" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">(<bold>28</bold>), (<bold>29</bold>), (<bold>30</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">HK2</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Micromolar potency; incomplete selectivity</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B117-molecules-30-03457" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">3k (<bold>31</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">PKM2</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Low potency; relative selectivity; no full pharmacological development</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B126-molecules-30-03457" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">10i (<bold>32</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">PKM2</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Neuroinflammatory/ischemic application only; no published antitumor validation</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B128-molecules-30-03457" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">ML-265 (<bold>33</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">PKM2</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2012</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Advanced Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Variable cell-based potency; poor solubility; need for optimized formulation; incomplete toxicological data</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B131-molecules-30-03457" ref-type="bibr">131</xref>,<xref rid="B132-molecules-30-03457" ref-type="bibr">132</xref>,<xref rid="B133-molecules-30-03457" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Silibinin (<bold>34</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">PKM2</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2003</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Effective only at micromolar range</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B134-molecules-30-03457" ref-type="bibr">134</xref>,<xref rid="B135-molecules-30-03457" ref-type="bibr">135</xref>,<xref rid="B136-molecules-30-03457" ref-type="bibr">136</xref>,<xref rid="B137-molecules-30-03457" ref-type="bibr">137</xref>,<xref rid="B138-molecules-30-03457" ref-type="bibr">138</xref>,<xref rid="B139-molecules-30-03457" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Ellagic acid (<bold>35</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">PKM2</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">1996</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Small phase I/II studies (in combination)</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Effective only at micromolar range</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B140-molecules-30-03457" ref-type="bibr">140</xref>,<xref rid="B141-molecules-30-03457" ref-type="bibr">141</xref>,<xref rid="B142-molecules-30-03457" ref-type="bibr">142</xref>,<xref rid="B143-molecules-30-03457" ref-type="bibr">143</xref>,<xref rid="B144-molecules-30-03457" ref-type="bibr">144</xref>,<xref rid="B145-molecules-30-03457" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Curcumin (<bold>36</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">mTOR-HIF1&#945; axis</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">1990</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Phase I/II completed, few phase III studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Low bioavailability; high dosing; standardization issues</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B146-molecules-30-03457" ref-type="bibr">146</xref>,<xref rid="B147-molecules-30-03457" ref-type="bibr">147</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">Resveratrol (<bold>37</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">PI3K/Akt/mTOR, HIF1&#945;</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">1997</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">Phase I/II</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">Very low bioavailability; rapid metabolism; high doses needed</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B148-molecules-30-03457" ref-type="bibr">148</xref>,<xref rid="B149-molecules-30-03457" ref-type="bibr">149</xref>,<xref rid="B150-molecules-30-03457" ref-type="bibr">150</xref>,<xref rid="B151-molecules-30-03457" ref-type="bibr">151</xref>,<xref rid="B152-molecules-30-03457" ref-type="bibr">152</xref>]</td></tr></tbody></table></table-wrap></sec></sec><sec id="sec2dot2-molecules-30-03457"><title>2.2. Glutamine Metabolisms</title><p>Mitochondrial glutaminases GLS1 and GLS2 catalyze the deamination of glutamine to glutamate. Glutamate is then converted into &#945;-ketoglutarate by glutamate dehydrogenase, glutamic-oxaloacetic transaminase (GOT) or glutamic&#8211;pyruvic transaminase (GPT), entering the TCA cycle (<xref rid="molecules-30-03457-f006" ref-type="fig">Figure 6</xref>).</p><p>ASCT2 (also known as SLC1A5) is a major sodium-dependent transporter responsible for glutamine uptake [<xref rid="B153-molecules-30-03457" ref-type="bibr">153</xref>], associated with the expression of oncogenic MYC and KRAS signaling and playing a role in many clinically relevant tumors [<xref rid="B154-molecules-30-03457" ref-type="bibr">154</xref>,<xref rid="B155-molecules-30-03457" ref-type="bibr">155</xref>]. Benzyloxy compound V-9302 (<bold>38</bold>, <xref rid="molecules-30-03457-ch006" ref-type="fig">Chart 6</xref>, <xref rid="molecules-30-03457-t002" ref-type="table">Table 2</xref>) significantly inhibited glutamine uptake mediated by the human ASCT2 isoform in HEK293 cells (IC<sub>50</sub> = 9.6 &#956;M) [<xref rid="B153-molecules-30-03457" ref-type="bibr">153</xref>]. However, ASCT2 deletion in two human cancer cell lines did not abolish the cell growth inhibition by compound <bold>38</bold> or other ASCT2 inhibitors belonging to the same 2-amino-4-bis(aryloxybenzyl) aminobutanoic acid (AABA) class. AABA compounds inhibited glutamine transport even in ASCT2-deficient cells, but not in parental cells. Deletion of ASCT2 prompted the upregulation of SNAT2, another glutamine transporter, which was also inhibited by AABA compounds. Additionally, AABAs inhibited isoleucine uptake via LAT1, a transporter co-upregulated with ASCT2 in cancer cells [<xref rid="B156-molecules-30-03457" ref-type="bibr">156</xref>], and essential for tumorigenesis in a KRAS-mutant model of CRC [<xref rid="B157-molecules-30-03457" ref-type="bibr">157</xref>].</p><p>JPH203 (<bold>39</bold>) is anticancer drug targeting L-type amino acid transporter 1 (LAT1, also known as SLC7A5), which plays a primary role in the uptake of essential amino acids in tumor cells. It inhibits LAT1, with an IC<sub>50</sub> value of 193 &#177; 50 nM. Compound <bold>39</bold> inhibits the uptake of branched-chain amino acids, including glutamine. Treatment of LAT1-positive HT-29 colon cancer cells with (<bold>39</bold>) resulted in a time-dependent reduction in leucine uptake activity. Its inhibitory effect on LAT1 was enhanced by preincubation, suggesting a synergistic mechanism when combined with co-incubation [<xref rid="B158-molecules-30-03457" ref-type="bibr">158</xref>].</p><p>6-Diazo-5-oxo-norleucine (DON, <bold>40</bold>) is a glutamine antagonist originally isolated from the fermentation broth of a Streptomyces in the 1950s [<xref rid="B159-molecules-30-03457" ref-type="bibr">159</xref>]. It inhibits several glutamine-utilizing enzymes by a two-step, mechanism-based inhibition [<xref rid="B160-molecules-30-03457" ref-type="bibr">160</xref>,<xref rid="B161-molecules-30-03457" ref-type="bibr">161</xref>]. Despite its broad enzymatic inhibition, compound <bold>40</bold> showed weak efficacy in vitro and poor tolerability in vivo [<xref rid="B162-molecules-30-03457" ref-type="bibr">162</xref>]. JHU-083 (<bold>41</bold>) is a dual DON prodrug developed to overcome its limitations. Simple alkyl ester-based prodrugs of (<bold>40</bold>) failed due to the formation of diazoimine byproducts. A successful strategy involved masking both the amine and carboxylate groups. The resulting prodrugs exhibited rapid metabolism in mouse plasma, with several analogs showing excellent stability in monkey and human plasma. These prodrugs achieved superior tumor cell-to-plasma ratio compared to DON [<xref rid="B163-molecules-30-03457" ref-type="bibr">163</xref>,<xref rid="B164-molecules-30-03457" ref-type="bibr">164</xref>]. The prodrug (<bold>41</bold>) inhibited cell growth and induced apoptosis in human MYC-expressing medulloblastoma cell lines. It also sensitized C57BL/6 mouse cerebellar stem and progenitor cells in a MYC-driven medulloblastoma mouse model. In immune-competent animals bearing orthotopic tumors, treatment with compound <bold>41</bold> increased survival [<xref rid="B165-molecules-30-03457" ref-type="bibr">165</xref>].</p><p>DRP-104, also known as Sirpiglenastat (<bold>42</bold>, <xref rid="molecules-30-03457-ch007" ref-type="fig">Chart 7</xref>), is another DON prodrug that is selectively bioactivated to DON within tumor by serine proteases, while it is inactivated to the M1 metabolite in gastrointestinal tissue by carboxylesterases. This strategy improved drug delivery and reduced systemic toxicity. Compound <bold>42</bold> exhibited antitumor activity similar to (<bold>40</bold>), but with significantly lower toxicity. It reduced glutamine flux into the TCA cycle and affected multiple metabolic pathways in tumor, including those related to amino acids, nucleotides and carbohydrates/TCA cycle intermediates. The combination of compound <bold>42</bold> with anti-PD-1 immunotherapy showed superior efficacy compared to monotherapies. The antitumor activity of (<bold>42</bold>) depended on CD8+ T cells, resulting in sustained immunologic memory [<xref rid="B166-molecules-30-03457" ref-type="bibr">166</xref>]. Additionally, compound <bold>42</bold> was shown to suppress KEAP1-mutant tumors frequently occurring in lung cancer by inhibiting glutamine-dependent nucleotide synthesis and promoting antitumor T cell responses [<xref rid="B167-molecules-30-03457" ref-type="bibr">167</xref>].</p><p>BPTES (bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide) (<bold>43,</bold>
<xref rid="molecules-30-03457-ch008" ref-type="fig">Chart 8</xref>) was shown to inhibit selectively the growth of glioma cells [<xref rid="B168-molecules-30-03457" ref-type="bibr">168</xref>]. Kinetic analysis indicated that BPTES is a potent uncompetitive inhibitor of GLS1, with a Ki of 0.2 &#956;M. Its structure differs significantly from that of glutamine. The kinetics of BPTES were characterized using human kidney-type glutaminase lacking the C-terminal sequence present in the KGA isoform, which is expressed in the kidney, brain, intestine and cells of the immune system, or in the GAC isoform, expressed in the heart, pancreas, placenta, lung and in many transformed cells [<xref rid="B169-molecules-30-03457" ref-type="bibr">169</xref>]. Compound <bold>43</bold> was more potent than DON but exhibited poor solubility and low bioavailability. Attempts to improve these properties through structural analogs were unsuccessful [<xref rid="B170-molecules-30-03457" ref-type="bibr">170</xref>,<xref rid="B171-molecules-30-03457" ref-type="bibr">171</xref>]. Drug resistance to GLS1-specific inhibitors, such as compound <bold>43</bold> or its analogue, CB-839 (<bold>44</bold>), also known as Teleglenstat, may be due to the compensatory activity of GLS2, suggesting the need for dual GLS1/GLS2 inhibitors.</p><p>Screening of 1280 compounds from the LOPAC<sup>1280</sup> library of pharmacologically active compounds led to the identification of ebselen (<bold>45</bold>), chelerythrine chloride (<bold>46</bold>) and (<italic toggle="yes">R</italic>)-apomorphine hydrochloride (<bold>47</bold>) as potent glutaminase inhibitors. All compounds showed time- and concentration-dependent inhibition of glutaminase activity. Compounds <bold>45</bold> and <bold>46</bold> were 5- to 10-fold, respectively, more potent against GLS1 than GLS2, with IC<sub>50</sub> values of 0.008 &#956;M and 0.1 &#956;M for <bold>45</bold> (GLS1 vs GLS2), and IC<sub>50</sub> = 0.03 &#956;M and 0.3 for <bold>46</bold> (GLS1 vs GLS2), while compound <bold>47</bold> showed similar activity against both isoforms (IC<sub>50</sub> = 0.4 &#956;M and 0.3 &#956;M). Mechanistic studies indicated non-competitive inhibition for (<bold>45</bold>) (possibly through covalent adduct formation) and competitive inhibition for (<bold>46</bold>) and (<bold>47</bold>) [<xref rid="B162-molecules-30-03457" ref-type="bibr">162</xref>]. The uncompetitive inhibition by compound <bold>45</bold> aligns with previous results [<xref rid="B172-molecules-30-03457" ref-type="bibr">172</xref>], suggesting the formation of a selenenylsulfide (&#8211;Se&#8211;S&#8211;) bond [<xref rid="B172-molecules-30-03457" ref-type="bibr">172</xref>] with cysteine residues in the active site of glutaminase [<xref rid="B173-molecules-30-03457" ref-type="bibr">173</xref>]. Both (<bold>45</bold>) and (<bold>46</bold>) may stabilize the enzyme in an inactive tetrameric configuration or disrupt tetramerization [<xref rid="B162-molecules-30-03457" ref-type="bibr">162</xref>].</p><table-wrap position="anchor" id="molecules-30-03457-t002" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-t002_Table 2</object-id><label>Table 2</label><caption><p>Compounds targeting glutamine metabolism.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Stage</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Limitation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">V-9302 (<bold>38</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">ASCT2</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Effective only at micromolar range</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B153-molecules-30-03457" ref-type="bibr">153</xref>,<xref rid="B154-molecules-30-03457" ref-type="bibr">154</xref>,<xref rid="B155-molecules-30-03457" ref-type="bibr">155</xref>,<xref rid="B156-molecules-30-03457" ref-type="bibr">156</xref>,<xref rid="B157-molecules-30-03457" ref-type="bibr">157</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">JPH203 (<bold>39</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">LAT1</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Phase I completed</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Hepatotoxicity; limited PK data</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B158-molecules-30-03457" ref-type="bibr">158</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">DON (<bold>40</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Glutamine antagonist</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">1979</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Phase I/II completed</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Weak in vitro efficacy; poo3,172&#8211;172r in vivo tolerability; severe GI toxicity</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B159-molecules-30-03457" ref-type="bibr">159</xref>,<xref rid="B160-molecules-30-03457" ref-type="bibr">160</xref>,<xref rid="B161-molecules-30-03457" ref-type="bibr">161</xref>,<xref rid="B162-molecules-30-03457" ref-type="bibr">162</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">JHU-083 (<bold>41</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Glutamine antagonist (DON prodrug)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Phase I/II</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Toxicity at high doses</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B163-molecules-30-03457" ref-type="bibr">163</xref>,<xref rid="B164-molecules-30-03457" ref-type="bibr">164</xref>,<xref rid="B165-molecules-30-03457" ref-type="bibr">165</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">DRP-104 (<bold>42</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Glutamine antagonist (DON prodrug)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Phase I/II</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Residual toxicity (GI and systemic); narrow therapeutic window; poor PK data</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B166-molecules-30-03457" ref-type="bibr">166</xref>,<xref rid="B167-molecules-30-03457" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">BPTES (<bold>43</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">GLS1</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2010</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Limited solubility and stability; micromolar activity</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B168-molecules-30-03457" ref-type="bibr">168</xref>,<xref rid="B169-molecules-30-03457" ref-type="bibr">169</xref>,<xref rid="B170-molecules-30-03457" ref-type="bibr">170</xref>,<xref rid="B171-molecules-30-03457" ref-type="bibr">171</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">CB-839 (telaglenastat) (<bold>44</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">GLS1</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2014</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Phase I completed</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Non-universal efficacy; moderate toxicity</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B170-molecules-30-03457" ref-type="bibr">170</xref>,<xref rid="B171-molecules-30-03457" ref-type="bibr">171</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">ebselen (<bold>45</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">GLS1</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Multi-target, redox reactive; off-target risk and mitochondrial toxicity</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B162-molecules-30-03457" ref-type="bibr">162</xref>,<xref rid="B172-molecules-30-03457" ref-type="bibr">172</xref>,<xref rid="B173-molecules-30-03457" ref-type="bibr">173</xref>,<xref rid="B174-molecules-30-03457" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">chelerythrine chloride (<bold>46</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">GLS1</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Significant inhibition but with off-target cytotoxic effects</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B162-molecules-30-03457" ref-type="bibr">162</xref>,<xref rid="B172-molecules-30-03457" ref-type="bibr">172</xref>,<xref rid="B173-molecules-30-03457" ref-type="bibr">173</xref>,<xref rid="B174-molecules-30-03457" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">(<italic toggle="yes">R</italic>)-apomorphine hydrochloride (<bold>47</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">GLS1, GLS2</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">Low selectivity</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B162-molecules-30-03457" ref-type="bibr">162</xref>,<xref rid="B172-molecules-30-03457" ref-type="bibr">172</xref>,<xref rid="B173-molecules-30-03457" ref-type="bibr">173</xref>,<xref rid="B174-molecules-30-03457" ref-type="bibr">174</xref>]</td></tr></tbody></table></table-wrap></sec><sec id="sec2dot3-molecules-30-03457"><title>2.3. Fatty Acid Synthesis</title><p>Lipid metabolism has attracted significant interest in cancer therapy because lipids are involved in many biochemical processes occurring in cancer initiation and progression [<xref rid="B15-molecules-30-03457" ref-type="bibr">15</xref>]. In fact, lipids which comprise a variety of biomolecules made up of fatty acids, play key roles in cancer cell growth, homeostasis, energy metabolism and as structural components of cell membrane [<xref rid="B174-molecules-30-03457" ref-type="bibr">174</xref>]. Moreover, they are involved in signal transduction cascades and can be converted into mediators of cancer development [<xref rid="B175-molecules-30-03457" ref-type="bibr">175</xref>]. During cancer cell proliferation, the rapid formation of biological membranes demands increased energy and a high rate of lipid synthesis [<xref rid="B14-molecules-30-03457" ref-type="bibr">14</xref>].</p><p><underline>MAGL</underline>. Monoacylglycerol lipase (MAGL) oversees the conversion of monoacylglycerols into free fatty acids during lipogenesis in cancer cells, often due to mutation in metabolic pathways. The MAGL overactivation in tumor calls correlates with increased aggressiveness [<xref rid="B176-molecules-30-03457" ref-type="bibr">176</xref>]. MAGL inhibition was shown to exert antitumor effects in several cancer cell lines [<xref rid="B16-molecules-30-03457" ref-type="bibr">16</xref>,<xref rid="B177-molecules-30-03457" ref-type="bibr">177</xref>]; however, the inhibition of MAGL may also cause neurodegenerative, inflammatory and metabolic side effects [<xref rid="B178-molecules-30-03457" ref-type="bibr">178</xref>] (<xref rid="molecules-30-03457-f007" ref-type="fig">Figure 7</xref>).</p><p>CAY10499 (<bold>48</bold>, <xref rid="molecules-30-03457-ch009" ref-type="fig">Chart 9</xref>, <xref rid="molecules-30-03457-t003" ref-type="table">Table 3</xref>) inhibited MAGL-mediated 4-nitrophenylacetate (4-NPA) hydrolysis, with IC<sub>50</sub> values of 0.5 &#177; 0.03 &#956;M and of 0.4 &#177; 0.04 &#956;M using 2-oleoylglycerol (2-OG) as a substrate. Preincubation with compound <bold>48</bold> strongly increased the inhibition to nanomolar IC<sub>50</sub> values, suggesting that it binds irreversibly to MAGL, even in the absence of a substrate [<xref rid="B179-molecules-30-03457" ref-type="bibr">179</xref>]. Compound <bold>48</bold> was tested against several lipases, including adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), <italic toggle="yes">sn</italic>-1-diacylglycerol lipase (DAGL), monoacylglycerol lipase, a/b-hydrolase domain 6 and carboxylesterase 1 (CES1), using recombinant human and mouse enzymes, either in cell extracts or using purified enzymes. While (<bold>48</bold>) inhibited both mouse ATGL and HSL, it showed weaker inhibition of human HSL [<xref rid="B180-molecules-30-03457" ref-type="bibr">180</xref>].</p><p>JZL184 (<bold>49</bold>), identified through activity-based protein profiling (ABPP) methods [<xref rid="B181-molecules-30-03457" ref-type="bibr">181</xref>], is a potent and selective MAGL inhibitor (IC<sub>50</sub> = 8 nM) that provides rapid and sustained MAGL blockade. In the mouse brain proteome, compound <bold>49</bold> potently and selectively inactivated MAGL and increased the 2-arachidonoylglycerol level (2-AG) in male C57Bl/6 mice [<xref rid="B182-molecules-30-03457" ref-type="bibr">182</xref>]. It has been proposed for use in treating bone diseases associated with primary bone cancer and bone metastasis; however, activation of the skeletal endocannabinoid system may limit its osteoprotective potential [<xref rid="B183-molecules-30-03457" ref-type="bibr">183</xref>]. In osteoblasts, treatment with (<bold>49</bold>) in the presence of multiple myeloma (MM) cell-derived factors reduced osteoblast proliferation, though not their maturation or bone nodule formation. In an in vivo assay, compound <bold>49</bold> caused moderate but significant bone loss in the long bones of immunocompetent mice inoculated with 5TGM1 MM cells [<xref rid="B184-molecules-30-03457" ref-type="bibr">184</xref>].</p><p>JJKK-048 (<bold>50</bold>) was discovered by combining the bulky benzhydryl group of (<bold>49</bold>), required for selectivity, with a triazole leaving group, leading to a potent human and rodent MAGL inhibitor, with IC<sub>50</sub> &lt; 0.4 nM. It likely targets the catalytic serine residue (S122) of MAGL, forming an irreversible covalent bond. In HEK293 cells transiently overexpressing human MAGL (hMAGL), compound <bold>50</bold> inhibited 2-AG hydrolysis in a dose-dependent manner at nanomolar concentrations [<xref rid="B185-molecules-30-03457" ref-type="bibr">185</xref>]. MAGL could promote hepatocellular carcinoma (HCC) progression via epithelial&#8211;mesenchymal transition (EMT), suggesting its role as a biomarker and potential therapeutic target [<xref rid="B186-molecules-30-03457" ref-type="bibr">186</xref>]. Hypoxia-induced resistance to the multi-kinase inhibitor regorafenib, mediated by ABCG2 overexpression, was reduced by MAGL inhibition. Compound <bold>50</bold> lowered ABCG2 overexpression in MDA-MB-231 cells, enhanced regorafenib accumulation and improved its therapeutic response [<xref rid="B187-molecules-30-03457" ref-type="bibr">187</xref>].</p><p>JNJ-42226314 (<bold>51</bold>) is a reversible and highly selective MAGL inhibitor (IC<sub>50</sub> = 1.1 nM) via a competitive mechanism with respect to the 2-AG substrate. In in vivo studies, it produced antinociceptive effects in both inflammatory and neuropathic pain models. At 30 mg/kg, it induced hippocampal synaptic depression, altered sleep onset and decreased electroencephalogram gamma power. However, at 3 mg/kg, it still achieved approximately 80% enzyme occupancy, increased 2-AG and norepinephrine levels, and maintained antinociceptive activity without cognitive impairment [<xref rid="B188-molecules-30-03457" ref-type="bibr">188</xref>].</p><p><underline>FAS</underline>. Fatty acid synthase (FAS, FASN), encoded in humans by the <italic toggle="yes">FASN</italic> gene, is a key enzyme in the endogenous lipogenesis. It catalyzes the synthesis of palmitate from acetyl-CoA and malonyl-CoA using NADPH as a reducing agent [<xref rid="B189-molecules-30-03457" ref-type="bibr">189</xref>].</p><p>GSK2194069 (<bold>52</bold>), developed at GSK, is a potent hFAS inhibitor, with an IC<sub>50</sub> of 7.7 &#177; 4.1 nM (CoA-release assay) and 29 &#177; 3.2 nM (acetoacetyl-CoA assay) [<xref rid="B190-molecules-30-03457" ref-type="bibr">190</xref>]. It showed little or no inhibition with b-hydroxybutyryl-CoA and crotonyl-CoA and did not inhibit the b-ketoacyl reductase (KR) domain. In gastric and non-small-cell lung cancer cell lines, compound <bold>52</bold> reduced de novo fatty acid synthesis. In the A549 non-small-cell lung cancer cell line, (<bold>52</bold>) also decreased phosphatidylcholine levels, with an EC<sub>50</sub> of 15.5 &#177; 9 nM, correlating with reduced palmitate production. A crystal structure of compound <bold>52</bold> in the KR domain has been reported [<xref rid="B191-molecules-30-03457" ref-type="bibr">191</xref>].</p><p>TVB-3166 (<bold>53</bold>) was reported as a FASN inhibitor (IC<sub>50</sub> = 42 nM) with antitumor effects and potential clinical relevance. It showed inhibition in oral squamous cell carcinoma (OSCC) SCC-9 ZsG and metastatic LN-1A cells. Compound <bold>53</bold> significantly reduced cell viability and proliferation, promoted cell cycle arrest and apoptosis, increased adhesion to myogel in both OSCC cell lines and reduced cell migration [<xref rid="B192-molecules-30-03457" ref-type="bibr">192</xref>].</p><p>TVB-2640 (<bold>54</bold>) is a selective, potent, reversible FASN inhibitor (IC<sub>50</sub> = 52 nM) evaluated for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) correlated with elevated hepatic de novo lipogenesis [<xref rid="B193-molecules-30-03457" ref-type="bibr">193</xref>]. In the randomized clinical trial n. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03938246">NCT03938246</ext-link>, ninety-nine patients received placebo or 25 mg or 50 mg of the drug (orally, once-daily for 12 weeks); compound <bold>54</bold> significantly reduced liver fat and improved biochemical, inflammatory and fibrotic biomarkers in a dose-dependent manner in patients with nonalcoholic steatohepatitis [<xref rid="B194-molecules-30-03457" ref-type="bibr">194</xref>].</p><p>IPI-9119 (<bold>55</bold>) is an irreversible FASN inhibitor (IC<sub>50</sub> of 0.3 nM) that acylates the thiesterase catalytic domain serine. It selectively inhibited the human purified FASN with negligible off-target effects and suppressed castration-resistant prostate cancer (CRPC) growth by reducing protein expression and transcriptional activity of both the full-length androgen receptor (AR) and the constitutively active AR variant V7 (AR-V7). In vivo, compound <bold>55</bold> inhibited AR-V7-driven CRPC xenografts and human metastatic CRPC-derived organoids and enhanced the efficacy of the androgen receptor inhibitor enzalutamide in CRPC cells [<xref rid="B195-molecules-30-03457" ref-type="bibr">195</xref>].</p><p><underline>ACLY</underline>. Human ATP citrate lyase (ACLY) is a cytosolic enzyme catalyzing the Mg-ATP-dependent conversion of citrate and CoA into acetyl-CoA and oxaloacetate [<xref rid="B196-molecules-30-03457" ref-type="bibr">196</xref>]. In mammalian cells, it is mainly localized in the cytosol bound to endoplasmic reticulum, but was also found in the nucleus of human glioblastoma and colon carcinoma cells [<xref rid="B197-molecules-30-03457" ref-type="bibr">197</xref>]. Given its central role in lipogenesis, ACLY is a promising target for the treatment of hyperlipidemia and hypercholesterolemia [<xref rid="B198-molecules-30-03457" ref-type="bibr">198</xref>,<xref rid="B199-molecules-30-03457" ref-type="bibr">199</xref>]. In cancer cells, ACLY plays a role between the glucose and lipid metabolism, two main metabolic alterations typical of tumors, being at the same time at the end of the glycolytic cascade and at the starting point of lipid synthesis. ACLY was shown to be a potential anticancer therapeutic target, since its inhibition interferes with both the glucose metabolism and lipid synthesis [<xref rid="B198-molecules-30-03457" ref-type="bibr">198</xref>].</p><p>(&#8211;)-Hydroxycitric acid (<bold>56</bold>, <xref rid="molecules-30-03457-ch010" ref-type="fig">Chart 10</xref>) is a naturally competitive ACLY inhibitor, with a Ki value of 300 &#956;M. In mice implanted with syngeneic cancer cells, LL/2 Lewis lung carcinoma or MBT-2 murine bladder cancer cells, the triple combination (<bold>56</bold>) + lipoic acid + cisplatin or methotrexate showed enhanced antitumor efficacy [<xref rid="B200-molecules-30-03457" ref-type="bibr">200</xref>].</p><p>NDI-091143 (<bold>57</bold>) was identified as part of a research project aimed at developing a class of 2-hydroxy-N-arylbenzensulfonamides as ACLY inhibitors. Compound <bold>57</bold> showed nanomolar inhibition of human ACLY, with IC<sub>50</sub> values in the range of 2.1&#8211;4.8 nM, depending on the enzymatic assay, and proved to be competitive with the substrate, citrate [<xref rid="B201-molecules-30-03457" ref-type="bibr">201</xref>,<xref rid="B202-molecules-30-03457" ref-type="bibr">202</xref>,<xref rid="B203-molecules-30-03457" ref-type="bibr">203</xref>]. Cryo-electron microscopy revealed an unexpected mechanism of inhibition: compound <bold>57</bold> binds to an allosteric hydrophobic pocket adjacent to the citrate-binding site, inducing extensive conformational changes in the enzyme that indirectly disrupt citrate binding [<xref rid="B201-molecules-30-03457" ref-type="bibr">201</xref>].</p><p>SC2193 (<bold>58</bold>), 2-chloro-1, 3, 8-trihydroxy-6-methyl-9-anthrone, is another naturally occurring anthrone derivative extracted from a soil fungus. The compound showed an IC<sub>50</sub> of 283 nM in the primary assay and, more specifically, a Ki of &lt;100 nM against Mg citrate. It demonstrated specific and competitive inhibition of ACL with respect to the substrate Mg citrate and mixed non-competitive inhibition with respect to the essential cofactor Mg-ATP and CoA [<xref rid="B204-molecules-30-03457" ref-type="bibr">204</xref>].</p><p>10,11-Dehydrocurvularin (DCV, <bold>59</bold>) is a fungal-derived natural macrolide lactone of dihydroxyphenylacetic acid, identified via chemical proteomics in living Jurkat cells (IC<sub>50</sub> = 0.93 &#181;M). It has demonstrated potential anti-infective, anticancer and immune-modulatory activities [<xref rid="B205-molecules-30-03457" ref-type="bibr">205</xref>]. Compound <bold>59</bold> acts as an irreversible inhibitor of ACLY through its &#945;,&#946;-unsaturated carbonyl group, which serves as a Michael acceptor for the alkylation of cysteine-thiol groups in the protein. DCV showed strong antineoplastic activity by inhibiting acute T-lymphocyte leukemia Jurkat cells, as well as HCT116 colorectal carcinoma cells and HeLa cervical adenocarcinoma cells [<xref rid="B206-molecules-30-03457" ref-type="bibr">206</xref>].</p><p><underline>ACC</underline>. Acetyl-CoA carboxylase (ACC) is a biotin-dependent multidomain enzyme that catalyzes the conversion of acetyl-CoA to malonyl-CoA, a critical precursor for fatty acid synthesis via FAS [<xref rid="B207-molecules-30-03457" ref-type="bibr">207</xref>]. Two main ACC isoforms have been reported in mammals: ACC1, which is primarily found in the cytosol of liver, adipose tissue and lactating mammary gland, and ACC2, which is commonly located in the outer mitochondrial membrane of oxidative tissues such as skeletal muscle, the heart and the metabolically active liver [<xref rid="B14-molecules-30-03457" ref-type="bibr">14</xref>]. ACC1 was found to be upregulated in several types of cancer [<xref rid="B208-molecules-30-03457" ref-type="bibr">208</xref>], while ACC2 functions as a key regulator of fatty acid &#946;-oxidation [<xref rid="B209-molecules-30-03457" ref-type="bibr">209</xref>].</p><p>MK-4074 (<bold>60</bold>) is a liver-specific, strong dual inhibitor of ACC1 and ACC2, with IC<sub>50</sub> values around 3 nM. It effectively suppressed de novo lipogenesis (DNL) and enhanced hepatic fatty acid oxidation (FAO) in cultured hepatocytes, preclinical animal models and clinical studies. Its hepatoselectivity is attributed to its function as a substrate for organic anion transporting polypeptide (OATP) transporters, which are expressed exclusively in hepatocytes. In Phase 1 human studies, conducted in healthy individuals, multiple-dose administration of (<bold>60</bold>) (140 mg, 7 days) led to maximal DNL inhibition. In a separate short-term study evaluating hepatic steatosis, a 4-week treatment with compound <bold>60</bold> resulted in a 36% reduction in hepatic fat content, compared to an 18% reduction observed with pioglitazone [<xref rid="B210-molecules-30-03457" ref-type="bibr">210</xref>].</p><p>OLE (<bold>61</bold>) was developed by replacing the alkyne unit with an olefin linker and modifying the aryl group at the central and left portions of Abbot compound A-908292. Compound <bold>61</bold> exhibited high hACC2 selectivity, with an IC<sub>50</sub> of 1.9 nM, compared to an IC<sub>50</sub> of 1950 nM for hACC1. These results were confirmed by in vivo studies, in which (<bold>61</bold>) was effective in C57BL/6 mice and showed no adverse cardiac effects or clinical signs in rats treated orally at 50 mg/kg/day for 4 days [<xref rid="B211-molecules-30-03457" ref-type="bibr">211</xref>].</p><p>BOX (<bold>62</bold>) was discovered in a medicinal chemistry campaign aimed at reducing the undesirable body weight effects associated with a previous hit compound. Substitution of the acetamide group with an ureido moiety led to compound <bold>62,</bold> which exhibited improved selectivity for mouse ACC1 over ACC2, with IC<sub>50</sub> values of 1.5 nM and 140 nM, respectively, and favorable PK in mice. Oral administration significantly reduced the malonyl-CoA concentration in <underline>HCT</underline>-116 xenograft tumors at doses exceeding 30 mg/kg. Furthermore, compound <bold>62</bold> showed significant antitumor efficacy in 786-O xenograft mice at an oral dose of 30 mg/kg [<xref rid="B212-molecules-30-03457" ref-type="bibr">212</xref>].</p><p>ND-630 (<bold>63</bold>) is a potent allosteric ACC inhibitor discovered through structure-based drug design. It binds within the phosphopeptide acceptor and dimerization domain of ACC, thereby preventing dimerization and inhibiting the enzymatic activity of both ACC1 and ACC2 (IC<sub>50</sub> = 2.1 nM and 6.1 nM). Compound <bold>63</bold> reduced fatty acid synthesis and promoted fatty acid oxidation in both cell cultures and animal models, displaying favorable drug-like properties. Chronic administration to diet-induced obese rats reduced hepatic steatosis, improved insulin sensitivity, decreased weight gain without affecting food intake and favorably affected dyslipidemia. In chronically treated Zucker diabetic fatty rats, (<bold>63</bold>) also reduced hepatic steatosis, enhanced glucose-stimulated insulin secretion and lowered hemoglobin A1c by 0.9% [<xref rid="B213-molecules-30-03457" ref-type="bibr">213</xref>].</p><table-wrap position="anchor" id="molecules-30-03457-t003" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-t003_Table 3</object-id><label>Table 3</label><caption><p>Compounds targeting fatty acid synthesis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Stage</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">Limitation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#007C7C" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">CAY10499 (<bold>48</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">MAGL</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2008</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Potential toxicity from normal lipid metabolism (liver, heart); poorly characterized bioavailability/toxicity; endocannabinoid accumulation</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B180-molecules-30-03457" ref-type="bibr">180</xref>,<xref rid="B181-molecules-30-03457" ref-type="bibr">181</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">JZL184 (<bold>49</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">MAGL</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2009</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Off-target effects at high doses; poorly characterized bioavailability/toxicity; endocannabinoid accumulation</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B182-molecules-30-03457" ref-type="bibr">182</xref>,<xref rid="B183-molecules-30-03457" ref-type="bibr">183</xref>,<xref rid="B184-molecules-30-03457" ref-type="bibr">184</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">JJKK-048 (<bold>50</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">MAGL</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Off-target effects at high doses; poorly characterized bioavailability/toxicity; endocannabinoid accumulation</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B186-molecules-30-03457" ref-type="bibr">186</xref>,<xref rid="B187-molecules-30-03457" ref-type="bibr">187</xref>,<xref rid="B188-molecules-30-03457" ref-type="bibr">188</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">JNJ-42226314 (<bold>51</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">MAGL</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Endocannabinoid accumulation</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B189-molecules-30-03457" ref-type="bibr">189</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">GSK2194069 (<bold>52</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">FASN</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Limited oral bioavailability; metabolic and lipid side effects</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B191-molecules-30-03457" ref-type="bibr">191</xref>,<xref rid="B192-molecules-30-03457" ref-type="bibr">192</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">TVB-3166 (<bold>53</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">FASN</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Advanced preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Metabolic and lipid side effects</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B193-molecules-30-03457" ref-type="bibr">193</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">TVB-2640 (<bold>54</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">FASN</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Risk of long-term resistance</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B194-molecules-30-03457" ref-type="bibr">194</xref>,<xref rid="B195-molecules-30-03457" ref-type="bibr">195</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">IPI-9119 (<bold>55</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">FASN</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Irreversible inhibitor</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B196-molecules-30-03457" ref-type="bibr">196</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">(&#8211;)-Hydroxycitric acid (<bold>56</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">ACLY</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2012</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Low bioavailability</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B201-molecules-30-03457" ref-type="bibr">201</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">NDI-091143 (<bold>57</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">ACLY</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">No PK studies; limited toxicity data</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B202-molecules-30-03457" ref-type="bibr">202</xref>,<xref rid="B203-molecules-30-03457" ref-type="bibr">203</xref>,<xref rid="B204-molecules-30-03457" ref-type="bibr">204</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">SC2193 (<bold>58</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">ACLY</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">No PK studies; limited toxicity data</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B205-molecules-30-03457" ref-type="bibr">205</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">10,11-Dehydrocurvularin, DCV (<bold>59</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">ACLY</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Poorly defined toxicity; instability; multi-target activity</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B206-molecules-30-03457" ref-type="bibr">206</xref>,<xref rid="B207-molecules-30-03457" ref-type="bibr">207</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">MK-4074 (<bold>60</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">ACC1, ACC2</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">No PK studies; limited toxicity data</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B211-molecules-30-03457" ref-type="bibr">211</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">OLE (<bold>61</bold>)</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">hACC2</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">No PK studies; limited toxicity data</td><td align="center" valign="middle" style="background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B212-molecules-30-03457" ref-type="bibr">212</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">BOX (<bold>62</bold>)</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">ACC1</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">No PK studies; limited toxicity data</td><td align="center" valign="middle" style="background:#CCE5E5" rowspan="1" colspan="1">[<xref rid="B213-molecules-30-03457" ref-type="bibr">213</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F8F8" rowspan="1" colspan="1">ND-630 (<bold>63</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F8F8" rowspan="1" colspan="1">ACC1, ACC2</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F8F8" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F8F8" rowspan="1" colspan="1">Preclinical studies</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2F8F8" rowspan="1" colspan="1">No PK studies; limited toxicity data</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F2F8F8" rowspan="1" colspan="1">[<xref rid="B214-molecules-30-03457" ref-type="bibr">214</xref>]</td></tr></tbody></table></table-wrap></sec><sec id="sec2dot4-molecules-30-03457"><title>2.4. Structural Considerations of Metabolic Targets</title><p>Recent structural studies of key metabolic enzymes targeted by small-molecule inhibitors have provided crucial insights into the binding and mechanisms of these potential antitumor compounds. These enzymes, often featuring conserved catalytic cores or allosteric regulatory domains, present well-defined pockets suitable for selective targeting.</p><p>For example, LDHA contains a highly conserved catalytic site, where residues such as Arg168, His192 and Asp165 play a critical role in pyruvate binding and NADH-mediated reduction to lactate. Co-crystal structures of LDHA-inhibitor complexes, such as TODP (<bold>5</bold>), highlight direct interactions with these residues, explaining the observed potency and selectivity [<xref rid="B42-molecules-30-03457" ref-type="bibr">42</xref>].</p><p>Similarly, in HK2, both the glucose and ATP-binding pockets are critical for enzymatic function. The interaction with VDAC1 at the mitochondrial membrane allows coupling with ATP synthesis. Structural models (e.g., PDB ID: 2NZT) demonstrate how small molecules and G6P-mimicking inhibitors, such as compounds <bold>28&#8211;30</bold>, exploit the enzyme&#8217;s flexible domain architecture [<xref rid="B78-molecules-30-03457" ref-type="bibr">78</xref>]. This structural flexibility, particularly in the G6P allosteric site, enables the rational design of compounds that either compete with endogenous ligands or prevent conformational transitions required for activity.</p><p>GLUT1, a transmembrane transporter, has a central channel composed of helical bundles that accommodate glucose transport. Inhibitors such as STF-31 (<bold>12</bold>) and BAY-876 (<bold>18</bold>) bind within this channel, occluding glucose passage. Docking studies of GLUT1 analogs have highlighted roles for residues such as Phe 379 and Trp 388 in ligand binding [<xref rid="B214-molecules-30-03457" ref-type="bibr">214</xref>].</p><p>Moreover, PKM2 represents another well-studied target, featuring both an active site and a regulatory allosteric pocket. The glycolytic flux can be modulated by allosteric activators (ML-265, <bold>33</bold>) or inhibitors such as (<bold>31</bold>), (<bold>32</bold>) or natural compounds (silibinin <bold>34</bold> and curcumin <bold>36</bold>), which can stabilize either the active tetrameric or inactive dimeric forms. Residues such as Arg399 have been implicated in conformational switching, particularly in the transition between inactive and active states, and are frequently involved in ligand binding [<xref rid="B215-molecules-30-03457" ref-type="bibr">215</xref>].</p><p>Regarding FASN, crystal structures have resolved several domains, including the &#946;-ketoacyl synthase and thioesterase domains, which are responsible for palmitate synthesis. Compounds such as TVB-2640 (<bold>54</bold>) bind selectively to the &#946;-ketoacyl reductase domain, interacting with key catalytic residues, thereby disrupting lipid biosynthesis [<xref rid="B216-molecules-30-03457" ref-type="bibr">216</xref>].</p><p>These structural insights guide the rational design of potent, selective inhibitors by targeting specific enzyme conformations or domains to overcome drug resistance and improve therapy. They also explain variations in compound efficacy across isoforms and tumor types, while the distinction between orthosteric and allosteric inhibition highlights the versatility of these targets and the opportunities to fine-tune therapeutic responses through domain-specific modulation.</p></sec></sec><sec id="sec3-molecules-30-03457"><title>3. Perspectives and Emerging Strategies in Tumor Metabolism</title><sec id="sec3dot1-molecules-30-03457"><title>3.1. Metabolic Crosstalk and Compensatory Mechanisms</title><p>Numerous recent studies have highlighted how altered metabolic pathways in cancer do not operate in isolation but are highly interconnected and subject to functional compensation. This dynamic network, commonly referred to as <italic toggle="yes">metabolic crosstalk</italic>, presents a significant challenge to the efficacy of targeted metabolic therapies, yet also opens new avenues for more rational combinatorial strategies.</p><p>In particular, the inhibition of a single metabolic pathway often induces the compensatory activation of alternative routes. For example, glutaminase (GLS) inhibition has been shown to result in increased utilization of glucose and fatty acids, which can be metabolized through glycolysis or &#946;-oxidation to support ATP production and the synthesis of biosynthetic intermediates. Furthermore, in certain cancer contexts, blockade of glutaminolysis has been associated with the reactivation of mitochondrial oxidative phosphorilation (OXPHOS), contributing to therapeutic resistance [<xref rid="B217-molecules-30-03457" ref-type="bibr">217</xref>].</p><p>A promising strategy to overcome such compensations is the use of combination therapies. One notable example is AZD3965 (<bold>11</bold>), an inhibitor of the lactate transporter MCT1, which has been shown to enhance the activity of glutaminase inhibitors. This synergistic effect stems from the simultaneous inhibition of lactate efflux and glutamine metabolism, leading to redox collapse and suppression of tumor proliferation [<xref rid="B218-molecules-30-03457" ref-type="bibr">218</xref>].</p><p>Similarly, inhibition of LDH-A, a key glycolysis enzyme, can be circumvented by cancer cells via enhancement of OXPHOS. In preclinical models of pancreatic cancer, treatment with GNE-140 (<bold>3</bold>), a potent LDH-A inhibitor, resulted in mitochondrial compensation, mediated by the activation of the AMPK-mTOR-S6K pathway. The combination of GNE-140 with phenformin (<bold>4</bold>), an OXPHOS inhibitor, successfully overcame metabolic resistance and restored treatment sensitivity [<xref rid="B219-molecules-30-03457" ref-type="bibr">219</xref>].</p><p>The accumulation of metabolic intermediates from compensatory pathways can also contribute to the epigenetic modification of the tumor genome, with direct effects on gene expression and cancer progression. For instance, intracellular lactate levels can influence histone lactylation (HKla), an epigenetic mark recently associated with the regulation of pro-inflammatory and pro-tumor genes [<xref rid="B220-molecules-30-03457" ref-type="bibr">220</xref>]. Thus, modulating metabolic crosstalk may also have significant epigenetic implications.</p><p>Overall, the expanding knowledge of tumor metabolic networks requires a paradigm shift: from single-target interventions to multi-target strategies capable of simultaneously inhibiting critical metabolic nodes and adaptive pathways. The identification and characterization of these adaptive circuits are increasingly facilitated by integrated metabolomics techniques, CRISPR-based screening systems and network modeling.</p></sec><sec id="sec3dot2-molecules-30-03457"><title>3.2. Emerging Technologies: PROTACs and Targeted Degradation of Metabolic Proteins</title><p>An area of growing interest in anticancer therapy is targeted protein degradation through technologies such as PROTACs (PROteolysis Targeting Chimeras). These bifunctional molecules promote the selective degradation of target proteins by recruiting specific E3 ligases, leading to polyubiquitination and subsequent proteasomal degradation.</p><p>Compared to traditional inhibitors, PROTACs offer several advantages: they act catalytically, require lower concentrations and can target previously considered &#8220;undruggable&#8221; proteins. Furthermore, by eliminating the entire protein rather than merely inhibiting its active site, PROTACs reduce the likelihood of resistance driven by binding site mutations [<xref rid="B221-molecules-30-03457" ref-type="bibr">221</xref>].</p><p>Recent studies have reported promising preclinical results for PROTACs targeting metabolic enzymes such as LDH-A, PKM2 and GLS1. Some of these agents have been designed as tumor-selective pro-drugs, activated under specific enzymatic or acidic conditions present in the tumor microenvironment, thus improving selectivity for neoplastic cells [<xref rid="B222-molecules-30-03457" ref-type="bibr">222</xref>].</p><p>Other emerging technologies include AUTACs (Autophagy-Targeting Chimeras) and ATTECs (Autophagosome-Tethering Compounds), which exploit the autophagic pathway to degrade not only proteins but also organelles and metabolic aggregates. These approaches offer novel therapeutic possibilities, particularly in tumors reliant on organelles such as mitochondria or lipid droplets [<xref rid="B223-molecules-30-03457" ref-type="bibr">223</xref>].</p></sec><sec id="sec3dot3-molecules-30-03457"><title>3.3. Precision Metabolic Oncology: New Therapeutic Frontiers</title><p>The marked metabolic heterogeneity both between patients and within individual tumors presents a challenge, but also a unique opportunity, for personalized therapy. The integration of high-resolution metabolomics, multi-omics profiling and technologies such as single-cell RNA sequencing enables the identification of tumor-specific metabolic signatures and the prediction of drug responses.</p><p>A prominent example is DRP-104 (<bold>42</bold>), a prodrug derived from DON (<bold>40</bold>), which is selectively activated in the tumor microenvironment. Compound <bold>42</bold> has demonstrated not only direct antitumor effects but also the ability to enhance antitumor immunity, acting synergistically with anti-PD-1 antibodies in mouse models [<xref rid="B224-molecules-30-03457" ref-type="bibr">224</xref>].</p><p>These findings suggest that metabolic modulation not only affects the intrinsic characteristics of tumor cells but can also reshape the tumor microenvironment, providing valuable support for immunotherapeutic strategies.</p></sec><sec id="sec3dot4-molecules-30-03457"><title>3.4. Concluding Remark</title><p>The identification of redundant metabolic pathways and crosstalk circuits, coupled with the advent of emerging technologies, such as PROTACs and targeted degradation platforms, is revolutionizing the landscape of metabolic cancer therapy. The future of the field lies in the integration of rational combinatorial approaches, grounded in a robust understanding of adaptive mechanisms and systems biology. In this context, precision metabolic medicine is no longer a distant goal, but a tangible and achievable reality.</p></sec></sec><sec id="sec4-molecules-30-03457"><title>4. Summary and Conclusions</title><p>Over the past decades, cancer metabolism has emerged as a promising and rapidly expanding field for the development of novel anticancer strategies. The reprogramming of metabolic pathways, long recognized as a hallmark of cancer, provides malignant cells with the necessary biochemical resources to support uncontrolled proliferation, resistance to apoptosis, immune evasion and metastasis. This review has highlighted recent advances in the identification and characterization of small-molecule inhibitors targeting key metabolic enzymes involved in glycolysis, glutaminolysis and fatty acid synthesis&#8212;processes that are consistently upregulated in various tumor types.</p><p>By targeting enzymes such as LDHA, GLUT1, HK2, PKM2, GLS1/2, FASN, ACLY and ACC, researchers have demonstrated the feasibility of disrupting tumor bioenergetics and biosynthetic machinery. Notably, several of these compounds, including BAY-876 (<bold>18</bold>), ML-265 (<bold>33</bold>), TVB-2640 (<bold>54</bold>) and DRP-104 (<bold>42</bold>), have progressed to preclinical or clinical stages, underscoring the translational potential of metabolism-targeting therapies. Additionally, the structural and mechanistic diversity of these inhibitors, including orthosteric, allosteric, covalent and substrate-mimicking strategies, offers new avenues for specificity and reduced off-target effects.</p><p>Moreover, the therapeutic relevance of metabolic modulation extends beyond tumor cell-intrinsic effects. Compounds such as (<bold>42</bold>) and MAGL inhibitors have demonstrated the ability to reshape the tumor microenvironment and potentiate antitumor immune responses. This aligns with a broader shift toward combinatorial approaches that integrate metabolic inhibitors with immunotherapies, chemotherapeutic agents, or targeted drugs.</p><p>Nevertheless, several challenges remain. Tumor heterogeneity, metabolic plasticity, and compensatory pathways can undermine the efficacy of single-agent treatments. The development of reliable metabolic biomarkers, patient stratification strategies and predictive models of response will be crucial to guide clinical application. Furthermore, a deeper understanding of the systemic effects and potential toxicities associated with long-term metabolic inhibition is needed.</p><p>Recent insights into metabolic crosstalk and compensatory mechanisms have further highlighted the need for multi-targeted and context-specific approaches. The emergence of targeted protein degradation technologies, such as PROTACs, and advances in metabolomic profiling are paving the way for precision oncology strategies that exploit tumor-specific metabolic vulnerabilities.</p><p>In conclusion, targeting tumor metabolism represents a compelling and versatile approach in the anticancer drug discovery landscape. Continued interdisciplinary efforts combining medicinal chemistry, structural biology, cancer biology and translational research will be key to unlocking the full therapeutic potential of metabolic interventions and delivering innovative treatments to patients with high unmet medical needs.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Investigation, M.P.; writing&#8212;review and editing, M.P.; writing&#8212;original draft preparation, R.S. and G.L.R.; supervision, R.S. and G.L.R. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">AAT</td><td align="left" valign="middle" rowspan="1" colspan="1">aspartate aminotransferase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACC</td><td align="left" valign="middle" rowspan="1" colspan="1">acetyl-coa carboxylase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACLY</td><td align="left" valign="middle" rowspan="1" colspan="1">human atp citrate lyase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AIF</td><td align="left" valign="middle" rowspan="1" colspan="1">apoptosis-inducing factor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ASCT2</td><td align="left" valign="middle" rowspan="1" colspan="1">alanine, serine, cysteine transporter 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ATP</td><td align="left" valign="middle" rowspan="1" colspan="1">adenosine triphosphate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BBB</td><td align="left" valign="middle" rowspan="1" colspan="1">blood&#8211;brain barrier</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDKs</td><td align="left" valign="middle" rowspan="1" colspan="1">cyclin-dependent kinases</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRPC</td><td align="left" valign="middle" rowspan="1" colspan="1">castration-resistant prostate cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DLBCL</td><td align="left" valign="middle" rowspan="1" colspan="1">diffuse large b cell lymphoma</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DNMT</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA methyltransferase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ECM</td><td align="left" valign="middle" rowspan="1" colspan="1">extracellular matrix</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FADH</td><td align="left" valign="middle" rowspan="1" colspan="1">flavin adenine dinucleotide</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FAS</td><td align="left" valign="middle" rowspan="1" colspan="1">fatty acid synthase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FASN</td><td align="left" valign="middle" rowspan="1" colspan="1">fatty acid synthase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G6P</td><td align="left" valign="middle" rowspan="1" colspan="1">glucose-6-phosphate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLS1</td><td align="left" valign="middle" rowspan="1" colspan="1">glutaminase 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLUT</td><td align="left" valign="middle" rowspan="1" colspan="1">glucose transporter</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLUT1</td><td align="left" valign="middle" rowspan="1" colspan="1">glucose transporter type 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLUT1DS</td><td align="left" valign="middle" rowspan="1" colspan="1">glucose transporter type 1 deficiency syndrome</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GOT</td><td align="left" valign="middle" rowspan="1" colspan="1">glutamic-oxaloacetic transaminase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GPT</td><td align="left" valign="middle" rowspan="1" colspan="1">glutamic&#8211;pyruvic transaminase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HCC</td><td align="left" valign="middle" rowspan="1" colspan="1">hepatocellular carcinoma</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HK</td><td align="left" valign="middle" rowspan="1" colspan="1">hexokinase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HKla</td><td align="left" valign="middle" rowspan="1" colspan="1">histone lysine lactylation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HNSCC</td><td align="left" valign="middle" rowspan="1" colspan="1">head and neck squamous cell carcinoma</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LAT1</td><td align="left" valign="middle" rowspan="1" colspan="1">l-type amino acid transporter 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDH</td><td align="left" valign="middle" rowspan="1" colspan="1">lactate dehydrogenase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDHA</td><td align="left" valign="middle" rowspan="1" colspan="1">lactate dehydrogenase type a</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDHB</td><td align="left" valign="middle" rowspan="1" colspan="1">lactate dehydrogenase type b</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAGL</td><td align="left" valign="middle" rowspan="1" colspan="1">monoacylglycerol lipase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MCT1</td><td align="left" valign="middle" rowspan="1" colspan="1">monocarboxylate transporter 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NADH</td><td align="left" valign="middle" rowspan="1" colspan="1">nicotinamide adenine dinucleotide</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NHL</td><td align="left" valign="middle" rowspan="1" colspan="1">non-Hodgkin lymphomas</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">non-small-cell lung cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OMM</td><td align="left" valign="middle" rowspan="1" colspan="1">outer mitochondrial membrane</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OXPHOS</td><td align="left" valign="middle" rowspan="1" colspan="1">oxidative phosphorylation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PK</td><td align="left" valign="middle" rowspan="1" colspan="1">pyruvate kinase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PKM1</td><td align="left" valign="middle" rowspan="1" colspan="1">pyruvate kinase m1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PKM2</td><td align="left" valign="middle" rowspan="1" colspan="1">pyruvate kinase m2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RCCs</td><td align="left" valign="middle" rowspan="1" colspan="1">renal cell carcinomas</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ROS</td><td align="left" valign="middle" rowspan="1" colspan="1">reactive oxygen species</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SAR</td><td align="left" valign="middle" rowspan="1" colspan="1">structure-activity relationship</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TCA</td><td align="left" valign="middle" rowspan="1" colspan="1">tricarboxylic acid</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TMJOA</td><td align="left" valign="middle" rowspan="1" colspan="1">temporomandibular joint osteoarthritis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TNBC</td><td align="left" valign="middle" rowspan="1" colspan="1">in triple-negative breast cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VDAC</td><td align="left" valign="middle" rowspan="1" colspan="1">voltage-dependent anion channels</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VHL</td><td align="left" valign="middle" rowspan="1" colspan="1">von Hippel&#8211;Lindau</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-molecules-30-03457"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warburg</surname><given-names>O.</given-names></name></person-group><article-title>On the Origin of Cancer Cells</article-title><source>Science</source><year>1956</year><volume>123</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1126/science.123.3191.309</pub-id><pub-id pub-id-type="pmid">13298683</pub-id></element-citation></ref><ref id="B2-molecules-30-03457"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Reyes</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chandel</surname><given-names>N.S.</given-names></name></person-group><article-title>Cancer Metabolism: Looking Forward</article-title><source>Nat. Rev. Cancer</source><year>2021</year><volume>21</volume><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00378-6</pub-id><pub-id pub-id-type="pmid">34272515</pub-id></element-citation></ref><ref id="B3-molecules-30-03457"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngo</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Ververis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tortorella</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Karagiannis</surname><given-names>T.C.</given-names></name></person-group><article-title>Introduction to the Molecular Basis of Cancer Metabolism and the Warburg Effect</article-title><source>Mol. Biol. Rep.</source><year>2015</year><volume>42</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1007/s11033-015-3857-y</pub-id><pub-id pub-id-type="pmid">25672512</pub-id></element-citation></ref><ref id="B4-molecules-30-03457"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lunt</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Vander Heiden</surname><given-names>M.G.</given-names></name></person-group><article-title>Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation</article-title><source>Annu. Rev. Cell Dev. Biol.</source><year>2011</year><volume>27</volume><fpage>441</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-092910-154237</pub-id><pub-id pub-id-type="pmid">21985671</pub-id></element-citation></ref><ref id="B5-molecules-30-03457"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>C.V.</given-names></name></person-group><article-title>Cancer&#8217;s Molecular Sweet Tooth and the Warburg Effect</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>8927</fpage><lpage>8930</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1501</pub-id><pub-id pub-id-type="pmid">16982728</pub-id></element-citation></ref><ref id="B6-molecules-30-03457"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeBerardinis</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Lum</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Hatzivassiliou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C.B.</given-names></name></person-group><article-title>The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation</article-title><source>Cell Metab.</source><year>2008</year><volume>7</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.002</pub-id><pub-id pub-id-type="pmid">18177721</pub-id></element-citation></ref><ref id="B7-molecules-30-03457"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liberti</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Locasale</surname><given-names>J.W.</given-names></name></person-group><article-title>The Warburg effect: How does it benefit cancer cells?</article-title><source>Trends Biochem. Sci.</source><year>2016</year><volume>41</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2015.12.001</pub-id><pub-id pub-id-type="pmid">26778478</pub-id><pub-id pub-id-type="pmcid">PMC4783224</pub-id></element-citation></ref><ref id="B8-molecules-30-03457"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Supuran</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Alfarouk</surname><given-names>O.K.</given-names></name></person-group><article-title>The Warburg effect and the hallmarks of cancer</article-title><source>Anti-Cancer Agents Med. Chem.</source><year>2017</year><volume>17</volume><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.2174/1871520616666161031143301</pub-id><pub-id pub-id-type="pmid">27804847</pub-id></element-citation></ref><ref id="B9-molecules-30-03457"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vander Heiden</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Cantley</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C.B.</given-names></name></person-group><article-title>Understanding the Warburg effect: The metabolic requirements of cell proliferation</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id><pub-id pub-id-type="pmcid">PMC2849637</pub-id></element-citation></ref><ref id="B10-molecules-30-03457"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>R.J.</given-names></name></person-group><article-title>Glucose metabolism and cancer</article-title><source>Curr. Opin. Cell Biol.</source><year>2006</year><volume>18</volume><fpage>598</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2006.10.005</pub-id><pub-id pub-id-type="pmid">17046224</pub-id></element-citation></ref><ref id="B11-molecules-30-03457"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillies</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Robey</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gatenby</surname><given-names>R.A.</given-names></name></person-group><article-title>Causes and consequences of increased glucose metabolism of cancers</article-title><source>J. Nucl. Med.</source><year>2008</year><volume>49</volume><fpage>24S</fpage><lpage>42S</lpage><pub-id pub-id-type="doi">10.2967/jnumed.107.047258</pub-id><pub-id pub-id-type="pmid">18523064</pub-id></element-citation></ref><ref id="B12-molecules-30-03457"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Hallmarks of cancer: The next generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="B13-molecules-30-03457"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name></person-group><article-title>Hallmarks of cancer: New dimensions</article-title><source>Cancer Discov.</source><year>2022</year><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id><pub-id pub-id-type="pmid">35022204</pub-id></element-citation></ref><ref id="B14-molecules-30-03457"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Currie</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zechner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walther</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Farese</surname><given-names>R.</given-names></name></person-group><article-title>V Jr. Cellular fatty acid metabolism and cancer</article-title><source>Cell Metab.</source><year>2013</year><volume>18</volume><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.05.017</pub-id><pub-id pub-id-type="pmid">23791484</pub-id><pub-id pub-id-type="pmcid">PMC3742569</pub-id></element-citation></ref><ref id="B15-molecules-30-03457"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beloribi-Djefaflia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vasseur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guillaumond</surname><given-names>F.</given-names></name></person-group><article-title>Lipid metabolic reprogramming in cancer cells</article-title><source>Oncogenesis</source><year>2016</year><volume>5</volume><fpage>e189</fpage><pub-id pub-id-type="doi">10.1038/oncsis.2015.49</pub-id><pub-id pub-id-type="pmid">26807644</pub-id><pub-id pub-id-type="pmcid">PMC4728678</pub-id></element-citation></ref><ref id="B16-molecules-30-03457"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montesdeoca</surname><given-names>N.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ariza</surname><given-names>X.</given-names></name><name name-style="western"><surname>Herrero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Makowski</surname><given-names>K.</given-names></name></person-group><article-title>Inhibitors of lipogenic enzymes as a potential therapy against cancer</article-title><source>FASEB J.</source><year>2020</year><volume>34</volume><fpage>11355</fpage><lpage>11381</lpage><pub-id pub-id-type="doi">10.1096/fj.202000705R</pub-id><pub-id pub-id-type="pmid">32761847</pub-id></element-citation></ref><ref id="B17-molecules-30-03457"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stine</surname><given-names>Z.E.</given-names></name><name name-style="western"><surname>Schug</surname><given-names>Z.T.</given-names></name><name name-style="western"><surname>Salvino</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>C.V.</given-names></name></person-group><article-title>Targeting cancer metabolism in the era of precision oncology</article-title><source>Nat. Rev. Drug Discov.</source><year>2022</year><volume>21</volume><fpage>141</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00339-6</pub-id><pub-id pub-id-type="pmid">34862480</pub-id><pub-id pub-id-type="pmcid">PMC8641543</pub-id></element-citation></ref><ref id="B18-molecules-30-03457"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Puxeddu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>R.</given-names></name><name name-style="western"><surname>La Regina</surname><given-names>G.</given-names></name></person-group><article-title>Metabolic rewiring in cancer: Small molecule inhibitors in colorectal cancer therapy</article-title><source>Molecules</source><year>2024</year><volume>29</volume><elocation-id>2110</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29092110</pub-id><pub-id pub-id-type="pmid">38731601</pub-id><pub-id pub-id-type="pmcid">PMC11085455</pub-id></element-citation></ref><ref id="B19-molecules-30-03457"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rattigan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ackerstaff</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sukenick</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koutcher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Glod</surname><given-names>J.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>D.</given-names></name></person-group><article-title>Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and, glycolytic tumor cells in the tumor microenvironment</article-title><source>Exp. Cell Res.</source><year>2012</year><volume>318</volume><fpage>326</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2011.11.014</pub-id><pub-id pub-id-type="pmid">22178238</pub-id><pub-id pub-id-type="pmcid">PMC3402174</pub-id></element-citation></ref><ref id="B20-molecules-30-03457"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ristow</surname><given-names>M.</given-names></name></person-group><article-title>Oxidative metabolism in cancer growth</article-title><source>Curr. Opin. Clin. Nutr. Metab. Care</source><year>2006</year><volume>9</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1097/01.mco.0000232892.43921.98</pub-id><pub-id pub-id-type="pmid">16778561</pub-id></element-citation></ref><ref id="B21-molecules-30-03457"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fantin</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>St-Pierre</surname><given-names>J.</given-names></name><name name-style="western"><surname>Philip</surname><given-names>L.</given-names></name></person-group><article-title>Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance</article-title><source>Cancer Cell</source><year>2006</year><volume>9</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.04.023</pub-id><pub-id pub-id-type="pmid">16766262</pub-id></element-citation></ref><ref id="B22-molecules-30-03457"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Magno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coluccia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bufano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ripa</surname><given-names>S.</given-names></name><name name-style="western"><surname>La Regina</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nalli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Pastena</surname><given-names>F.</given-names></name><name name-style="western"><surname>Canettieri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Frati</surname><given-names>L.</given-names></name></person-group><article-title>Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment</article-title><source>Eur. J. Med. Chem.</source><year>2022</year><volume>240</volume><fpage>114605</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2022.114605</pub-id><pub-id pub-id-type="pmid">35868126</pub-id></element-citation></ref><ref id="B23-molecules-30-03457"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>P.</given-names></name><name name-style="western"><surname>You</surname><given-names>Q.</given-names></name></person-group><article-title>Development of novel human lactate dehydrogenase A inhibitors: High-throughput screening, synthesis, and biological evaluations</article-title><source>Eur. J. Med. Chem.</source><year>2019</year><volume>177</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.05.033</pub-id><pub-id pub-id-type="pmid">31129449</pub-id></element-citation></ref><ref id="B24-molecules-30-03457"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bononi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Bussolo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tuccinardi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Minutolo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Granchi</surname><given-names>C.</given-names></name></person-group><article-title>A patent review of lactate dehydrogenase inhibitors (2014&#8211;present)</article-title><source>Expert Opin. Ther. Pat.</source><year>2024</year><volume>34</volume><fpage>1121</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1080/13543776.2024.2412575</pub-id><pub-id pub-id-type="pmid">39358962</pub-id></element-citation></ref><ref id="B25-molecules-30-03457"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>K.Y.</given-names></name></person-group><article-title>Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH)5 inhibitors</article-title><source>Drug Discov. Today</source><year>2018</year><volume>23</volume><fpage>1407</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2018.05.014</pub-id><pub-id pub-id-type="pmid">29750903</pub-id></element-citation></ref><ref id="B26-molecules-30-03457"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Farhana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lappin</surname><given-names>S.L.</given-names></name></person-group><source>Biochemistry, Lactate Dehydrogenase</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2023</year><pub-id pub-id-type="pmid">32491468</pub-id></element-citation></ref><ref id="B27-molecules-30-03457"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dang</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Semenza</surname><given-names>G.L.</given-names></name></person-group><article-title>Oncogenic alterations of metabolism</article-title><source>Trends Biochem. Sci.</source><year>1999</year><volume>24</volume><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(98)01344-9</pub-id><pub-id pub-id-type="pmid">10098401</pub-id></element-citation></ref><ref id="B28-molecules-30-03457"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>H.S.</given-names></name></person-group><article-title>Natural compounds as lactate dehydrogenase inhibitors: Potential therapeutics for lactate dehydrogenase inhibitors-related diseases</article-title><source>Front. Pharmacol.</source><year>2023</year><volume>14</volume><elocation-id>1275000</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2023.1275000</pub-id><pub-id pub-id-type="pmid">37915411</pub-id><pub-id pub-id-type="pmcid">PMC10616500</pub-id></element-citation></ref><ref id="B29-molecules-30-03457"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granchi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Macchia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Minutolo</surname><given-names>F.</given-names></name></person-group><article-title>Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials</article-title><source>Curr. Med. Chem.</source><year>2010</year><volume>17</volume><fpage>672</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.2174/092986710790416263</pub-id><pub-id pub-id-type="pmid">20088761</pub-id></element-citation></ref><ref id="B30-molecules-30-03457"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thornburg</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Clem</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Telang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chesney</surname><given-names>S.J.</given-names></name></person-group><article-title>Targeting aspartate aminotransferase in breast cancer</article-title><source>Breast Cancer Res.</source><year>2008</year><volume>10</volume><fpage>R84</fpage><pub-id pub-id-type="doi">10.1186/bcr2154</pub-id><pub-id pub-id-type="pmid">18922152</pub-id><pub-id pub-id-type="pmcid">PMC2614520</pub-id></element-citation></ref><ref id="B31-molecules-30-03457"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiume</surname><given-names>L.</given-names></name><name name-style="western"><surname>Manerba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vettraino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Stefano</surname><given-names>G.</given-names></name></person-group><article-title>Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines</article-title><source>Pharmacology</source><year>2010</year><volume>86</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1159/000317519</pub-id><pub-id pub-id-type="pmid">20699632</pub-id></element-citation></ref><ref id="B32-molecules-30-03457"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nitowsky</surname><given-names>H.</given-names></name><name name-style="western"><surname>Colowick</surname><given-names>S.</given-names></name></person-group><article-title>The role of glycolysis in the growth of tumor cells The basis of glucose toxicity in oxamate-treated cultured cells</article-title><source>J. Biol. Chem.</source><year>1965</year><volume>240</volume><fpage>2791</fpage><lpage>2796</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)97248-0</pub-id><pub-id pub-id-type="pmid">14342296</pub-id></element-citation></ref><ref id="B33-molecules-30-03457"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billiard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dennison</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Briand</surname><given-names>J.</given-names></name><name name-style="western"><surname>Annan</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Colon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Greshock</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells</article-title><source>Cancer Metab.</source><year>2013</year><volume>1</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/2049-3002-1-19</pub-id><pub-id pub-id-type="pmid">24280423</pub-id><pub-id pub-id-type="pmcid">PMC4178217</pub-id></element-citation></ref><ref id="B34-molecules-30-03457"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cisewski</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H.</given-names></name></person-group><article-title>Thee ffects of oxygen level and glucose concentration on the metabolism of porcine TMJ disc cells</article-title><source>Osteoarthr. Cartil.</source><year>2015</year><volume>23</volume><fpage>1790</fpage><lpage>1796</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2015.05.021</pub-id><pub-id pub-id-type="pmcid">PMC4577453</pub-id><pub-id pub-id-type="pmid">26033165</pub-id></element-citation></ref><ref id="B35-molecules-30-03457"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Inhibition of glycolysis by targeting lactate dehydrogenase A facilitates hyaluronan synthase 2 synthesis in synovial fibroblasts of temporomandibular joint osteoarthritis</article-title><source>Bone</source><year>2020</year><volume>141</volume><fpage>115584</fpage><pub-id pub-id-type="doi">10.1016/j.bone.2020.115584</pub-id><pub-id pub-id-type="pmid">32795674</pub-id></element-citation></ref><ref id="B36-molecules-30-03457"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>N.</given-names></name><name name-style="western"><surname>De Melo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name></person-group><article-title>PKM2, a central point of regulation in cancer metabolism</article-title><source>Int. J. Cell Biol.</source><year>2013</year><volume>2013</volume><elocation-id>242513</elocation-id><pub-id pub-id-type="doi">10.1155/2013/242513</pub-id><pub-id pub-id-type="pmid">23476652</pub-id><pub-id pub-id-type="pmcid">PMC3586519</pub-id></element-citation></ref><ref id="B37-molecules-30-03457"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boudreau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Purkey</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Hitz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robarge</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Labadie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Del Nagro</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition</article-title><source>Nat. Chem. Biol.</source><year>2016</year><volume>12</volume><fpage>779</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2143</pub-id><pub-id pub-id-type="pmid">27479743</pub-id></element-citation></ref><ref id="B38-molecules-30-03457"><label>38.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Abcam</collab></person-group><article-title>Oxidative Phosphorylation Pathway</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.abcam.com/en-us/technical-resources/pathways/oxidative-phosphorylation-pathway" ext-link-type="uri">https://www.abcam.com/en-us/technical-resources/pathways/oxidative-phosphorylation-pathway</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-01">(accessed on 1 November 2024)</date-in-citation></element-citation></ref><ref id="B39-molecules-30-03457"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.L.</given-names></name></person-group><article-title>Lactate regulates pathological cardiac hypertrophy via histone lactylation modification</article-title><source>J. Cell Mol. Med.</source><year>2024</year><volume>28</volume><fpage>e70022</fpage><pub-id pub-id-type="doi">10.1111/jcmm.70022</pub-id><pub-id pub-id-type="pmid">39205384</pub-id><pub-id pub-id-type="pmcid">PMC11358213</pub-id></element-citation></ref><ref id="B40-molecules-30-03457"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>F.</given-names></name></person-group><article-title>Mechanical force modulates alveolar bone marrow mesenchymal cells characteristics for bone remodeling during orthodontic tooth movement through lactate production</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>3724</elocation-id><pub-id pub-id-type="doi">10.3390/cells11233724</pub-id><pub-id pub-id-type="pmid">36496983</pub-id><pub-id pub-id-type="pmcid">PMC9738738</pub-id></element-citation></ref><ref id="B41-molecules-30-03457"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Methylsulfonylmethane protects against lethal dose MRSA-induced sepsis through promoting M2 macrophage polarization</article-title><source>Mol. Immunol.</source><year>2022</year><volume>146</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2022.04.001</pub-id><pub-id pub-id-type="pmid">35461144</pub-id></element-citation></ref><ref id="B42-molecules-30-03457"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dragovich</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Fauber</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Corson</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C.Z.</given-names></name><name name-style="western"><surname>Eigenbrot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>H.</given-names></name><name name-style="western"><surname>Giannetti</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hunsaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Labadie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2013</year><volume>23</volume><fpage>3186</fpage><lpage>3194</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2013.04.001</pub-id><pub-id pub-id-type="pmid">23628333</pub-id></element-citation></ref><ref id="B43-molecules-30-03457"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fauber</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Dragovich</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Corson</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C.Z.</given-names></name><name name-style="western"><surname>Eigenbrot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giannetti</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hunsaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Labadie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2013</year><volume>23</volume><fpage>5533</fpage><lpage>5539</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2013.08.060</pub-id><pub-id pub-id-type="pmid">24012183</pub-id></element-citation></ref><ref id="B44-molecules-30-03457"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brimacombe</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Mott</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Cheff</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Kouznetsova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Benavides</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>9184</fpage><lpage>9204</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00941</pub-id><pub-id pub-id-type="pmid">29120638</pub-id><pub-id pub-id-type="pmcid">PMC5894102</pub-id></element-citation></ref><ref id="B45-molecules-30-03457"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Mott</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Benavides</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Squadrito</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Brimacombe</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.D.</given-names></name><etal/></person-group><article-title>Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><fpage>10984</fpage><lpage>11011</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00916</pub-id><pub-id pub-id-type="pmid">32902275</pub-id><pub-id pub-id-type="pmcid">PMC7830743</pub-id></element-citation></ref><ref id="B46-molecules-30-03457"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludwig</surname><given-names>J.A.</given-names></name></person-group><article-title>Ewing sarcoma: Historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future</article-title><source>Curr. Opin. Oncol.</source><year>2008</year><volume>20</volume><fpage>412</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1097/CCO.0b013e328303ba1d</pub-id><pub-id pub-id-type="pmid">18525337</pub-id></element-citation></ref><ref id="B47-molecules-30-03457"><label>47.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Durer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gasalberti</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>H.</given-names></name></person-group><article-title>Ewing Sarcoma</article-title><source>StatPearls [Internet]</source><publisher-name>NIH, National Library of Medicine</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK559183/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK559183/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-15">(accessed on 15 November 2024)</date-in-citation></element-citation></ref><ref id="B48-molecules-30-03457"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Issaq</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Oshima</surname><given-names>N.</given-names></name><name name-style="western"><surname>Baumgart</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Edessa</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Benavides</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Targeting Glycolysis through inhibition of lactate dehydrogenase impairs tumor growth in preclinical models of Ewing sarcoma</article-title><source>Cancer Res.</source><year>2019</year><volume>79</volume><fpage>5060</fpage><lpage>5073</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-0217</pub-id><pub-id pub-id-type="pmid">31431459</pub-id><pub-id pub-id-type="pmcid">PMC6774872</pub-id></element-citation></ref><ref id="B49-molecules-30-03457"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rehwinkel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.</given-names></name><name name-style="western"><surname>P&#252;tter</surname><given-names>V.</given-names></name><name name-style="western"><surname>Quanz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weiske</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ebersp&#228;cher</surname><given-names>U.</given-names></name><name name-style="western"><surname>Heisler</surname><given-names>I.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>G.</given-names></name></person-group><article-title>Structural Evidence for Isoform-Selective Allosteric Inhibition of Lactate Dehydrogenase A</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>13034</fpage><lpage>13041</lpage><pub-id pub-id-type="doi">10.1021/acsomega.0c00715</pub-id><pub-id pub-id-type="pmid">32548488</pub-id><pub-id pub-id-type="pmcid">PMC7288559</pub-id></element-citation></ref><ref id="B50-molecules-30-03457"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>M.</given-names></name></person-group><article-title>Subunit cooperativity in the action of lactate dehydrogenase</article-title><source>Biochim. Biophys. Acta</source><year>1972</year><volume>258</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/0005-2744(72)90963-1</pub-id><pub-id pub-id-type="pmid">5061993</pub-id></element-citation></ref><ref id="B51-molecules-30-03457"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masterson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>S.D.</given-names></name></person-group><article-title>Changes in protein architecture and subpicosecond protein dynamics impact the reaction catalyzed by lactate dehydrogenase</article-title><source>J. Phys. Chem. A</source><year>2013</year><volume>17</volume><fpage>7107</fpage><lpage>7113</lpage><pub-id pub-id-type="doi">10.1021/jp400376h</pub-id><pub-id pub-id-type="pmcid">PMC3695017</pub-id><pub-id pub-id-type="pmid">23441954</pub-id></element-citation></ref><ref id="B52-molecules-30-03457"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hopcroft</surname><given-names>L.</given-names></name><name name-style="western"><surname>Michopoulos</surname><given-names>F.</given-names></name><name name-style="western"><surname>Whalley</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>C.</given-names></name><name name-style="western"><surname>Logie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Revill</surname><given-names>M.</given-names></name><name name-style="western"><surname>Byth</surname><given-names>K.F.</given-names></name><etal/></person-group><article-title>Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt&#8217;s lymphoma anti-tumor activity</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>69219</fpage><lpage>69236</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18215</pub-id><pub-id pub-id-type="pmid">29050199</pub-id><pub-id pub-id-type="pmcid">PMC5642474</pub-id></element-citation></ref><ref id="B53-molecules-30-03457"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doherty</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Fallahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Amelio</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>908</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2034</pub-id><pub-id pub-id-type="pmid">24285728</pub-id><pub-id pub-id-type="pmcid">PMC3946415</pub-id></element-citation></ref><ref id="B54-molecules-30-03457"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beloueche-Babari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casals Galobart</surname><given-names>T.</given-names></name><name name-style="western"><surname>Delgado-Goni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wantuch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parkes</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Tandy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Harker</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>M.O.</given-names></name></person-group><article-title>Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration</article-title><source>Br. J. Cancer</source><year>2020</year><volume>122</volume><fpage>895</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1038/s41416-019-0717-x</pub-id><pub-id pub-id-type="pmid">31937921</pub-id><pub-id pub-id-type="pmcid">PMC7078321</pub-id></element-citation></ref><ref id="B55-molecules-30-03457"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halford</surname><given-names>S.</given-names></name><name name-style="western"><surname>Veal</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Wedge</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Bacon</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dragoni</surname><given-names>I.</given-names></name><name name-style="western"><surname>Heinzmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salisbury</surname><given-names>B.M.</given-names></name><etal/></person-group><article-title>A phase I dose-escalation dtudy of AZD3965, an oral Monocarboxylate Transporter 1 inhibitor, in patients with advanced cancer</article-title><source>Clin. Cancer Res.</source><year>2023</year><volume>29</volume><fpage>1429</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-2263</pub-id><pub-id pub-id-type="pmid">36652553</pub-id><pub-id pub-id-type="pmcid">PMC7614436</pub-id></element-citation></ref><ref id="B56-molecules-30-03457"><label>56.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Landowski</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hediger</surname><given-names>M.A.</given-names></name></person-group><article-title>The Mammalian Transporter Families</article-title><source>Seldin and Giebisch&#8217;s The Kidney: Physiology and Pathophysiology</source><edition>4th ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Alpern</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Hebert</surname><given-names>S.C.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2008</year><fpage>91</fpage><lpage>146</lpage></element-citation></ref><ref id="B57-molecules-30-03457"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueckler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Panico</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blench</surname><given-names>I.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Allard</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Lienhard</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Lodish</surname><given-names>H.F.</given-names></name></person-group><article-title>Sequence and structure of a human glucose transporter</article-title><source>Science</source><year>1985</year><volume>229</volume><fpage>941</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1126/science.3839598</pub-id><pub-id pub-id-type="pmid">3839598</pub-id></element-citation></ref><ref id="B58-molecules-30-03457"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Monani</surname><given-names>U.R.</given-names></name></person-group><article-title>Therapeutic strategies for glucose transporter 1 deficiency syndrome</article-title><source>Ann. Clin. Transl. Neurol.</source><year>2019</year><volume>6</volume><fpage>1923</fpage><lpage>1932</lpage><pub-id pub-id-type="doi">10.1002/acn3.50881</pub-id><pub-id pub-id-type="pmid">31464092</pub-id><pub-id pub-id-type="pmcid">PMC6764625</pub-id></element-citation></ref><ref id="B59-molecules-30-03457"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Vivo</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Trifiletti</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Ronen</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Behmand</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Harik</surname><given-names>S.I.</given-names></name></person-group><article-title>Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay</article-title><source>N. Engl. J. Med.</source><year>1991</year><volume>325</volume><fpage>703</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1056/NEJM199109053251006</pub-id><pub-id pub-id-type="pmid">1714544</pub-id></element-citation></ref><ref id="B60-molecules-30-03457"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vulturar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chi&#537;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pintilie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Farca&#537;</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Botezatu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Login</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Sitar-Taut</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Orasan</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>Stan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lazea</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>One molecule for mental nourishment and more: Glucose transporter type 1-biology and deficiency syndrome</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>1249</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10061249</pub-id><pub-id pub-id-type="pmid">35740271</pub-id><pub-id pub-id-type="pmcid">PMC9219734</pub-id></element-citation></ref><ref id="B61-molecules-30-03457"><label>61.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Santer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Klepper</surname><given-names>J.</given-names></name></person-group><source>Disorders of Glucose Transport in Inherited Metabolic Diseases, Diagnostic and Treatment</source><edition>6th ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Saudubray</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Waler</surname><given-names>J.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2016</year><fpage>175</fpage><lpage>184</lpage></element-citation></ref><ref id="B62-molecules-30-03457"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Sutphin</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Turcotte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Banh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Solow-Cordero</surname><given-names>D.E.</given-names></name><etal/></person-group><article-title>Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality</article-title><source>Sci. Transl. Med.</source><year>2011</year><volume>3</volume><fpage>94ra70</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002394</pub-id><pub-id pub-id-type="pmcid">PMC3683134</pub-id><pub-id pub-id-type="pmid">21813754</pub-id></element-citation></ref><ref id="B63-molecules-30-03457"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turcotte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Sutphin</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Hay</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Denny</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Giaccia</surname><given-names>A.J.</given-names></name></person-group><article-title>A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy</article-title><source>Cancer Cell</source><year>2008</year><volume>14</volume><fpage>90</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.06.004</pub-id><pub-id pub-id-type="pmid">18598947</pub-id><pub-id pub-id-type="pmcid">PMC2819422</pub-id></element-citation></ref><ref id="B64-molecules-30-03457"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hay</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Turcotte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Sutphin</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Giaccia</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Denny</surname><given-names>W.A.</given-names></name></person-group><article-title>4-Pyridylanilinothiazoles that selectively target von Hippel&#8211;Lindau deficient renal cell carcinoma cells by inducing autophagic cell death</article-title><source>J. Med. Chem.</source><year>2010</year><volume>53</volume><fpage>787</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1021/jm901457w</pub-id><pub-id pub-id-type="pmid">19994864</pub-id><pub-id pub-id-type="pmcid">PMC2838715</pub-id></element-citation></ref><ref id="B65-molecules-30-03457"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Dalili</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Hurren</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Saiz</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Gronda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eberhard</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Minden</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Bilan</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death</article-title><source>Mol. Cancer Ther.</source><year>2008</year><volume>7</volume><fpage>3546</fpage><lpage>3555</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0569</pub-id><pub-id pub-id-type="pmid">19001437</pub-id></element-citation></ref><ref id="B66-molecules-30-03457"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Chatain</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Bugarini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Ray-Chaudhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Merrill</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lonser</surname><given-names>R.R.</given-names></name><etal/></person-group><article-title>Corticotropin releasing hormone can selectively stimulate glucose uptake in corticotropinoma via glucose transporter 1</article-title><source>Mol. Cell Endocrinol.</source><year>2018</year><volume>470</volume><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2017.10.003</pub-id><pub-id pub-id-type="pmid">28986303</pub-id><pub-id pub-id-type="pmcid">PMC5882598</pub-id></element-citation></ref><ref id="B67-molecules-30-03457"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oca&#241;a</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Poveda</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mar&#237;-Beffa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quesada</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>M.&#193;.</given-names></name></person-group><article-title>Fasentin diminishes endothelial cell proliferation, differentiation and invasion in a glucose metabolism-independent manner</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>6132</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-63232-z</pub-id><pub-id pub-id-type="pmid">32273578</pub-id><pub-id pub-id-type="pmcid">PMC7145862</pub-id></element-citation></ref><ref id="B68-molecules-30-03457"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bergmeier</surname><given-names>S.C.</given-names></name></person-group><article-title>Novel inhibitors of basal glucose transport as potential anticancer agents</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2010</year><volume>20</volume><fpage>2191</fpage><lpage>2194</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2010.02.027</pub-id><pub-id pub-id-type="pmid">20194024</pub-id></element-citation></ref><ref id="B69-molecules-30-03457"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bergmeier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms</article-title><source>Cancer Lett.</source><year>2010</year><volume>298</volume><fpage>176</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2010.07.002</pub-id><pub-id pub-id-type="pmid">20678861</pub-id></element-citation></ref><ref id="B70-molecules-30-03457"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bergmeier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akbar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Colvin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo</article-title><source>Mol. Cancer Ther.</source><year>2012</year><volume>11</volume><fpage>1672</fpage><lpage>1682</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0131</pub-id><pub-id pub-id-type="pmid">22689530</pub-id></element-citation></ref><ref id="B71-molecules-30-03457"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ojelabi</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>De Zutter</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Carruthers</surname><given-names>A.</given-names></name></person-group><article-title>WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxybenzoate) Inhibits GLUT1-mediated Sugar Transport by Binding Reversibly at the Exofacial Sugar Binding Site</article-title><source>J. Biol. Chem.</source><year>2016</year><volume>291</volume><fpage>26762</fpage><lpage>26772</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.759175</pub-id><pub-id pub-id-type="pmid">27836974</pub-id><pub-id pub-id-type="pmcid">PMC5207184</pub-id></element-citation></ref><ref id="B72-molecules-30-03457"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siebeneicher</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cleve</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rehwinkel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Neuhaus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heisler</surname><given-names>I.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bauser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Buchmann</surname><given-names>B.</given-names></name></person-group><article-title>Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876</article-title><source>ChemMedChem</source><year>2016</year><volume>11</volume><fpage>2261</fpage><lpage>2271</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201600276</pub-id><pub-id pub-id-type="pmid">27552707</pub-id><pub-id pub-id-type="pmcid">PMC5095872</pub-id></element-citation></ref><ref id="B73-molecules-30-03457"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Muthuswami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Sywanycz</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Naik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brody</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Diab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>GLUT1 inhibitor BAY-876 induces apoptosis and enhances anti-cancer effects of bitter receptor agonists in head and neck squamous carcinoma cells</article-title><source>Cell Death Discov.</source><year>2024</year><volume>10</volume><fpage>339</fpage><pub-id pub-id-type="doi">10.1038/s41420-024-02106-z</pub-id><pub-id pub-id-type="pmid">39060287</pub-id><pub-id pub-id-type="pmcid">PMC11282258</pub-id></element-citation></ref><ref id="B74-molecules-30-03457"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>P.L.</given-names></name></person-group><article-title>Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers&#8217; most common phenotypes, the &#8220;Warburg Effect&#8221;, i.e., elevated glycolysis in the presence of oxygen</article-title><source>J. Bioenerg. Biomembr.</source><year>2007</year><volume>39</volume><fpage>211</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1007/s10863-007-9094-x</pub-id><pub-id pub-id-type="pmid">17879147</pub-id></element-citation></ref><ref id="B75-molecules-30-03457"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irwin</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.</given-names></name></person-group><article-title>Molecular evolution of the vertebrate hexokinase gene family: Identification of a conserved fifth vertebrate hexokinase gene</article-title><source>Comp. Biochem. Physiol. Part D Genom. Proteom.</source><year>2008</year><volume>3</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.cbd.2007.11.002</pub-id><pub-id pub-id-type="pmid">20483211</pub-id></element-citation></ref><ref id="B76-molecules-30-03457"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patra</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bhaskar</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wheaton</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chandel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Laakso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>E.L.</given-names></name><etal/></person-group><article-title>Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer</article-title><source>Cancer Cell</source><year>2013</year><volume>24</volume><fpage>213</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.06.014</pub-id><pub-id pub-id-type="pmid">23911236</pub-id><pub-id pub-id-type="pmcid">PMC3753022</pub-id></element-citation></ref><ref id="B77-molecules-30-03457"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marayati</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moffitt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>J.J.</given-names></name></person-group><article-title>Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer</article-title><source>Oncotarget</source><year>2016</year><volume>8</volume><fpage>56081</fpage><lpage>56094</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9760</pub-id><pub-id pub-id-type="pmid">28915575</pub-id><pub-id pub-id-type="pmcid">PMC5593546</pub-id></element-citation></ref><ref id="B78-molecules-30-03457"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>K.Y.</given-names></name></person-group><article-title>The development of small-molecule inhibitors targeting hexokinase 2</article-title><source>Drug Discov. Today</source><year>2022</year><volume>27</volume><fpage>2574</fpage><lpage>2585</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2022.05.017</pub-id><pub-id pub-id-type="pmid">35609742</pub-id></element-citation></ref><ref id="B79-molecules-30-03457"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benz</surname><given-names>R.</given-names></name></person-group><article-title>Permeation of hydrophilic solutes through mitochondrial outer membranes-review on mitochondrial porins</article-title><source>Biophys. Acta</source><year>1994</year><volume>1197</volume><fpage>167</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/0304-4157(94)90004-3</pub-id><pub-id pub-id-type="pmid">8031826</pub-id></element-citation></ref><ref id="B80-molecules-30-03457"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Pinto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Guarino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guarnera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Messina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reina</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tomasello</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mazzoni</surname><given-names>C.</given-names></name></person-group><article-title>Characterization of human VDAC isoforms: A peculiar function for VDAC3?</article-title><source>Biochim. Biophys. Acta</source><year>2010</year><volume>1797</volume><fpage>1268</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2010.01.031</pub-id><pub-id pub-id-type="pmid">20138821</pub-id></element-citation></ref><ref id="B81-molecules-30-03457"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pastorino</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Hoek</surname><given-names>J.B.</given-names></name></person-group><article-title>Regulation of hexokinase binding to VDAC</article-title><source>J. Bioenerg. Biomembr.</source><year>2008</year><volume>40</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1007/s10863-008-9148-8</pub-id><pub-id pub-id-type="pmid">18683036</pub-id><pub-id pub-id-type="pmcid">PMC2662512</pub-id></element-citation></ref><ref id="B82-molecules-30-03457"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rio</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Ravera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Massollo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Orengo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Amaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Passalacqua</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maffioli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pfeffer</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Metformin impairs glucose con- sumption and survival in Calu-1 cells by direct inhibition of hexokinase-II</article-title><source>Sci. Rep.</source><year>2013</year><volume>3</volume><elocation-id>2070</elocation-id><pub-id pub-id-type="doi">10.1038/srep02070</pub-id><pub-id pub-id-type="pmid">23797762</pub-id><pub-id pub-id-type="pmcid">PMC3691576</pub-id></element-citation></ref><ref id="B83-molecules-30-03457"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Massollo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Orengo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Capitanio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Emionite</surname><given-names>L.</given-names></name><name name-style="western"><surname>Riondato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bottoni</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer</article-title><source>Cell Cycle</source><year>2013</year><volume>12</volume><fpage>3490</fpage><lpage>3499</lpage><pub-id pub-id-type="doi">10.4161/cc.26461</pub-id><pub-id pub-id-type="pmid">24240433</pub-id><pub-id pub-id-type="pmcid">PMC3906335</pub-id></element-citation></ref><ref id="B84-molecules-30-03457"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Ribalet</surname><given-names>B.</given-names></name></person-group><article-title>Subcellular localization of hexokinases I and II directs the metabolic fate of glucose</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e17674</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017674</pub-id><pub-id pub-id-type="pmid">21408025</pub-id><pub-id pub-id-type="pmcid">PMC3052386</pub-id></element-citation></ref><ref id="B85-molecules-30-03457"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bustamante</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>P.L.</given-names></name></person-group><article-title>High aerobic glycolysis of rat hepatoma cells in culture: Role of mitochondrial hexokinase</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1977</year><volume>74</volume><fpage>3735</fpage><lpage>3739</lpage><pub-id pub-id-type="doi">10.1073/pnas.74.9.3735</pub-id><pub-id pub-id-type="pmid">198801</pub-id><pub-id pub-id-type="pmcid">PMC431708</pub-id></element-citation></ref><ref id="B86-molecules-30-03457"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name></person-group><article-title>Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate</article-title><source>Biochim. Biophys. Acta</source><year>2009</year><volume>1787</volume><fpage>553</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2009.03.003</pub-id><pub-id pub-id-type="pmid">19285479</pub-id><pub-id pub-id-type="pmcid">PMC2731236</pub-id></element-citation></ref><ref id="B87-molecules-30-03457"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#237;os</surname><given-names>J.L.</given-names></name></person-group><article-title>Chemical constituents and pharmacological properties of Poria cocos</article-title><source>Planta Med.</source><year>2011</year><volume>77</volume><fpage>681</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1055/s-0030-1270823</pub-id><pub-id pub-id-type="pmid">21347995</pub-id></element-citation></ref><ref id="B88-molecules-30-03457"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>G.</given-names></name></person-group><article-title>Targeting Pyruvate Kinase M2 and Hexokinase II, Pachymic acid impairs glucose metabolism and induces mitochondrial apoptosis</article-title><source>Biol. Pharm. Bull.</source><year>2019</year><volume>42</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1248/bpb.b18-00730</pub-id><pub-id pub-id-type="pmid">30381614</pub-id></element-citation></ref><ref id="B89-molecules-30-03457"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Floridi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paggi</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Marcante</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Silvestrini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Martino</surname><given-names>C.</given-names></name></person-group><article-title>Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells</article-title><source>J. Natl. Cancer Inst.</source><year>1981</year><volume>66</volume><fpage>497</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">6937706</pub-id></element-citation></ref><ref id="B90-molecules-30-03457"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Yoseph</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>B.D.</given-names></name></person-group><article-title>Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification</article-title><source>J. Neurooncol.</source><year>1998</year><volume>36</volume><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1023/A:1005819604858</pub-id><pub-id pub-id-type="pmid">9525814</pub-id></element-citation></ref><ref id="B91-molecules-30-03457"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravagnan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marzo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Costantini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Susin</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Zamzami</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petit</surname><given-names>P.X.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Goulbern</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poupon</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Miccoli</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>2537</fpage><lpage>2546</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202625</pub-id><pub-id pub-id-type="pmid">10353597</pub-id></element-citation></ref><ref id="B92-molecules-30-03457"><label>92.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Tidmarsh</surname><given-names>G.</given-names></name></person-group><article-title>Therapies for the Treatment of Cancer</article-title><source>U.S. Patent</source><patent>US20060276527A1</patent><day>7</day><month>December</month><year>2006</year></element-citation></ref><ref id="B93-molecules-30-03457"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name></person-group><article-title>Directional modification of chrysin for exerting apoptosis and enhancing significantly anti-cancer effects of 10- hydroxy camptothecin</article-title><source>Biomed. Pharmacother.</source><year>2016</year><volume>82</volume><fpage>693</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2016.06.008</pub-id><pub-id pub-id-type="pmid">27470413</pub-id></element-citation></ref><ref id="B94-molecules-30-03457"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pichichero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cicconi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mattei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muzi</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Canini</surname><given-names>A.</given-names></name></person-group><article-title>Acacia honey and chrysin reduce proliferation of melanoma cells through alterations in cell cycle progression</article-title><source>Int. J. Oncol.</source><year>2010</year><volume>37</volume><fpage>973</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.3892/ijo_00000748</pub-id><pub-id pub-id-type="pmid">20811719</pub-id></element-citation></ref><ref id="B95-molecules-30-03457"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khoi</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Chay</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y.D.</given-names></name></person-group><article-title>Chrysin inhibits cell invasion by inhibition of Recepteur d&#8217;origine Nantais via suppressing early growth response-1 and NF-kappaB transcription factor activities in gastric cancer cells</article-title><source>Int. J. Oncol.</source><year>2015</year><volume>46</volume><fpage>1835</fpage><lpage>1843</lpage><pub-id pub-id-type="doi">10.3892/ijo.2015.2847</pub-id><pub-id pub-id-type="pmid">25625479</pub-id></element-citation></ref><ref id="B96-molecules-30-03457"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>Z.P.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>Chrysin enhances sensitivity of BEL- 7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway</article-title><source>Chem. Biol. Interact.</source><year>2013</year><volume>206</volume><fpage>100</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2013.08.008</pub-id><pub-id pub-id-type="pmid">23994249</pub-id></element-citation></ref><ref id="B97-molecules-30-03457"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name></person-group><article-title>Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2017</year><volume>36</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s13046-017-0514-4</pub-id><pub-id pub-id-type="pmid">28320429</pub-id><pub-id pub-id-type="pmcid">PMC5359903</pub-id></element-citation></ref><ref id="B98-molecules-30-03457"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Repression of hexokinases II-mediated glycolysis contributes to piperlongumine-induced tumor suppression in non- small cell lung cancer cells</article-title><source>Int. J. Biol. Sci.</source><year>2019</year><volume>15</volume><fpage>826</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.7150/ijbs.31749</pub-id><pub-id pub-id-type="pmid">30906213</pub-id><pub-id pub-id-type="pmcid">PMC6429016</pub-id></element-citation></ref><ref id="B99-molecules-30-03457"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelicano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name></person-group><article-title>Glycolysis inhibition for anticancer treatment</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>4633</fpage><lpage>4646</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209597</pub-id><pub-id pub-id-type="pmid">16892078</pub-id></element-citation></ref><ref id="B100-molecules-30-03457"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Q.</given-names></name></person-group><article-title>Effect of 2-deoxy-D-glucose on gellan gum biosynthesis by Sphingomonas paucimobilis</article-title><source>Bioprocess. Biosyst. Eng.</source><year>2019</year><volume>42</volume><fpage>897</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1007/s00449-019-02078-w</pub-id><pub-id pub-id-type="pmid">30671627</pub-id></element-citation></ref><ref id="B101-molecules-30-03457"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name></person-group><article-title>2-Deoxy-D-glucose: A novel pharmacological agent for killing hypoxic tumor cells, oxygen dependence-lowering in COVID-19, and other pharmacological activities</article-title><source>Adv. Pharmacol. Pharm. Sci.</source><year>2023</year><volume>2023</volume><fpage>9993386</fpage><pub-id pub-id-type="doi">10.1155/2023/9993386</pub-id><pub-id pub-id-type="pmid">36911357</pub-id><pub-id pub-id-type="pmcid">PMC9998157</pub-id></element-citation></ref><ref id="B102-molecules-30-03457"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>IFokt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Skora</surname><given-names>C.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Madden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Emmett</surname><given-names>W.</given-names></name></person-group><article-title>Priebe- D-glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifcally deuterated D-glucose, -mannose, and 2-deoxy-D-glucose</article-title><source>Carbohydr. Res.</source><year>2013</year><volume>368</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">23376241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carres.2012.11.021</pub-id><pub-id pub-id-type="pmcid">PMC3893820</pub-id></element-citation></ref><ref id="B103-molecules-30-03457"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kurtoglu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lampidis</surname><given-names>T.J.</given-names></name></person-group><article-title>The wonders of 2- deoxy-D-glucose</article-title><source>IUBMB Life</source><year>2014</year><volume>66</volume><fpage>110</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1002/iub.1251</pub-id><pub-id pub-id-type="pmid">24578297</pub-id></element-citation></ref><ref id="B104-molecules-30-03457"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bai&#227;o</surname><given-names>A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sarmento</surname><given-names>B.</given-names></name><name name-style="western"><surname>Queir&#243;s</surname><given-names>O.</given-names></name></person-group><article-title>Glycolytic inhibitors potentiated the activity of paclitaxel and their nanoencapsulation increased their delivery in a lung cancer model</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>2021</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14102021</pub-id><pub-id pub-id-type="pmid">36297455</pub-id><pub-id pub-id-type="pmcid">PMC9611291</pub-id></element-citation></ref><ref id="B105-molecules-30-03457"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name></person-group><article-title>Glycolytic inhibitor 2-deoxyglucose suppresses inflammatory response in innate immune cells and experimental staphylococcal endophthalmitis</article-title><source>Exp. Eye Res.</source><year>2020</year><volume>97</volume><fpage>108079</fpage><pub-id pub-id-type="doi">10.1016/j.exer.2020.108079</pub-id><pub-id pub-id-type="pmid">32454039</pub-id><pub-id pub-id-type="pmcid">PMC7484014</pub-id></element-citation></ref><ref id="B106-molecules-30-03457"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohanty</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>K.S.</given-names></name></person-group><article-title>2-deoxy-D-glucose inhibition of herpes simplex virus type-1 receptor expression</article-title><source>Antivir. Res.</source><year>1986</year><volume>6</volume><fpage>137</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(86)90008-2</pub-id><pub-id pub-id-type="pmid">3015018</pub-id></element-citation></ref><ref id="B107-molecules-30-03457"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murmu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manna</surname><given-names>R.</given-names></name><name name-style="western"><surname>Haldar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dash</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Giri</surname><given-names>B.</given-names></name></person-group><article-title>Multifaceted entrancing role of glucose and its analogue, 2-deoxy-D-glucose in cancer cell proliferation, inflammation, and virus infection</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>156</volume><elocation-id>113801</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113801</pub-id><pub-id pub-id-type="pmid">36228369</pub-id></element-citation></ref><ref id="B108-molecules-30-03457"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ellisman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kitada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>J.C.</given-names></name></person-group><article-title>Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e24102</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0024102</pub-id><pub-id pub-id-type="pmid">21949692</pub-id><pub-id pub-id-type="pmcid">PMC3176271</pub-id></element-citation></ref><ref id="B109-molecules-30-03457"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name></person-group><article-title>2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy</article-title><source>Cancer Lett.</source><year>2014</year><volume>355</volume><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2014.09.003</pub-id><pub-id pub-id-type="pmid">25218591</pub-id></element-citation></ref><ref id="B110-molecules-30-03457"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lampidis</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Kurtoglu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maher</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Krishan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sheft</surname><given-names>V.</given-names></name><name name-style="western"><surname>Szymanski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fokt</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rudnicki</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Ginalski</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing &#8220;hypoxic tumor cells&#8221;</article-title><source>Cancer Chemother. Pharmacol.</source><year>2006</year><volume>58</volume><fpage>725</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1007/s00280-006-0207-8</pub-id><pub-id pub-id-type="pmid">16555088</pub-id></element-citation></ref><ref id="B111-molecules-30-03457"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.Y.</given-names></name></person-group><article-title>Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism</article-title><source>Cell Death Discov.</source><year>2019</year><volume>5</volume><fpage>76</fpage><pub-id pub-id-type="doi">10.1038/s41420-019-0156-8</pub-id><pub-id pub-id-type="pmid">30886744</pub-id><pub-id pub-id-type="pmcid">PMC6411866</pub-id></element-citation></ref><ref id="B112-molecules-30-03457"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheong</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dennison</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Tsavachidou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nguyen-Charles</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wa Cheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models</article-title><source>Mol. Cancer Ther.</source><year>2011</year><volume>10</volume><fpage>2350</fpage><lpage>2362</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0497</pub-id><pub-id pub-id-type="pmid">21992792</pub-id><pub-id pub-id-type="pmcid">PMC3237863</pub-id></element-citation></ref><ref id="B113-molecules-30-03457"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Min</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2017</year><volume>36</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/s13046-017-0530-4</pub-id><pub-id pub-id-type="pmid">28427443</pub-id><pub-id pub-id-type="pmcid">PMC5399312</pub-id></element-citation></ref><ref id="B114-molecules-30-03457"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiara</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castellaro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Petronilli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Brusilow</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Juhaszova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sollott</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Forte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rasola</surname><given-names>A.</given-names></name></person-group><article-title>Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e1852</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0001852</pub-id><pub-id pub-id-type="pmid">18350175</pub-id><pub-id pub-id-type="pmcid">PMC2267038</pub-id></element-citation></ref><ref id="B115-molecules-30-03457"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis</article-title><source>Pharmacol. Res.</source><year>2021</year><volume>164</volume><fpage>105367</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.105367</pub-id><pub-id pub-id-type="pmid">33307221</pub-id></element-citation></ref><ref id="B116-molecules-30-03457"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulichak</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Padmanabhan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Garavito</surname><given-names>R.M.</given-names></name></person-group><article-title>The mammalian hexokinase-1</article-title><source>Nat. Struct. Biol.</source><year>1998</year><volume>5</volume><fpage>555</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1038/811</pub-id><pub-id pub-id-type="pmid">9665168</pub-id></element-citation></ref><ref id="B117-molecules-30-03457"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Tedesco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Erhard</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Raha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rendina</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Discovery of a novel 2,6-disubstituted glucosamine series of potent and selective Hexokinase 2 inhibitors</article-title><source>ACS Med. Chem. Lett.</source><year>2015</year><volume>7</volume><fpage>217</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.5b00214</pub-id><pub-id pub-id-type="pmid">26985301</pub-id><pub-id pub-id-type="pmcid">PMC4789681</pub-id></element-citation></ref><ref id="B118-molecules-30-03457"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deeb</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Malkki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laakso</surname><given-names>M.</given-names></name></person-group><article-title>human hexokinase II: Sequence and homology to other hexokinases</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1993</year><volume>197</volume><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1993.2442</pub-id><pub-id pub-id-type="pmid">8250948</pub-id></element-citation></ref><ref id="B119-molecules-30-03457"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name></person-group><article-title>Pyruvate kinase M2 at a glance</article-title><source>J. Cell Sci.</source><year>2015</year><volume>128</volume><fpage>1655</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1242/jcs.166629</pub-id><pub-id pub-id-type="pmid">25770102</pub-id><pub-id pub-id-type="pmcid">PMC4446733</pub-id></element-citation></ref><ref id="B120-molecules-30-03457"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heng</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Painter</surname><given-names>M.W.</given-names></name><collab>The Immunological Genome Project Consortium</collab>\
<name name-style="western"><surname>Elpek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lukacs-Kornek</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mauermann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Turley</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Wagers</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>The Immunological Genome Project: Networks of gene expression in immune cells</article-title><source>Nat. Immunol.</source><year>2008</year><volume>9</volume><fpage>1091</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/ni1008-1091</pub-id><pub-id pub-id-type="pmid">18800157</pub-id></element-citation></ref><ref id="B121-molecules-30-03457"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves-Filho</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>P&#229;lsson-McDermott</surname><given-names>E.M.</given-names></name></person-group><article-title>Pyruvate kinase M2: A potential target for regulating inflammation</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><elocation-id>145</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2016.00145</pub-id><pub-id pub-id-type="pmid">27148264</pub-id><pub-id pub-id-type="pmcid">PMC4838608</pub-id></element-citation></ref><ref id="B122-molecules-30-03457"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toller-Kawahisa</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Hiroki</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>de Souza Silva</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>P&#249;blio</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Varela Martins</surname><given-names>T.</given-names></name><name name-style="western"><surname>Alves Damascenco</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Prot&#224;sio Veras</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ramos Viacava</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yuji Sukesada</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The metabolic function of pyruvate kinase M2 regulates reactive oxygen species production and microbial killing by neutrophils</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>4280</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40021-6</pub-id><pub-id pub-id-type="pmid">37460614</pub-id><pub-id pub-id-type="pmcid">PMC10352279</pub-id></element-citation></ref><ref id="B123-molecules-30-03457"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leland</surname><given-names>P.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moudgil</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>B.H.</given-names></name></person-group><article-title>Subcellular compartmentalization of PKM2 identifies anti-PKM2 therapy response in vitro and in vivo mouse model of human non-small-cell lung cancer</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0217131</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0217131</pub-id><pub-id pub-id-type="pmid">31120964</pub-id><pub-id pub-id-type="pmcid">PMC6532891</pub-id></element-citation></ref><ref id="B124-molecules-30-03457"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Su</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment</article-title><source>Int. J. Cancer</source><year>2020</year><volume>147</volume><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1002/ijc.32756</pub-id><pub-id pub-id-type="pmid">31652354</pub-id></element-citation></ref><ref id="B125-molecules-30-03457"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Druzhyna</surname><given-names>N.</given-names></name><name name-style="western"><surname>Szczesny</surname><given-names>B.</given-names></name><name name-style="western"><surname>Olah</surname><given-names>G.</given-names></name><name name-style="western"><surname>M&#243;dis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Asimakopoulou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pavlidou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szoleczky</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ger&#246;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yanagi</surname><given-names>K.</given-names></name><name name-style="western"><surname>T&#246;r&#246;</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine &#946;-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer</article-title><source>Pharmacol. Res.</source><year>2016</year><volume>113</volume><fpage>18</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">27521834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2016.08.016</pub-id><pub-id pub-id-type="pmcid">PMC5107130</pub-id></element-citation></ref><ref id="B126-molecules-30-03457"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McNutt</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name></person-group><article-title>Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>138</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.06.064</pub-id><pub-id pub-id-type="pmid">28688274</pub-id></element-citation></ref><ref id="B127-molecules-30-03457"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McNutt</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name></person-group><article-title>Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform</article-title><source>J. Enzym. Inhib. Med. Chem.</source><year>2018</year><volume>33</volume><fpage>126</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1080/14756366.2017.1404591</pub-id><pub-id pub-id-type="pmcid">PMC6010099</pub-id><pub-id pub-id-type="pmid">29185365</pub-id></element-citation></ref><ref id="B128-molecules-30-03457"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ru</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.W.</given-names></name><etal/></person-group><article-title>Synthesis and target identification of benzoxepane derivatives as potential anti-neuroinflammatory agents for ischemic stroke</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2020</year><volume>59</volume><fpage>2429</fpage><lpage>2439</lpage><pub-id pub-id-type="doi">10.1002/anie.201912489</pub-id><pub-id pub-id-type="pmid">31782597</pub-id></element-citation></ref><ref id="B129-molecules-30-03457"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.X.</given-names></name><etal/></person-group><article-title>Inhibition of glycolysis alleviates lipopolysaccharide-induced acute lung injury in a mouse model</article-title><source>J. Cell Physiol.</source><year>2019</year><volume>234</volume><fpage>4641</fpage><lpage>4654</lpage><pub-id pub-id-type="doi">10.1002/jcp.27261</pub-id><pub-id pub-id-type="pmid">30256406</pub-id></element-citation></ref><ref id="B130-molecules-30-03457"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Billiar</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13280</fpage><pub-id pub-id-type="doi">10.1038/ncomms13280</pub-id><pub-id pub-id-type="pmid">27779186</pub-id><pub-id pub-id-type="pmcid">PMC5093342</pub-id></element-citation></ref><ref id="B131-molecules-30-03457"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wubben</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sajjakulnukit</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hager</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Lyssiotis</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Small molecule activation of metabolic enzyme pyruvate kinase muscle isozyme 2, PKM2, circumvents photoreceptor apoptosis</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>2990</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-59999-w</pub-id><pub-id pub-id-type="pmid">32076076</pub-id><pub-id pub-id-type="pmcid">PMC7031539</pub-id></element-citation></ref><ref id="B132-molecules-30-03457"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayyad</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sirohi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Radha</surname><given-names>V.</given-names></name><name name-style="western"><surname>Swarp</surname><given-names>G.</given-names></name></person-group><article-title>661W is a retinal ganglion precursor-like cell line in which glaucoma-associated optineurin mutants induce cell death selectively</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>16855</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-17241-0</pub-id><pub-id pub-id-type="pmid">29203899</pub-id><pub-id pub-id-type="pmcid">PMC5715133</pub-id></element-citation></ref><ref id="B133-molecules-30-03457"><label>133.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Brimacombe</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Anastasiou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Israelsen</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Tempel</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dimov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Veith</surname><given-names>H.</given-names></name><etal/></person-group><article-title>ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model</article-title><source>Probe Reports from the NIH Molecular Libraries Program [Internet]</source><publisher-name>National Center for Biotechnology Information</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>2012</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK153222/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK153222/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-09">(accessed on 9 July 2025)</date-in-citation><pub-id pub-id-type="pmid">23905203</pub-id></element-citation></ref><ref id="B134-molecules-30-03457"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarfraz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rasul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jabeen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>T.</given-names></name><name name-style="western"><surname>Adem</surname><given-names>&#350;.</given-names></name></person-group><article-title>Identification of natural compounds as inhibitors of pyruvate kinase M2 for cancer treatment</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>7113</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27207113</pub-id><pub-id pub-id-type="pmid">36296707</pub-id><pub-id pub-id-type="pmcid">PMC9609560</pub-id></element-citation></ref><ref id="B135-molecules-30-03457"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuli</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Mittal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parashar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Parashar</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Barwal</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>G.</given-names></name><name name-style="western"><surname>Savla</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance</article-title><source>Semin. Cancer Biol.</source><year>2021</year><volume>73</volume><fpage>196</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2020.09.014</pub-id><pub-id pub-id-type="pmid">33130037</pub-id></element-citation></ref><ref id="B136-molecules-30-03457"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name></person-group><article-title>Silibinin: A potential old drug for cancer therapy</article-title><source>Expert. Rev. Clin. Pharmacol.</source><year>2016</year><volume>9</volume><fpage>1323</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1080/17512433.2016.1208563</pub-id><pub-id pub-id-type="pmid">27362364</pub-id></element-citation></ref><ref id="B137-molecules-30-03457"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mateen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raina</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>R.</given-names></name></person-group><article-title>Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2013</year><volume>345</volume><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1124/jpet.113.203471</pub-id><pub-id pub-id-type="pmid">23461975</pub-id><pub-id pub-id-type="pmcid">PMC3629797</pub-id></element-citation></ref><ref id="B138-molecules-30-03457"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kauntz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bousserouel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goss&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Raul</surname><given-names>F.</given-names></name></person-group><article-title>Epigenetic effects of the natural flavonolignan silibinin on colon adenocarcinoma cells and their derived metastatic cells</article-title><source>Oncol. Lett.</source><year>2013</year><volume>5</volume><fpage>1273</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.3892/ol.2013.1190</pub-id><pub-id pub-id-type="pmid">23599778</pub-id><pub-id pub-id-type="pmcid">PMC3629096</pub-id></element-citation></ref><ref id="B139-molecules-30-03457"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqbal</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Ur Rehman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prakasam</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bamezai</surname><given-names>R.N.</given-names></name></person-group><article-title>Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: Potential therapeutic implications</article-title><source>FEBS J.</source><year>2021</year><volume>288</volume><fpage>471</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1111/febs.15353</pub-id><pub-id pub-id-type="pmid">32356386</pub-id></element-citation></ref><ref id="B140-molecules-30-03457"><label>140.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Existing Food Additives, Ministry of Health, Labor and Welfare of Japan, Notification n.120</collab></person-group><year>1996</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ffcr.or.jp/en/tenka/list-of-existing-food-additives/list-of-existing-food-additives.html" ext-link-type="uri">https://www.ffcr.or.jp/en/tenka/list-of-existing-food-additives/list-of-existing-food-additives.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-02-26">(accessed on 26 February 2020)</date-in-citation></element-citation></ref><ref id="B141-molecules-30-03457"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tasaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Umemura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuroiwa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hirose</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>A.</given-names></name></person-group><article-title>Safety assessment of ellagic acid, a food additive, in a subchronic toxicity study using F344 rats</article-title><source>Food Chem. Toxicol.</source><year>2008</year><volume>46</volume><fpage>1119</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2007.10.043</pub-id><pub-id pub-id-type="pmid">18155344</pub-id></element-citation></ref><ref id="B142-molecules-30-03457"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devipriya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sudheer</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>V.P.</given-names></name></person-group><article-title>Effect of ellagic acid, a natural polyphenol, on alcohol-induced prooxidant and antioxidant imbalance: A drug dose dependent study</article-title><source>Singap. Med. J.</source><year>2007</year><volume>48</volume><fpage>311</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">17384878</pub-id></element-citation></ref><ref id="B143-molecules-30-03457"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceci</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lacal</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Tentori</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Martino</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Miano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Graziani</surname><given-names>G.</given-names></name></person-group><article-title>Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><elocation-id>1756</elocation-id><pub-id pub-id-type="doi">10.3390/nu10111756</pub-id><pub-id pub-id-type="pmid">30441769</pub-id><pub-id pub-id-type="pmcid">PMC6266224</pub-id></element-citation></ref><ref id="B144-molecules-30-03457"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yousuf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shamsi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shahbaaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>AlAjmi</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rizwanul Haque</surname><given-names>Q.M.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>M.I.</given-names></name></person-group><article-title>Ellagic acid controls cell proliferation and induces apoptosis in breast cancer cells via inhibition of cyclin-dependent kinase 6</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>3526</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21103526</pub-id><pub-id pub-id-type="pmid">32429317</pub-id><pub-id pub-id-type="pmcid">PMC7278979</pub-id></element-citation></ref><ref id="B145-molecules-30-03457"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alajmi</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>M.I.</given-names></name></person-group><article-title>Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: A targeted approach towards anticancer therapy</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>118</volume><elocation-id>109245</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109245</pub-id><pub-id pub-id-type="pmid">31352240</pub-id></element-citation></ref><ref id="B146-molecules-30-03457"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stani&#263;</surname><given-names>Z.</given-names></name></person-group><article-title>Curcumin, a compound from natural sources, a true scientific challenge&#8212;A review</article-title><source>Plant Foods Hum. Nutr.</source><year>2017</year><volume>72</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s11130-016-0590-1</pub-id><pub-id pub-id-type="pmid">27995378</pub-id></element-citation></ref><ref id="B147-molecules-30-03457"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Prakasam</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Padder</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Irshad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mangalhara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bamezai</surname><given-names>R.N.K.</given-names></name><name name-style="western"><surname>Husain</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1&#945; inhibition</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>8323</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-25524-3</pub-id><pub-id pub-id-type="pmid">29844464</pub-id><pub-id pub-id-type="pmcid">PMC5974195</pub-id></element-citation></ref><ref id="B148-molecules-30-03457"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baur</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>D.A.</given-names></name></person-group><article-title>Therapeutic potential of resveratrol: The in vivo evidence</article-title><source>Nat. Rev. Drug Discov.</source><year>2006</year><volume>5</volume><fpage>493</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/nrd2060</pub-id><pub-id pub-id-type="pmid">16732220</pub-id></element-citation></ref><ref id="B149-molecules-30-03457"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Udeani</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Slowing</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Beecher</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Farnsworth</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Kinghorn</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>R.G.</given-names></name><etal/></person-group><article-title>Cancer chemopreventive activity of resveratrol, a natural product derived from grapes</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>218</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1126/science.275.5297.218</pub-id><pub-id pub-id-type="pmid">8985016</pub-id></element-citation></ref><ref id="B150-molecules-30-03457"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqbal</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bamezai</surname><given-names>R.N.</given-names></name></person-group><article-title>Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e36764</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0036764</pub-id><pub-id pub-id-type="pmid">22574221</pub-id><pub-id pub-id-type="pmcid">PMC3344940</pub-id></element-citation></ref><ref id="B151-molecules-30-03457"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zha</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>4129</fpage><lpage>4134</lpage><pub-id pub-id-type="doi">10.1073/pnas.1014769108</pub-id><pub-id pub-id-type="pmid">21325052</pub-id><pub-id pub-id-type="pmcid">PMC3054028</pub-id></element-citation></ref><ref id="B152-molecules-30-03457"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varoni</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lo Faro</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Sharifi-Rad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Iriti</surname><given-names>M.</given-names></name></person-group><article-title>Anticancer molecular mechanisms of resveratrol</article-title><source>Front. Nutr.</source><year>2016</year><volume>3</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.3389/fnut.2016.00008</pub-id><pub-id pub-id-type="pmid">27148534</pub-id><pub-id pub-id-type="pmcid">PMC4828556</pub-id></element-citation></ref><ref id="B153-molecules-30-03457"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulte</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Cuthbertson</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Manning</surname><given-names>H.C.</given-names></name></person-group><article-title>2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2016</year><volume>26</volume><fpage>1044</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.12.031</pub-id><pub-id pub-id-type="pmid">26750251</pub-id><pub-id pub-id-type="pmcid">PMC4727990</pub-id></element-citation></ref><ref id="B154-molecules-30-03457"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaira</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tomizawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sunaga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>O.</given-names></name><name name-style="western"><surname>Oriuchi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tominaga</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nagamori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M.</given-names></name><etal/></person-group><article-title>ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer</article-title><source>Br. J. Cancer</source><year>2014</year><volume>110</volume><fpage>2030</fpage><pub-id pub-id-type="doi">10.1038/bjc.2014.88</pub-id><pub-id pub-id-type="pmid">24603303</pub-id><pub-id pub-id-type="pmcid">PMC3992511</pub-id></element-citation></ref><ref id="B155-molecules-30-03457"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaira</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sunose</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sunaga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tominaga</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oriuchi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nagamori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oyama</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma</article-title><source>Histopathology.</source><year>2015</year><volume>66</volume><fpage>234</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1111/his.12464</pub-id><pub-id pub-id-type="pmid">24845232</pub-id></element-citation></ref><ref id="B156-molecules-30-03457"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#246;er</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fairweather</surname><given-names>S.</given-names></name><name name-style="western"><surname>Br&#246;er</surname><given-names>S.</given-names></name></person-group><article-title>Disruption of amino acid homeostasis by novel ASCT2 inhibitors involves multiple targets</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><elocation-id>785</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2018.00785</pub-id><pub-id pub-id-type="pmid">30072900</pub-id><pub-id pub-id-type="pmcid">PMC6060247</pub-id></element-citation></ref><ref id="B157-molecules-30-03457"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Najumudeen</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Ceteci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fey</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Hamm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Steven</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nikula</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Dexter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Race</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer</article-title><source>Nat. Genet.</source><year>2021</year><volume>53</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-00753-3</pub-id><pub-id pub-id-type="pmid">33414552</pub-id></element-citation></ref><ref id="B158-molecules-30-03457"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okunushi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Furihata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morio</surname><given-names>H.</given-names></name><name name-style="western"><surname>Muto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Reien</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function</article-title><source>J. Pharmacol. Sci.</source><year>2020</year><volume>144</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jphs.2020.06.006</pub-id><pub-id pub-id-type="pmid">32653341</pub-id></element-citation></ref><ref id="B159-molecules-30-03457"><label>159.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Investigational Drug Branch CTTP</collab></person-group><source>Clinical Brochure: DON&#8212;NSC 7365</source><publisher-name>Investigational Drug Branch CTTP</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>1979</year><fpage>1</fpage><lpage>53</lpage></element-citation></ref><ref id="B160-molecules-30-03457"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemberg</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Vornov</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Rais</surname><given-names>R.</given-names></name><name name-style="western"><surname>Slusher</surname><given-names>B.S.</given-names></name></person-group><article-title>We&#8217;re Not &#8220;DON&#8221; Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine</article-title><source>Mol. Cancer Ther.</source><year>2018</year><volume>17</volume><fpage>1824</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-1148</pub-id><pub-id pub-id-type="pmid">30181331</pub-id><pub-id pub-id-type="pmcid">PMC6130910</pub-id></element-citation></ref><ref id="B161-molecules-30-03457"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinkus</surname><given-names>L.M.</given-names></name></person-group><article-title>Glutamine binding sites</article-title><source>Methods Enzymol.</source><year>1977</year><volume>46</volume><fpage>414</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">909432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0076-6879(77)46049-x</pub-id></element-citation></ref><ref id="B162-molecules-30-03457"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tanega</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simeonov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boxer</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Auld</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Ferraris</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Tsukamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Slusher</surname><given-names>B.S.</given-names></name></person-group><article-title>Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2013</year><volume>438</volume><fpage>243</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.06.110</pub-id><pub-id pub-id-type="pmid">23850693</pub-id><pub-id pub-id-type="pmcid">PMC4094369</pub-id></element-citation></ref><ref id="B163-molecules-30-03457"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rais</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jan&#269;a&#345;&#237;k</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tenora</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nedelcovych</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Englert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Le</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elgogary</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Discovery of 6-diazo-5-oxo-l-norleucine (DON) prodrugs with enhanced csf delivery in monkeys: A potential treatment for glioblastoma</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>8621</fpage><lpage>8633</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01069</pub-id><pub-id pub-id-type="pmid">27560860</pub-id></element-citation></ref><ref id="B164-molecules-30-03457"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tenora</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dash</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Gadiano</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Novotn&#225;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Veeravalli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>Q.R.</given-names></name><name name-style="western"><surname>Lemberg</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Majer</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>3524</fpage><lpage>3538</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b02009</pub-id><pub-id pub-id-type="pmid">30892035</pub-id><pub-id pub-id-type="pmcid">PMC8025739</pub-id></element-citation></ref><ref id="B165-molecules-30-03457"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanaford</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Alt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rais</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thorek</surname><given-names>D.L.J.</given-names></name><name name-style="western"><surname>Eberhart</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Slusher</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Raabe</surname><given-names>E.H.</given-names></name></person-group><article-title>Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma</article-title><source>Transl. Oncol.</source><year>2019</year><volume>12</volume><fpage>1314</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1016/j.tranon.2019.05.013</pub-id><pub-id pub-id-type="pmid">31340195</pub-id><pub-id pub-id-type="pmcid">PMC6657308</pub-id></element-citation></ref><ref id="B166-molecules-30-03457"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rais</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lemberg</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Tenora</surname><given-names>L.</given-names></name><name name-style="western"><surname>Arwood</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>J.M.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug</article-title><source>Sci. Adv.</source><year>2022</year><volume>8</volume><fpage>eabq5925</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abq5925</pub-id><pub-id pub-id-type="pmid">36383674</pub-id><pub-id pub-id-type="pmcid">PMC9668306</pub-id></element-citation></ref><ref id="B167-molecules-30-03457"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillai</surname><given-names>R.</given-names></name><name name-style="western"><surname>LeBoeuf</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>New</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blum</surname><given-names>J.L.E.</given-names></name><name name-style="western"><surname>Rashidfarrokhi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bahamon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Karadal-Ferrena</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer</article-title><source>Sci. Adv.</source><year>2024</year><volume>10</volume><fpage>eadm9859</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adm9859</pub-id><pub-id pub-id-type="pmid">38536921</pub-id><pub-id pub-id-type="pmcid">PMC10971495</pub-id></element-citation></ref><ref id="B168-molecules-30-03457"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seltzer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Ferraris</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Tsukamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Slusher</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Rabinowitz</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>8981</fpage><lpage>8987</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1666</pub-id><pub-id pub-id-type="pmid">21045145</pub-id><pub-id pub-id-type="pmcid">PMC3058858</pub-id></element-citation></ref><ref id="B169-molecules-30-03457"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elgadi</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Meguid</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Souba</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Abcouwer</surname><given-names>S.F.</given-names></name></person-group><article-title>Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing</article-title><source>Physiol. Genom.</source><year>1999</year><volume>1</volume><fpage>51</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1152/physiolgenomics.1999.1.2.51</pub-id><pub-id pub-id-type="pmid">11015561</pub-id></element-citation></ref><ref id="B170-molecules-30-03457"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartwick</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Curthoys</surname><given-names>N.P.</given-names></name></person-group><article-title>BPTES inhibition of hGA(124&#8211;551), a truncated form of human kidney-type glutaminase</article-title><source>J. Enzym. Inhib. Med. Chem.</source><year>2012</year><volume>27</volume><fpage>861</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.3109/14756366.2011.622272</pub-id><pub-id pub-id-type="pmid">21999665</pub-id></element-citation></ref><ref id="B171-molecules-30-03457"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ferraris</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Stathis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duvall</surname><given-names>B.</given-names></name><name name-style="western"><surname>Delahanty</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rais</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors</article-title><source>J. Med. Chem.</source><year>2012</year><volume>5</volume><fpage>10551</fpage><lpage>10563</lpage><pub-id pub-id-type="doi">10.1021/jm301191p</pub-id><pub-id pub-id-type="pmcid">PMC3539823</pub-id><pub-id pub-id-type="pmid">23151085</pub-id></element-citation></ref><ref id="B172-molecules-30-03457"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakurai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kanayama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>K.</given-names></name></person-group><article-title>Ebselen, a seleno-organic antioxidant, as an electrophile</article-title><source>Chem. Res. Toxicol.</source><year>2006</year><volume>19</volume><fpage>1196</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1021/tx0601105</pub-id><pub-id pub-id-type="pmid">16978024</pub-id></element-citation></ref><ref id="B173-molecules-30-03457"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De La Barre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hurov</surname><given-names>J.B.</given-names></name></person-group><article-title>Full-length human glutaminase in complex with an allosteric inhibitor</article-title><source>Biochemistry</source><year>2011</year><volume>50</volume><fpage>10764</fpage><lpage>10770</lpage><pub-id pub-id-type="doi">10.1021/bi201613d</pub-id><pub-id pub-id-type="pmid">22049910</pub-id></element-citation></ref><ref id="B174-molecules-30-03457"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>A.</given-names></name></person-group><article-title>Lipid metabolism in cancer</article-title><source>FEBS J.</source><year>2012</year><volume>279</volume><fpage>2610</fpage><lpage>2623</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08644.x</pub-id><pub-id pub-id-type="pmid">22621751</pub-id></element-citation></ref><ref id="B175-molecules-30-03457"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baenke</surname><given-names>F.</given-names></name><name name-style="western"><surname>Peck</surname><given-names>B.</given-names></name><name name-style="western"><surname>Miess</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>A.</given-names></name></person-group><article-title>Hooked on fat: The role of lipid synthesis in cancer metabolism and tumour development</article-title><source>Dis. Models Mech.</source><year>2013</year><volume>6</volume><fpage>1353</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1242/dmm.011338</pub-id><pub-id pub-id-type="pmcid">PMC3820259</pub-id><pub-id pub-id-type="pmid">24203995</pub-id></element-citation></ref><ref id="B176-molecules-30-03457"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nomura</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Long</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Niessen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Cravatt</surname><given-names>B.F.</given-names></name></person-group><article-title>Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis</article-title><source>Cell</source><year>2010</year><volume>140</volume><fpage>49</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.11.027</pub-id><pub-id pub-id-type="pmid">20079333</pub-id><pub-id pub-id-type="pmcid">PMC2885975</pub-id></element-citation></ref><ref id="B177-molecules-30-03457"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>J.</given-names></name></person-group><article-title>Monoacylglycerol Lipase: A Novel Potential Therapeutic Target and Prognostic Indicator for Hepatocellular Carcinoma</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>35784</elocation-id><pub-id pub-id-type="doi">10.1038/srep35784</pub-id><pub-id pub-id-type="pmid">27767105</pub-id><pub-id pub-id-type="pmcid">PMC5073346</pub-id></element-citation></ref><ref id="B178-molecules-30-03457"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Monoacylglycerol lipase inhibitors: Modulators for lipid metabolism in cancer malignancy, neurological and met- abolic disorders</article-title><source>Acta Pharm. Sin. B</source><year>2020</year><volume>10</volume><fpage>582</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2019.10.006</pub-id><pub-id pub-id-type="pmid">32322464</pub-id><pub-id pub-id-type="pmcid">PMC7161712</pub-id></element-citation></ref><ref id="B179-molecules-30-03457"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muccioli</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Labar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>D.M.</given-names></name></person-group><article-title>CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay</article-title><source>ChemBioChem</source><year>2008</year><volume>9</volume><fpage>2704</fpage><lpage>2710</lpage><pub-id pub-id-type="doi">10.1002/cbic.200800428</pub-id><pub-id pub-id-type="pmid">18855964</pub-id></element-citation></ref><ref id="B180-molecules-30-03457"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iglesias</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lamontagne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Erb</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gezzar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joly</surname><given-names>E.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Skorey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Crane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Madiraju</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>Simplified assays of lipolysis enzymes for drug discovery and specificity assessment of known inhibitors</article-title><source>J. Lipid Res.</source><year>2016</year><volume>57</volume><fpage>131</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1194/jlr.D058438</pub-id><pub-id pub-id-type="pmid">26423520</pub-id><pub-id pub-id-type="pmcid">PMC4689331</pub-id></element-citation></ref><ref id="B181-molecules-30-03457"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cravatt</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Kozarich</surname><given-names>J.W.</given-names></name></person-group><article-title>Activity-based protein profiling: From enzyme chemistry to proteomic chemistry</article-title><source>Annu. Rev. Biochem.</source><year>2008</year><volume>77</volume><fpage>383</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.75.101304.124125</pub-id><pub-id pub-id-type="pmid">18366325</pub-id></element-citation></ref><ref id="B182-molecules-30-03457"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Booker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Burston</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kinsey</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Schlosburg</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Pav&#243;n</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Selley</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>L.H.</given-names></name><etal/></person-group><article-title>Selective blockade of -arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects</article-title><source>Nat. Chem. Biol.</source><year>2009</year><volume>5</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nchembio.129</pub-id><pub-id pub-id-type="pmid">19029917</pub-id><pub-id pub-id-type="pmcid">PMC2605181</pub-id></element-citation></ref><ref id="B183-molecules-30-03457"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Ridder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Renema</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ponzetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sophocleous</surname><given-names>A.</given-names></name><name name-style="western"><surname>Capulli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aljeffery</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gens</surname><given-names>M.D.</given-names></name><etal/></person-group><article-title>Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice</article-title><source>EBioMedicine</source><year>2019</year><volume>44</volume><fpage>452</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.05.048</pub-id><pub-id pub-id-type="pmid">31151929</pub-id><pub-id pub-id-type="pmcid">PMC6606522</pub-id></element-citation></ref><ref id="B184-molecules-30-03457"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Lath</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Sophocleous</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Idris</surname><given-names>A.I.</given-names></name></person-group><article-title>JZL184, A Monoacylglycerol Lipase Inhibitor, Induces Bone Loss in a Multiple Myeloma Model of Immunocompetent Mice</article-title><source>Calcif. Tissue Int.</source><year>2020</year><volume>107</volume><fpage>72</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s00223-020-00689-0</pub-id><pub-id pub-id-type="pmid">32285169</pub-id><pub-id pub-id-type="pmcid">PMC7271071</pub-id></element-citation></ref><ref id="B185-molecules-30-03457"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aaltonen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Savinainen</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Ribas</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>R&#246;nkk&#246;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuusisto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Korhonen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Navia-Paldanius</surname><given-names>D.</given-names></name><name name-style="western"><surname>H&#228;yrinen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Takabe</surname><given-names>P.</given-names></name><name name-style="western"><surname>K&#228;sn&#228;nen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase</article-title><source>Chem. Biol.</source><year>2013</year><volume>20</volume><fpage>379</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2013.01.012</pub-id><pub-id pub-id-type="pmid">23521796</pub-id></element-citation></ref><ref id="B186-molecules-30-03457"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Monoacylglycerol lipase promotes progression of hepatocellular carcinoma via NF-&#954;B-mediated epithelial-mesenchymal transition</article-title><source>J. Hematol. Oncol.</source><year>2016</year><volume>9</volume><fpage>127</fpage><pub-id pub-id-type="doi">10.1186/s13045-016-0361-3</pub-id><pub-id pub-id-type="pmid">27884159</pub-id><pub-id pub-id-type="pmcid">PMC5123220</pub-id></element-citation></ref><ref id="B187-molecules-30-03457"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puris</surname><given-names>E.</given-names></name><name name-style="western"><surname>Petralla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Auriola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kidron</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fricker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gynther</surname><given-names>M.</given-names></name></person-group><article-title>Monoacylglycerol Lipase Inhibitor JJKK048 Ameliorates ABCG2 Transporter-Mediated Regorafenib Resistance Induced by Hypoxia in Triple Negative Breast Cancer Cells</article-title><source>J. Pharm. Sci.</source><year>2023</year><volume>112</volume><fpage>2581</fpage><lpage>2590</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2023.05.012</pub-id><pub-id pub-id-type="pmid">37220829</pub-id></element-citation></ref><ref id="B188-molecules-30-03457"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyatt</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>I.</given-names></name><name name-style="western"><surname>Welty</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wennerholm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ameriks</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Dugovic</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>S.</given-names></name><name name-style="western"><surname>White</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pharmacologic Characterization of JNJ-42226314, [1-(4-fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a reversible, selective, and potent monoacylglycerol lipase inhibitor</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2020</year><volume>372</volume><fpage>339</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1124/jpet.119.262139</pub-id><pub-id pub-id-type="pmid">31818916</pub-id></element-citation></ref><ref id="B189-molecules-30-03457"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>J.R.</given-names></name></person-group><article-title>Molecular pathways: Fatty acid synthase</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>5434</fpage><lpage>5438</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0126</pub-id><pub-id pub-id-type="pmid">26519059</pub-id></element-citation></ref><ref id="B190-molecules-30-03457"><label>190.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Aquino</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Chaudhari</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ghergurovich</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kiesow</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Parrish</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Reif</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Wiggall</surname><given-names>K.</given-names></name></person-group><article-title>Triazolones as Fatty Acid Synthase inhibitors. World Intellectual Property</article-title><source>Organization. Patent</source><patent>No. WO2011103546</patent><day>25</day><month>August</month><year>2011</year></element-citation></ref><ref id="B191-molecules-30-03457"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardwicke</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rendina</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Plant</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Totoritis</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Briand</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A human fatty acid synthase inhibitor binds &#946;-ketoacyl reductase in the keto-substrate site</article-title><source>Nat. Chem. Biol.</source><year>2014</year><volume>10</volume><fpage>774</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1603</pub-id><pub-id pub-id-type="pmid">25086508</pub-id></element-citation></ref><ref id="B192-molecules-30-03457"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aquino</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Cuadra-Zelaya</surname><given-names>F.J.M.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Salo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Coletta</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Graner</surname><given-names>E.</given-names></name></person-group><article-title>Anticancer properties of the fatty acid synthase inhibitor TVB-3166 on oral squamous cell carcinoma cell lines</article-title><source>Arch. Oral Biol.</source><year>2020</year><volume>113</volume><elocation-id>104707</elocation-id><pub-id pub-id-type="doi">10.1016/j.archoralbio.2020.104707</pub-id><pub-id pub-id-type="pmid">32197133</pub-id></element-citation></ref><ref id="B193-molecules-30-03457"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Syed-Abdul</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Parks</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Gaballah</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Bingham</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hammoud</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Kemble</surname><given-names>G.</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>D.</given-names></name><name name-style="western"><surname>McCulloch</surname><given-names>W.</given-names></name><name name-style="western"><surname>Manrique-Acevedo</surname><given-names>C.</given-names></name></person-group><article-title>Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities</article-title><source>Hepatology</source><year>2020</year><volume>72</volume><fpage>103</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1002/hep.31000</pub-id><pub-id pub-id-type="pmid">31630414</pub-id></element-citation></ref><ref id="B194-molecules-30-03457"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loomba</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mohseni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Trotter</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ajmera</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wayne</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial</article-title><source>Gastroenterology.</source><year>2021</year><volume>161</volume><fpage>1475</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2021.07.025</pub-id><pub-id pub-id-type="pmid">34310978</pub-id></element-citation></ref><ref id="B195-molecules-30-03457"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zadra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Chetta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cacciatore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Syamala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bango</surname><given-names>C.</given-names></name><name name-style="western"><surname>Photopoulos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>116</volume><fpage>631</fpage><lpage>640</lpage><comment>Erratum in <italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic><bold>2020</bold>, <italic toggle="yes">117</italic>, 18893</comment><pub-id pub-id-type="doi">10.1073/pnas.1808834116</pub-id><pub-id pub-id-type="pmcid">PMC6329966</pub-id><pub-id pub-id-type="pmid">30578319</pub-id></element-citation></ref><ref id="B196-molecules-30-03457"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chypre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Smans</surname><given-names>K.</given-names></name></person-group><article-title>ATP-citrate lyase: A mini-review</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2012</year><volume>422</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.04.144</pub-id><pub-id pub-id-type="pmid">22575446</pub-id></element-citation></ref><ref id="B197-molecules-30-03457"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granchi</surname><given-names>C.</given-names></name></person-group><article-title>ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>157</volume><fpage>1276</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.09.001</pub-id><pub-id pub-id-type="pmid">30195238</pub-id></element-citation></ref><ref id="B198-molecules-30-03457"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>B.P.</given-names></name></person-group><article-title>Acetyl-CoA and the regulation of metabolism: Mechanisms and consequences</article-title><source>Curr. Opin. Cell Biol.</source><year>2015</year><volume>33</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2015.02.003</pub-id><pub-id pub-id-type="pmid">25703630</pub-id><pub-id pub-id-type="pmcid">PMC4380630</pub-id></element-citation></ref><ref id="B199-molecules-30-03457"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemus</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Mendivil</surname><given-names>C.O.</given-names></name></person-group><article-title>Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia</article-title><source>J. Clin. Lipidol.</source><year>2015</year><volume>9</volume><fpage>384</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.jacl.2015.01.002</pub-id><pub-id pub-id-type="pmid">26073398</pub-id></element-citation></ref><ref id="B200-molecules-30-03457"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guais</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baronzio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>E.</given-names></name><name name-style="western"><surname>Campion</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mainini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fiorentini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Montagnani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Behzadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abolhassani</surname><given-names>M.</given-names></name></person-group><article-title>Adding a combination of hydroxycitrate and lipoic acid (METABLOC&#8482;) to chemotherapy improves effectiveness against tumor development: Experimental results and case report</article-title><source>Investig. New Drugs</source><year>2012</year><volume>30</volume><fpage>200</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1007/s10637-010-9552-x</pub-id><pub-id pub-id-type="pmid">20931262</pub-id></element-citation></ref><ref id="B201-molecules-30-03457"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Therrien</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rafi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>De La Barre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L.</given-names></name></person-group><article-title>An allosteric mechanism for potent inhibition of human ATP-citrate lyase</article-title><source>Nature</source><year>2019</year><volume>568</volume><fpage>566</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1094-6</pub-id><pub-id pub-id-type="pmid">30944472</pub-id></element-citation></ref><ref id="B202-molecules-30-03457"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granchi</surname><given-names>C.</given-names></name></person-group><article-title>Discovery of Allosteric Inhibition of Human ATP-Citrate Lyase</article-title><source>Trends Pharmacol. Sci.</source><year>2019</year><volume>40</volume><fpage>364</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2019.04.008</pub-id><pub-id pub-id-type="pmid">31072639</pub-id></element-citation></ref><ref id="B203-molecules-30-03457"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tino</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Robl</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Herpin</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Biller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jamil</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ponticiello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2007</year><volume>17</volume><fpage>3208</fpage><lpage>3211</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2007.03.017</pub-id><pub-id pub-id-type="pmid">17383874</pub-id></element-citation></ref><ref id="B204-molecules-30-03457"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oleynek</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Barrow</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Sedlock</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kaplita</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Copper</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gillum</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Chadwick</surname><given-names>C.C.</given-names></name></person-group><article-title>Anthrones, naturally occurring competitive inhibitors of adenosine-triphosphate-citrate lyase</article-title><source>Drug Dev. Res.</source><year>1995</year><volume>36</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/ddr.430360106</pub-id></element-citation></ref><ref id="B205-molecules-30-03457"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denga</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Denga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Luoa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gongb</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zoua</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pengc</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guoa</surname><given-names>Z.</given-names></name></person-group><article-title>Biotransformation of (-)-(10E,15S)-10,11-Dehydrocurvularin</article-title><source>Nat. Prod. Commun.</source><year>2015</year><volume>10</volume><fpage>1277</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1177/1934578X1501000735</pub-id><pub-id pub-id-type="pmid">26411029</pub-id></element-citation></ref><ref id="B206-molecules-30-03457"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Dehydrocurvularin is a potent antineoplastic agent irreversibly blocking ATP-citrate lyase: Evidence from chemoproteomics</article-title><source>Chem. Commun.</source><year>2019</year><volume>55</volume><fpage>4194</fpage><lpage>4197</lpage><pub-id pub-id-type="doi">10.1039/C9CC00256A</pub-id><pub-id pub-id-type="pmid">30895984</pub-id></element-citation></ref><ref id="B207-molecules-30-03457"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>The acetyl-CoA carboxylase enzyme: A target for cancer therapy?</article-title><source>Expert Rev. Anticancer Ther.</source><year>2015</year><volume>15</volume><fpage>667</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1586/14737140.2015.1038246</pub-id><pub-id pub-id-type="pmid">25979092</pub-id></element-citation></ref><ref id="B208-molecules-30-03457"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yahagi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shimano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsuzaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Najima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sekiya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tomita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma</article-title><source>Eur. J. Cancer</source><year>2005</year><volume>41</volume><fpage>1316</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2004.12.037</pub-id><pub-id pub-id-type="pmid">15869874</pub-id></element-citation></ref><ref id="B209-molecules-30-03457"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brownsey</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Boone</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kulpa</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.M.</given-names></name></person-group><article-title>Regulation of acetyl-CoA carboxylase</article-title><source>Biochem. Soc. Trans.</source><year>2006</year><volume>34</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1042/BST0340223</pub-id><pub-id pub-id-type="pmid">16545081</pub-id></element-citation></ref><ref id="B210-molecules-30-03457"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Addy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kusunoki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Deja</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ruddy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chakravarthy</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation</article-title><source>Cell Metab.</source><year>2017</year><volume>23</volume><fpage>94</fpage><lpage>406</lpage><comment>Erratum in <italic toggle="yes">Cell Metab.</italic><bold>2017</bold>, <italic toggle="yes">26</italic>, 576</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2017.07.009</pub-id><pub-id pub-id-type="pmcid">PMC5603267</pub-id><pub-id pub-id-type="pmid">28768177</pub-id></element-citation></ref><ref id="B211-molecules-30-03457"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishiura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shimazaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kitade</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tonomura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Okuno</surname><given-names>T.</given-names></name></person-group><article-title>Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2018</year><volume>28</volume><fpage>2498</fpage><lpage>2503</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2018.05.055</pub-id><pub-id pub-id-type="pmid">29903660</pub-id></element-citation></ref><ref id="B212-molecules-30-03457"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizojiri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Asano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sumi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maezaki</surname><given-names>H.</given-names></name></person-group><article-title>The identification and pharmacological evaluation of potent, selective and orally available ACC1 inhibitor</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2019</year><volume>29</volume><elocation-id>126749</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmcl.2019.126749</pub-id><pub-id pub-id-type="pmid">31672259</pub-id></element-citation></ref><ref id="B213-molecules-30-03457"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harriman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Greenwood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Westlin</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Kapeller</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E1796</fpage><lpage>E1805</lpage><pub-id pub-id-type="doi">10.1073/pnas.1520686113</pub-id><pub-id pub-id-type="pmid">26976583</pub-id><pub-id pub-id-type="pmcid">PMC4822632</pub-id></element-citation></ref><ref id="B214-molecules-30-03457"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almahmoud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Vennerstrom</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>H.A.</given-names></name></person-group><article-title>Conformational Studies of Glucose Transporter 1 (GLUT1) as an Anticancer Drug Target</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>2159</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24112159</pub-id><pub-id pub-id-type="pmid">31181707</pub-id><pub-id pub-id-type="pmcid">PMC6600248</pub-id></element-citation></ref><ref id="B215-molecules-30-03457"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>Structural basis of PKM2 regulation</article-title><source>Protein Cell</source><year>2015</year><volume>6</volume><fpage>238</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1007/s13238-015-0146-4</pub-id><pub-id pub-id-type="pmid">25773278</pub-id><pub-id pub-id-type="pmcid">PMC4383752</pub-id></element-citation></ref><ref id="B216-molecules-30-03457"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vander Steen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Espinoza</surname><given-names>I.</given-names></name><name name-style="western"><surname>Duran</surname><given-names>C.</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>G.</given-names></name><name name-style="western"><surname>Serrano-Herv&#225;s</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cuy&#224;s</surname><given-names>E.</given-names></name><name name-style="western"><surname>Verdura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kemble</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>McWilliams</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer</article-title><source>Neoplasia</source><year>2025</year><volume>62</volume><fpage>101143</fpage><pub-id pub-id-type="doi">10.1016/j.neo.2025.101143</pub-id><pub-id pub-id-type="pmid">39999714</pub-id><pub-id pub-id-type="pmcid">PMC11908614</pub-id></element-citation></ref><ref id="B217-molecules-30-03457"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leone</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Englert</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Blosser</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Siska</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Rathmell</surname><given-names>J.C.</given-names></name></person-group><article-title>Crosstalk between glutaminolysis and mitochondrial respiration in cancer resistance</article-title><source>Trends Cancer</source><year>2023</year><volume>9</volume><fpage>345</fpage><lpage>358</lpage></element-citation></ref><ref id="B218-molecules-30-03457"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faubert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zacharias</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Do</surname><given-names>Q.N.</given-names></name><name name-style="western"><surname>Doucette</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burguete</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Targeting Lactate Transport Augments Glutaminase Inhibition in Lymphoma</article-title><source>Nat. Cancer</source><year>2023</year><volume>4</volume><fpage>1193</fpage><lpage>1205</lpage></element-citation></ref><ref id="B219-molecules-30-03457"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#224;zquez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chandel</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>DeBerardinis</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Venneti</surname><given-names>S.</given-names></name></person-group><article-title>Phenformin Enhances LDH Inhibitor Sensitivity via AMPK Reprogramming</article-title><source>Cell Metab.</source><year>2024</year><volume>36</volume><fpage>235</fpage><lpage>248</lpage></element-citation></ref><ref id="B220-molecules-30-03457"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perez-Neut</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Lactylation-Dependent Epigenetic Regulation Links Metabolism to Inflammation</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2022</year><volume>23</volume><fpage>587</fpage><lpage>604</lpage></element-citation></ref><ref id="B221-molecules-30-03457"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vetma</surname><given-names>V.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Novakova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Garza</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name></person-group><article-title>Development of PROTAC Degrader Drugs for Cancer</article-title><source>Annu. Rev. Cancer Biol.</source><year>2025</year><volume>9</volume><fpage>119</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1146/annurev-cancerbio-061824-105806</pub-id></element-citation></ref><ref id="B222-molecules-30-03457"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Development of Tumor-Specific PROTAC Prodrugs for LDHA Degradation</article-title><source>Mol. Cancer</source><year>2024</year><volume>23</volume><fpage>75</fpage></element-citation></ref><ref id="B223-molecules-30-03457"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Emerging Targeted Protein Degradation Platforms: AUTACs, ATTECs and LYTACs</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>111</fpage></element-citation></ref><ref id="B224-molecules-30-03457"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajagopalan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>D.R.</given-names></name><etal/></person-group><article-title>DRP-104 Induces Durable Immune-Mediated Tumor Regression</article-title><source>Cancer Immunol. Res.</source><year>2024</year><volume>12</volume><fpage>420</fpage><lpage>434</lpage></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Charts and Tables</title><fig position="float" id="molecules-30-03457-f001" orientation="portrait"><label>Figure 1</label><caption><p>Aerobic glycolysis in normal and cancer cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-g001.jpg"/></fig><fig position="float" id="molecules-30-03457-f002" orientation="portrait"><label>Figure 2</label><caption><p>The general reaction catalyzed by LDH.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-g002.jpg"/></fig><fig position="float" id="molecules-30-03457-ch001" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch001_Chart 1</object-id><label>Chart 1</label><caption><p>Chemical structures of LDH inhibitors <bold>1</bold>&#8211;<bold>11.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch001.jpg"/></fig><fig position="float" id="molecules-30-03457-f003" orientation="portrait"><label>Figure 3</label><caption><p>GLUT1 function.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-g003.jpg"/></fig><fig position="float" id="molecules-30-03457-ch002" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch002_Chart 2</object-id><label>Chart 2</label><caption><p>Chemical structures of GLUT1 inhibitors <bold>12</bold>&#8211;<bold>18.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch002.jpg"/></fig><fig position="float" id="molecules-30-03457-f004" orientation="portrait"><label>Figure 4</label><caption><p>Hexokinase function in glucose metabolism.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-g004.jpg"/></fig><fig position="float" id="molecules-30-03457-ch003" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch003_Chart 3</object-id><label>Chart 3</label><caption><p>Chemical structures of HK2-VDAC1 inhibitors <bold>19</bold>&#8211;<bold>24</bold> and glucose binding site inhibitors <bold>25</bold>&#8211;<bold>27.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch003.jpg"/></fig><fig position="float" id="molecules-30-03457-ch004" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch004_Chart 4</object-id><label>Chart 4</label><caption><p>Chemical structures of glucose-6P-mimicking binding site <bold>28</bold>&#8211;<bold>30.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch004.jpg"/></fig><fig position="float" id="molecules-30-03457-f005" orientation="portrait"><label>Figure 5</label><caption><p>PK role in glycolysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-g005.jpg"/></fig><fig position="float" id="molecules-30-03457-ch005" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch005_Chart 5</object-id><label>Chart 5</label><caption><p>Chemical structures of PKM1 inhibitors and agonists <bold>31</bold>&#8211;<bold>37.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch005.jpg"/></fig><fig position="float" id="molecules-30-03457-f006" orientation="portrait"><label>Figure 6</label><caption><p>Glutamine metabolism.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-g006.jpg"/></fig><fig position="float" id="molecules-30-03457-ch006" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch006_Chart 6</object-id><label>Chart 6</label><caption><p>Chemical structures of glutamine uptake inhibitors <bold>38</bold>&#8211;<bold>41.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch006.jpg"/></fig><fig position="float" id="molecules-30-03457-ch007" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch007_Chart 7</object-id><label>Chart 7</label><caption><p>Chemical structures and bioactivation of <bold>42.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch007.jpg"/></fig><fig position="float" id="molecules-30-03457-ch008" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch008_Chart 8</object-id><label>Chart 8</label><caption><p>Chemical structures of glutamine metabolism inhibitors <bold>43</bold>&#8211;<bold>47.</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch008.jpg"/></fig><fig position="float" id="molecules-30-03457-f007" orientation="portrait"><label>Figure 7</label><caption><p>Fatty acid metabolism. ACC: acetyl-CoA carboxylase; ACLY: acetyl-CoA lyase; ACSS: acetyl-CoA synthetase short chain family member; FAS: fatty acid synthase; MAGL: monoacylglycerol lipase.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-g007.jpg"/></fig><fig position="float" id="molecules-30-03457-ch009" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch009_Chart 9</object-id><label>Chart 9</label><caption><p>Chemical structures of MAGL inhibitors (<bold>48</bold>&#8211;<bold>52</bold>) and FAS inhibitors (<bold>53</bold>&#8211;<bold>55</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch009.jpg"/></fig><fig position="float" id="molecules-30-03457-ch010" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03457-ch010_Chart 10</object-id><label>Chart 10</label><caption><p>Chemical structures of ACLY (<bold>56</bold>&#8211;<bold>59</bold>) and ACC inhibitors (<bold>60</bold>&#8211;<bold>63</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03457-ch010.jpg"/></fig></sec></back></article></pmc-articleset>